{"matching_results": 32645, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1103, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 875}, {"key": "negative", "matching_results": 220}, {"key": "neutral", "matching_results": 8}]}]}, {"key": "tickerreport.com", "matching_results": 797, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 659}, {"key": "negative", "matching_results": 137}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 772, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 533}, {"key": "negative", "matching_results": 239}]}]}, {"key": "wkrb13.com", "matching_results": 753, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 588}, {"key": "negative", "matching_results": 164}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 729, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 498}, {"key": "negative", "matching_results": 231}]}]}, {"key": "dailypolitical.com", "matching_results": 726, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 592}, {"key": "negative", "matching_results": 134}]}]}, {"key": "freelancer.com.co", "matching_results": 636, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 596}, {"key": "negative", "matching_results": 39}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "marketscreener.com", "matching_results": 596, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 453}, {"key": "negative", "matching_results": 143}]}]}, {"key": "theolympiareport.com", "matching_results": 538, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 360}, {"key": "negative", "matching_results": 177}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "prnewswire.com", "matching_results": 492, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 443}, {"key": "negative", "matching_results": 48}, {"key": "neutral", "matching_results": 1}]}]}]}], "results": [{"id": "08mE4H7ZgRFcVZV3EpFrXCCD33-zUmvNU8HBPzqCkhMf3asdMNxzgJrKyMJGyAyK", "result_metadata": {"score": 35.89519}, "author": "Ankush Nikam", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Fabry Disease", "keywords": [{"text": "Fabry Disease"}]}, "sentence": "Fabry Disease Likely to Emerge over a Period of 2016 \u2013 2026", "action": {"verb": {"text": "Emerge", "tense": "future"}, "text": "to Emerge", "normalized": "to Emerge"}}], "concepts": [{"text": "Years in the future", "relevance": 0.842933, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Diseases and disorders", "relevance": 0.653999, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}], "categories": [{"score": 0.968294, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Fabry Disease Likely", "sentiment": {"score": -0.415989, "label": "negative"}, "relevance": 0.958678}, {"text": "Period", "sentiment": {"score": -0.415989, "label": "negative"}, "relevance": 0.337433}]}, "crawl_date": "2018-11-15T08:36:01Z", "url": "https://www.findmarketresearch.org/2018/11/fabry-disease-market-likely-to-emerge-over-a-period-of-2016-2026/", "host": "findmarketresearch.org", "text": "Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T06:53:00+05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.736695, "label": "negative"}, "text": "fabry disease", "relevance": 0.90083, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"count": 1, "sentiment": {"score": -0.576522, "label": "negative"}, "text": "Fabry diseaseis", "relevance": 0.352387, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.786549, "label": "negative"}, "text": "APAC", "relevance": 0.144928, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.708726, "label": "negative"}, "text": "multiple organ failure", "relevance": 0.119889, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}, {"count": 1, "sentiment": {"score": -0.581545, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.11786, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.11757, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.111374, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.107302, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": -0.302207, "label": "negative"}, "text": "Gene", "relevance": 0.104854, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.103584, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi-Aventis LLC", "relevance": 0.102003, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.101062, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.0998379, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.428499, "label": "negative"}, "text": "Neuraltus Pharmaceuticals", "relevance": 0.0971278, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme Corporation", "relevance": 0.0964426, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0.26394, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0940622, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0939481, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.0938284, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.093597, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0927609, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.258776, "label": "positive"}, "text": "Western Europe", "relevance": 0.0924451, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0875668, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merc & Co., Inc.", "relevance": 0.0849323, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "iBio, Inc.", "relevance": 0.083304, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.0823172, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0823172, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.784576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Fabry", "keywords": [{"text": "Fabry"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "also known as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "Anderson-Fabry disease"}, {"text": "deficiency"}]}, "action": {"verb": {"text": "diseaseis", "tense": "present"}, "text": "diseaseis", "normalized": "diseaseis"}}, {"subject": {"text": "Fabry diseaseis", "keywords": [{"text": "Fabry diseaseis"}], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, "sentence": "Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency.", "object": {"text": "as Anderson-Fabry disease and alpha-galactosidase A deficiency", "keywords": [{"text": "deficiency"}, {"text": "Anderson-Fabry disease"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "It"}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "lipid metabolism"}, {"text": "rare genetic disorder"}, {"text": "deficient activity"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "deficient activity"}, {"text": "enzyme"}, {"text": "alpha-galactosidase"}]}, "sentence": " It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "lipid metabolism", "keywords": [{"text": "lipid metabolism"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme", "keywords": [{"text": "alterations"}, {"text": "enzyme"}, {"text": "genes"}, {"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "The deficiency of the enzyme", "keywords": [{"text": "deficiency"}, {"text": "enzyme"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "the alterations in the genes", "keywords": [{"text": "alterations"}, {"text": "genes"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "the cells", "keywords": [{"text": "cells"}]}, "action": {"verb": {"text": "instruct", "tense": "present"}, "text": "instructs", "normalized": "instruct"}}, {"subject": {"text": "the cells", "keywords": [{"text": "cells"}]}, "sentence": " The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme.", "object": {"text": "alpha-galactosidase", "keywords": [{"text": "alpha-galactosidase"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "to make", "normalized": "to make"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "known to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Fabry disease", "keywords": [{"text": "Fabry disease"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "sentence": " Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "object": {"text": "to cause variety of systemic symptoms and complications, one of them being metabolic disorders", "keywords": [{"text": "systemic symptoms"}, {"text": "metabolic disorders"}, {"text": "complications"}, {"text": "variety"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "The metabolism of sphingolipids", "keywords": [{"text": "metabolism"}, {"text": "sphingolipids"}]}, "sentence": " The metabolism of sphingolipids is minimized, in fabry disease which results in the multiple organ failure and death.", "object": {"text": "minimized, in fabry disease which results in the multiple organ failure and death", "keywords": [{"text": "multiple organ failure"}, {"text": "fabry disease"}, {"text": "death"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"type": "HealthCondition", "text": "multiple organ failure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Multiple organ dysfunction syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_organ_dysfunction_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "A enzyme, glycolipid called Gb3", "keywords": [{"text": "glycolipid"}, {"text": "enzyme"}, {"text": "Gb3"}]}, "sentence": " Owing to the deficiency of alpha galactosidase A enzyme, glycolipid called Gb3 accumulates in the blood vessels and other organs and thus results in formation of blockage or clots that leads to malfunctioning of the system.", "action": {"verb": {"text": "accumulate", "tense": "present"}, "text": "accumulates", "normalized": "accumulate"}}, {"subject": {"text": "The major drivers that drive the fabry disease market growth", "keywords": [{"text": "fabry disease market"}, {"text": "major drivers"}]}, "sentence": " Fabry Disease Market: Drivers and Restraints : The major drivers that drive the fabry disease market growth are extensive R&D activities, adoption of advanced technologies in the research practices.", "object": {"text": "extensive R&D activities, adoption of advanced technologies in the research practices", "keywords": [{"text": "extensive R&D activities"}, {"text": "advanced technologies"}, {"text": "research practices"}, {"text": "adoption"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "complications in physiological systems, such as cardiac system, urinary system and others", "keywords": [{"text": "physiological systems"}, {"text": "complications"}], "entities": []}, "sentence": " Due to hereditary nature and severity of the disease, complications in physiological systems, such as cardiac system, urinary system and others are expected to increase the demand for trustworthy treatment.", "object": {"text": "the demand for trustworthy treatment", "keywords": [{"text": "trustworthy treatment"}, {"text": "demand"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "are expected to increase", "normalized": "be expect to increase"}}, {"subject": {"text": "Extensive R&D practices", "keywords": [{"text": "Extensive R&D practices"}]}, "sentence": " Extensive R&D practices is one of the valuable drivers of the market.", "object": {"text": "one of the valuable drivers of the market", "keywords": [{"text": "valuable drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others,", "keywords": [{"text": "various therapeutic products"}, {"text": "JR-051"}, {"text": "NP-003"}, {"text": "GC-1119"}]}, "sentence": " Due to this, various therapeutic products, such as, PRX-102, JR-051, NP-003, GC-1119 and others, are under pipeline studies.", "object": {"text": "under pipeline studies", "keywords": [{"text": "pipeline studies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "technological limitations in certain region of the world", "keywords": [{"text": "technological limitations"}, {"text": "certain region"}, {"text": "world"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "some of the restraining factors that may affect the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "restraining factors"}, {"text": "growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some of the restraining factors", "keywords": [{"text": "restraining factors"}]}, "sentence": " However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "object": {"text": "the growth of the fabry disease market", "keywords": [{"text": "fabry disease market"}, {"text": "growth"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "may affect", "normalized": "may affect"}}, {"subject": {"text": "The enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " Fabry Disease Market: Overview : The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "enzyme", "keywords": [{"text": "enzyme"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "is designed to provide", "normalized": "be design to provide"}}, {"subject": {"text": "enzyme to the patients", "keywords": [{"text": "enzyme"}, {"text": "patients"}]}, "sentence": " Fabry Disease Market: Overview : The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "from enzyme deficiency", "keywords": [{"text": "enzyme deficiency"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "Enzyme replacement therapy", "keywords": [{"text": "Enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "the most expensive and unaffordable treatment among the treatments for fabry disease", "keywords": [{"text": "fabry disease"}, {"text": "unaffordable treatment"}, {"text": "treatments"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "moderate growth", "keywords": [{"text": "moderate growth"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The analgesics, anticonvulsants and NSAIDs", "keywords": [{"text": "analgesics"}, {"text": "NSAIDs"}, {"text": "anticonvulsants"}]}, "sentence": " The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "object": {"text": "for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market", "keywords": [{"text": "fabry disease"}, {"text": "pain"}, {"text": "treatment"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe", "keywords": [{"text": "lucrative region"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Africa.North America"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "to be the most lucrative region", "keywords": [{"text": "lucrative region"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "the affordability of the treatment", "keywords": [{"text": "affordability"}, {"text": "treatment"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "The rare incidences in APAC and MEA countries", "keywords": [{"text": "rare incidences"}, {"text": "MEA countries"}, {"text": "APAC"}], "entities": []}, "sentence": " The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "object": {"text": "the growth of fabry disease market in these regions", "keywords": [{"text": "fabry disease market"}, {"text": "regions"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "are expected to limit", "normalized": "be expect to limit"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Segmentation : The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "been classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Segmentation : The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "classified on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Segmentation : The global fabry disease market has been classified on the basis of treatment, end use and geography.", "object": {"text": "on the basis of treatment, end use and geography", "keywords": [{"text": "basis"}, {"text": "geography"}, {"text": "treatment"}, {"text": "end"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "has been classified", "normalized": "have be classify"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "object": {"text": "divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "global fabry disease"}, {"text": "end user type"}, {"text": "agalsidase alpha"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "object": {"text": "into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics", "keywords": [{"text": "Enzyme replacement therapy"}, {"text": "global fabry disease"}, {"text": "end user type"}, {"text": "agalsidase alpha"}], "entities": [{"type": "Person", "text": "Gene"}]}, "action": {"verb": {"text": "divide", "tense": "past"}, "text": "is divided", "normalized": "be divide"}}, {"subject": {"text": "The major players", "keywords": [{"text": "major players"}]}, "sentence": " Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "The major players", "keywords": [{"text": "major players"}]}, "sentence": " Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "in development of new medications", "keywords": [{"text": "new medications"}, {"text": "development"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc", "keywords": [{"text": "GlaxoSmithKline plc"}, {"text": "Sanofi-Aventis LLC"}, {"text": "Genzyme Corporation"}, {"text": "Neuraltus Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Sanofi-Aventis LLC"}, {"type": "Company", "text": "iBio, Inc."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Genzyme Corporation", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"type": "Company", "text": "Neuraltus Pharmaceuticals"}]}, "sentence": " Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "new medications", "keywords": [{"text": "new medications"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Some of the existing key players in the global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "key players"}]}, "sentence": " Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd.", "object": {"text": "Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Teva pharmaceutical Industries"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Pfizer Inc."}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merc & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Fabry disease", "relevance": 0.97566, "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}, {"text": "Enzyme replacement therapy", "relevance": 0.9683, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_replacement_therapy"}, {"text": "Bristol-Myers Squibb", "relevance": 0.838425, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.757695, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Therapy", "relevance": 0.650216, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Clopidogrel", "relevance": 0.632619, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Metabolism", "relevance": 0.615042, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Medicine", "relevance": 0.600767, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Sphingolipidoses", "relevance": 0.600747, "dbpedia_resource": "http://dbpedia.org/resource/Sphingolipidoses"}], "categories": [{"score": 0.899041, "label": "/health and fitness/disease"}, {"score": 0.318253, "label": "/health and fitness/disorders"}], "relations": [{"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.469575, "arguments": [{"text": "Fabry", "location": [370, 375], "entities": [{"type": "Person", "text": "Fabry diseaseis"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "agentOf", "sentence": "Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.979201, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [3724, 3754], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [3755, 3762], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "affectedBy", "sentence": "Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.437365, "arguments": [{"text": "Sample", "location": [3766, 3772], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Request", "location": [3755, 3762], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "agentOf", "sentence": "Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.8898, "arguments": [{"text": "Sample", "location": [3766, 3772], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Report", "location": [3776, 3782], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "hasAttribute", "sentence": "Fabry disease is known to cause variety of systemic symptoms and complications, one of them being metabolic disorders.", "score": 0.782799, "arguments": [{"text": "them", "location": [457, 461], "entities": [{"type": "Person", "text": "them"}]}, {"text": "metabolic disorders", "location": [468, 487], "entities": [{"type": "HealthCondition", "text": "metabolic disorders"}]}]}, {"type": "locatedAt", "sentence": "However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic sciences, technological limitations in certain region of the world are some of the restraining factors that may affect the growth of the fabry disease market.", "score": 0.243329, "arguments": [{"text": "region", "location": [1571, 1577], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "world", "location": [1585, 1590], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "score": 0.518347, "arguments": [{"text": "NSAIDs", "location": [2192, 2198], "entities": [{"type": "Person", "text": "NSAIDs"}]}, {"text": "disease hence", "location": [2286, 2299], "entities": [{"type": "HealthCondition", "text": "disease hence"}]}]}, {"type": "locatedAt", "sentence": "Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.513586, "arguments": [{"text": "Eastern Europe", "location": [2508, 2522], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}, {"text": "APAC", "location": [2524, 2528], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "locatedAt", "sentence": "Fabry Disease Market: Regional Overview : Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.72389, "arguments": [{"text": "APAC", "location": [2524, 2528], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}, {"text": "Japan", "location": [2530, 2535], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.80263, "arguments": [{"text": "countries", "location": [2719, 2728], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "APAC", "location": [2706, 2710], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "partOf", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.651857, "arguments": [{"text": "MEA", "location": [2715, 2718], "entities": [{"type": "Organization", "text": "MEA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "countries", "location": [2719, 2728], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Based on treatment, the global fabry disease market is divided into following: Enzyme replacement therapy, Gene therapy, Pharmaceutical formulations containing agalsidase alpha, Analgesics, Anticonvulsants, NSAIDs Based on end user type, the global fabry disease market is divided into following: Hospitals, Clinics Fabry Disease Market: Key Players : The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "score": 0.506998, "arguments": [{"text": "Clinics\nFabry Disease Market", "location": [3251, 3279], "entities": [{"type": "Organization", "text": "Clinics\nFabry Disease Market"}]}, {"text": "Key Players", "location": [3281, 3292], "entities": [{"type": "Organization", "text": "Key Players", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "fabry disease market", "sentiment": {"score": -0.545357, "label": "negative"}, "relevance": 0.971448}, {"text": "global fabry disease", "sentiment": {"score": -0.470547, "label": "negative"}, "relevance": 0.731161}, {"text": "enzyme replacement therapy", "sentiment": {"score": -0.616438, "label": "negative"}, "relevance": 0.639799}, {"text": "overall fabry disease", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.577184}, {"text": "disease market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.495605}, {"text": "enzyme deficiency", "sentiment": {"score": -0.581187, "label": "negative"}, "relevance": 0.473981}, {"text": "rare genetic disorder", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.469482}, {"text": "extensive r&d", "sentiment": {"score": 0.701252, "label": "positive"}, "relevance": 0.466402}, {"text": "extensive R&D activities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4622}, {"text": "multiple organ failure", "sentiment": {"score": -0.708726, "label": "negative"}, "relevance": 0.461007}, {"text": "Extensive R&D practices", "sentiment": {"score": 0.701252, "label": "positive"}, "relevance": 0.460924}, {"text": "various therapeutic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45962}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45923}, {"text": "Teva pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458873}, {"text": "rare incidence rate", "sentiment": {"score": -0.300761, "label": "negative"}, "relevance": 0.458857}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457931}, {"text": "Anderson-Fabry disease", "sentiment": {"score": -0.576522, "label": "negative"}, "relevance": 0.456256}, {"text": "end user type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454935}, {"text": "key players", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.45408}, {"text": "lipid metabolism", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.442901}, {"text": "trustworthy treatment", "sentiment": {"score": 0.36224, "label": "positive"}, "relevance": 0.439445}, {"text": "deficient activity", "sentiment": {"score": -0.649562, "label": "negative"}, "relevance": 0.43936}, {"text": "unaffordable treatment", "sentiment": {"score": -0.729756, "label": "negative"}, "relevance": 0.43624}, {"text": "NSAIDs Based", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435267}, {"text": "systemic symptoms", "sentiment": {"score": -0.797483, "label": "negative"}, "relevance": 0.435115}, {"text": "metabolic disorders", "sentiment": {"score": -0.785664, "label": "negative"}, "relevance": 0.434753}, {"text": "Amgen Inc.", "sentiment": {"score": 0.26394, "label": "positive"}, "relevance": 0.43465}, {"text": "major drivers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434431}, {"text": "alpha galactosidase", "sentiment": {"score": -0.485789, "label": "negative"}, "relevance": 0.434347}, {"text": "advanced technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43402}, {"text": "research practices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433813}, {"text": "hereditary nature", "sentiment": {"score": -0.731825, "label": "negative"}, "relevance": 0.433763}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4337}, {"text": "physiological systems", "sentiment": {"score": -0.43068, "label": "negative"}, "relevance": 0.433333}, {"text": "Sanofi-Aventis LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433198}, {"text": "rare incidences", "sentiment": {"score": -0.786549, "label": "negative"}, "relevance": 0.433189}, {"text": "valuable drivers", "sentiment": {"score": 0.701252, "label": "positive"}, "relevance": 0.43315}, {"text": "moderate growth", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.433046}, {"text": "AbbVie Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432998}, {"text": "lucrative region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432641}, {"text": "blood vessels", "sentiment": {"score": -0.691556, "label": "negative"}, "relevance": 0.432638}, {"text": "genetic sciences", "sentiment": {"score": -0.539806, "label": "negative"}, "relevance": 0.432631}, {"text": "Genzyme Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432598}, {"text": "agalsidase alpha", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432505}, {"text": "pipeline studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432006}, {"text": "restraining factors", "sentiment": {"score": -0.704272, "label": "negative"}, "relevance": 0.431943}, {"text": "MEA countries", "sentiment": {"score": -0.786549, "label": "negative"}, "relevance": 0.431898}, {"text": "Novartis Pharmaceuticals", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.431753}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431591}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431574}]}, "extracted_metadata": {"sha1": "2ad637f1201d8c5a640ff0518b5507b4f6a24001", "filename": "1542270961041.zip-0cfda987bfc99891cb66d115badd360d.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/sample/rep-gb-1365", "https://www.futuremarketinsights.com/reports/fabry-disease-market"], "title": "Fabry Disease Likely to Emerge over a Period of 2016 \u2013 2026", "forum_title": "Research Insights \u2013 Page 14 \u2013 Find Market Research"}, {"id": "S7RT1M1-Tf7SBw-V_k_naBsoY1tYfh_FvoLfRu-wjeWfxLfckW8pZ5CG74LCt1mi", "result_metadata": {"score": 35.749687}, "author": "Donna Armstrong", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.358275, "label": "positive"}, "text": "Seattle", "relevance": 0.928493, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.559395, "label": "/science/biology"}, {"score": 0.53718, "label": "/science/biology/molecular biology"}, {"score": 0.404271, "label": "/science/biology/cytology"}], "relations": [{"type": "hasAttribute", "sentence": "Arsanis (ASNS) vs. Seattle Genetics (SGEN) Head to Head Survey", "score": 0.744456, "arguments": [{"text": "Seattle Genetics", "location": [19, 35], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "SGEN", "location": [37, 41], "entities": [{"type": "Ticker", "text": "SGEN"}]}]}, {"type": "employedBy", "sentence": "Arsanis (ASNS) vs. Seattle Genetics (SGEN) Head to Head Survey", "score": 0.793082, "arguments": [{"text": "Head", "location": [43, 47], "entities": [{"type": "Person", "text": "Head"}]}, {"text": "Seattle Genetics", "location": [19, 35], "entities": [{"type": "Organization", "text": "Seattle Genetics", "disambiguation": {"subtype": ["Sports"]}}]}]}], "keywords": [{"text": "ASNS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.97585}, {"text": "Seattle Genetics", "sentiment": {"score": 0.358275, "label": "positive"}, "relevance": 0.811644}, {"text": "Head Survey", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.684829}, {"text": "vs", "sentiment": {"score": 0.359033, "label": "positive"}, "relevance": 0.629439}, {"text": "Arsanis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372962}, {"text": "SGEN", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.361654}]}, "crawl_date": "2018-11-14T16:19:16Z", "url": "https://www.thelincolnianonline.com/2018/11/14/arsanis-asns-vs-seattle-genetics-sgen-head-to-head-survey.html", "host": "thelincolnianonline.com", "text": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with", "main_image_url": "https://www.marketbeat.com/logos/Seagen_logo_r_RGB_hi-res-lrg.gif", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T16:00:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.11432, "label": "positive"}, "text": "Seattle", "relevance": 0.909038, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "classical Hodgkin lymphoma", "relevance": 0.598675, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arsanis, Inc.", "relevance": 0.504671, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "large cell lymphoma", "relevance": 0.43973, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 2, "sentiment": {"score": -0.613982, "label": "negative"}, "text": "solid tumors", "relevance": 0.416305, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.39562, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arsanis", "relevance": 0.391715, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.406588, "label": "positive"}, "text": "Agensys, Inc", "relevance": 0.381532, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.430104, "label": "negative"}, "text": "Hodgkin", "relevance": 0.368349, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PSMA Development Company LLC", "relevance": 0.3674, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "enfortumab vedotin", "relevance": 0.360322, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADCETRIS", "relevance": 0.347367, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Biotechnology Ltd.", "relevance": 0.336682, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genmab A/S", "relevance": 0.332152, "type": "Company", "disambiguation": {"subtype": [], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bothell", "relevance": 0.329731, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Waltham", "relevance": 0.326684, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Massachusetts", "relevance": 0.312449, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unum Therapeutics, Inc.", "relevance": 0.310531, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celldex Therapeutics, Inc.", "relevance": 0.295528, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer Pharma AG", "relevance": 0.295413, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Washington", "relevance": 0.281796, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline LLC", "relevance": 0.279565, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech, Inc.", "relevance": 0.260934, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.258689, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.88", "relevance": 0.258689, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418791, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Arsanis", "keywords": [{"text": "Arsanis"}]}, "sentence": " Arsanis has higher earnings, but lower revenue than Seattle Genetics.", "object": {"text": "higher earnings", "keywords": [{"text": "higher earnings"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics is trading at a lower price-to-earnings ratio than Arsanis, indicating that it is currently the more affordable of the two stocks.", "object": {"text": "trading at a lower price-to-earnings ratio than Arsanis", "keywords": [{"text": "lower price-to-earnings ratio"}, {"text": "trading"}, {"text": "Arsanis"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics is trading at a lower price-to-earnings ratio than Arsanis, indicating that it is currently the more affordable of the two stocks.", "object": {"text": "that it is currently the more affordable of the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicating", "normalized": "indicate"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "Arsanis", "keywords": [{"text": "Arsanis"}]}, "action": {"verb": {"text": "beat", "tense": "present"}, "text": "beats", "normalized": "beat"}}, {"subject": {"text": "the 11 factors", "keywords": [{"text": "factors"}]}, "sentence": " Seattle Genetics beats Arsanis on 6 of the 11 factors compared between the two stocks.", "object": {"text": "between the two stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Arsanis, Inc., a clinical-stage biopharmaceutical company,", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "Arsanis"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "monoclonal antibody (mAb) immunotherapies", "keywords": [{"text": ") immunotherapies"}, {"text": "monoclonal antibody"}]}, "action": {"verb": {"text": "apply", "tense": "future"}, "text": "applying", "normalized": "apply"}}, {"subject": {"text": "monoclonal antibody (mAb)", "keywords": [{"text": "monoclonal antibody"}, {"text": "mAb"}]}, "sentence": " Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases.", "object": {"text": "infectious diseases", "keywords": [{"text": "infectious diseases"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "immunotherapies to address", "normalized": "immunotherapies to address"}}, {"subject": {"text": "Its lead product candidate", "keywords": [{"text": "lead product candidate"}]}, "sentence": " Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "object": {"text": "ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia", "keywords": [{"text": "staphylococcus aureus pneumonia"}, {"text": "clinical development"}, {"text": "mAb"}, {"text": "Phase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "mAbs", "keywords": [{"text": "mAbs"}]}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "target", "tense": "present"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "respiratory syncytial virus", "keywords": [{"text": "respiratory syncytial virus"}], "entities": []}, "sentence": " The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.", "object": {"text": "various bacterial and viral pathogens", "keywords": [{"text": "viral pathogens"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "founded in 2010"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "object": {"text": "headquartered in Waltham, Massachusetts", "keywords": [{"text": "Waltham"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "Waltham", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Waltham, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Waltham,_Massachusetts"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Arsanis, Inc.", "entities": [{"type": "Company", "text": "Arsanis, Inc."}]}, "sentence": " Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "It"}, "sentence": " It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.", "object": {"text": "ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma", "keywords": [{"text": "Hodgkin lymphoma"}, {"text": "antibody-drug conjugate"}, {"text": "ADCETRIS"}, {"text": "treatment"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "Hodgkin"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer", "keywords": [{"text": "Nectin-4-positive solid tumors"}, {"text": "bladder cancer"}, {"text": "enfortumab vedotin"}, {"text": "clinical trial"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}, {"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "enfortumab vedotin", "keywords": [{"text": "enfortumab vedotin"}], "entities": [{"type": "Person", "text": "enfortumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase 1 clinical trial", "keywords": [{"text": "Phase"}, {"text": "clinical trial"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "tisotumab vedotin that", "keywords": [{"text": "tisotumab vedotin"}]}, "sentence": " The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "object": {"text": "in Phase II clinical trial for patients with cervical cancer and solid tumors", "keywords": [{"text": "cervical cancer"}, {"text": "solid tumors"}, {"text": "clinical trial"}, {"text": "Phase"}], "entities": [{"type": "HealthCondition", "text": "solid tumors", "disambiguation": {"subtype": ["DiseaseCause", "RiskFactor", "Symptom"], "name": "Tumor", "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "stage classical Hodgkin"}, {"text": "clinical trials"}, {"text": "CD30-expressing MTCL"}], "entities": [{"type": "Company", "text": "ADCETRIS"}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "sentence": " In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma.", "object": {"text": "3 clinical trials of ADCETRIS", "keywords": [{"text": "clinical trials"}, {"text": "ADCETRIS"}], "entities": [{"type": "Company", "text": "ADCETRIS"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF", "keywords": [{"text": "ADC programs"}, {"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "immuno-oncology agents"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "the company's earlier stage clinical pipeline", "keywords": [{"text": "stage clinical pipeline"}, {"text": "company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "six other ADC programs", "keywords": [{"text": "ADC programs"}]}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A,", "keywords": [{"text": "ladiratuzumab vedotin"}, {"text": "denintuzumab mafodotin"}, {"text": "SGN-CD19B"}, {"text": "SGN-CD123A"}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consisting", "normalized": "consist"}}, {"subject": {"text": "SEA-CD40 and SGN-2FF"}, "sentence": " Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF.", "object": {"text": "two immuno-oncology agents", "keywords": [{"text": "immuno-oncology agents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "It"}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}, {"text": "various biotechnology"}, {"text": "ADC technology"}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "AbbVie Biotechnology Ltd.; Bayer Pharma AG", "keywords": [{"text": "Bayer Pharma AG"}, {"text": "AbbVie Biotechnology Ltd."}], "entities": [{"type": "Company", "text": "AbbVie Biotechnology Ltd."}, {"type": "Company", "text": "Bayer Pharma AG"}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "various biotechnology and pharmaceutical companies", "keywords": [{"text": "various biotechnology"}, {"text": "pharmaceutical companies"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S", "keywords": [{"text": "PSMA Development Company"}, {"text": "Unum Therapeutics"}, {"text": "Genmab A/S"}, {"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "PSMA Development Company LLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Unum Therapeutics, Inc."}, {"type": "Company", "text": "Genmab A/S", "disambiguation": {"subtype": ["Company"], "name": "Genmab", "dbpedia_resource": "http://dbpedia.org/resource/Genmab"}}]}, "sentence": " It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc.", "object": {"text": "co-development agreement with Agensys, Inc", "keywords": [{"text": "co-development agreement"}, {"text": "Agensys"}], "entities": [{"type": "Company", "text": "Agensys, Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "founded in 1998"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "object": {"text": "headquartered in Bothell, Washington", "keywords": [{"text": "Bothell"}, {"text": "Washington"}], "entities": [{"type": "Location", "text": "Bothell", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Bothell, Washington", "dbpedia_resource": "http://dbpedia.org/resource/Bothell,_Washington"}}, {"type": "Location", "text": "Washington", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Seattle Genetics, Inc.", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "News & Ratings", "keywords": [{"text": "News"}, {"text": "Ratings"}]}, "sentence": " Receive News & Ratings for Arsanis analysts' ratings for Arsanis and related companies daily email newsletter . \u00ab", "object": {"text": "for Arsanis analysts' ratings for Arsanis and related companies daily email newsletter", "keywords": [{"text": "companies daily email"}, {"text": "Arsanis analysts"}, {"text": "ratings"}, {"text": "newsletter"}], "entities": [{"type": "Company", "text": "Arsanis"}]}, "action": {"verb": {"text": "Receive", "tense": "present"}, "text": "Receive", "normalized": "Receive"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.966771, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Pharmaceutical industry", "relevance": 0.913585, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmacology", "relevance": 0.825906, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pre-clinical development", "relevance": 0.761218, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Biotechnology", "relevance": 0.717557, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Drug discovery", "relevance": 0.648966, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Drug development", "relevance": 0.646916, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "The Canon of Medicine", "relevance": 0.579703, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.55714, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "Cancer", "relevance": 0.541692, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Lymphoma", "relevance": 0.539403, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Hodgkin's lymphoma", "relevance": 0.5148, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use", "relevance": 0.513416, "dbpedia_resource": "http://dbpedia.org/resource/International_Conference_on_Harmonisation_of_Technical_Requirements_for_Registration_of_Pharmaceuticals_for_Human_Use"}, {"text": "Clinical trial protocol", "relevance": 0.503676, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial_protocol"}, {"text": "Medicine", "relevance": 0.503642, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Clinical research", "relevance": 0.499398, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Monoclonal antibodies", "relevance": 0.485905, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Good clinical practice", "relevance": 0.474645, "dbpedia_resource": "http://dbpedia.org/resource/Good_clinical_practice"}, {"text": "Staphylococcus aureus", "relevance": 0.473834, "dbpedia_resource": "http://dbpedia.org/resource/Staphylococcus_aureus"}, {"text": "Informed consent", "relevance": 0.466188, "dbpedia_resource": "http://dbpedia.org/resource/Informed_consent"}], "categories": [{"score": 0.564576, "label": "/health and fitness/disease/cancer"}, {"score": 0.47813, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.457051, "label": "/health and fitness/therapy"}], "relations": [{"type": "employedBy", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.401099, "arguments": [{"text": "candidate", "location": [512, 521], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "Its", "location": [495, 498], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Arsanis analysts' ratings for Arsanis and related companies daily email newsletter . \u00ab", "score": 0.832543, "arguments": [{"text": "analysts", "location": [2634, 2642], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "Arsanis", "location": [2626, 2633], "entities": [{"type": "Organization", "text": "Arsanis\nArsanis, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.950221, "arguments": [{"text": "ASN100", "location": [525, 531], "entities": [{"type": "Person", "text": "ASN100"}]}, {"text": "pneumonia", "location": [628, 637], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "hasAttribute", "sentence": "Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.", "score": 0.845239, "arguments": [{"text": "patients", "location": [665, 673], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pneumonia", "location": [628, 637], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "foundedOn", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.72754, "arguments": [{"text": "Arsanis, Inc.", "location": [813, 826], "entities": [{"type": "Organization", "text": "Arsanis\nArsanis, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "2010", "location": [842, 846], "entities": [{"type": "Date", "text": "2010", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "locatedAt", "sentence": "Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.", "score": 0.990399, "arguments": [{"text": "Waltham", "location": [871, 878], "entities": [{"type": "GeopoliticalEntity", "text": "Waltham"}]}, {"text": "Massachusetts", "location": [880, 893], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "hasAttribute", "sentence": "The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors.", "score": 0.813646, "arguments": [{"text": "patients", "location": [1430, 1438], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cervical cancer", "location": [1444, 1459], "entities": [{"type": "HealthCondition", "text": "cervical cancer"}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.586522, "arguments": [{"text": "AbbVie Biotechnology Ltd.", "location": [2218, 2243], "entities": [{"type": "Organization", "text": "AbbVie Biotechnology Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [2182, 2206], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.621299, "arguments": [{"text": "Bayer Pharma AG", "location": [2245, 2260], "entities": [{"type": "Organization", "text": "Bayer Pharma AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical companies", "location": [2182, 2206], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.", "score": 0.985491, "arguments": [{"text": "Bothell", "location": [2578, 2585], "entities": [{"type": "GeopoliticalEntity", "text": "Bothell"}]}, {"text": "Washington", "location": [2587, 2597], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}]}], "keywords": [{"text": "Seattle Genetics", "sentiment": {"score": -0.0105176, "label": "negative"}, "relevance": 0.982776}, {"text": "classical Hodgkin lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.831015}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0.284432, "label": "positive"}, "relevance": 0.647231}, {"text": "large cell lymphoma", "sentiment": {"score": -0.430104, "label": "negative"}, "relevance": 0.628692}, {"text": "stage classical Hodgkin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.615573}, {"text": "staphylococcus aureus pneumonia", "sentiment": {"score": -0.402514, "label": "negative"}, "relevance": 0.612669}, {"text": "lower price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606251}, {"text": "PSMA Development Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600052}, {"text": "respiratory syncytial virus", "sentiment": {"score": -0.521716, "label": "negative"}, "relevance": 0.595025}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594623}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589027}, {"text": "Nectin-4-positive solid tumors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583118}, {"text": "stage clinical pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581288}, {"text": "AbbVie Biotechnology Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570126}, {"text": "daily email newsletter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565851}, {"text": "Bayer Pharma AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564165}, {"text": "clinical trial", "sentiment": {"score": -0.613982, "label": "negative"}, "relevance": 0.55135}, {"text": "Arsanis", "sentiment": {"score": 0.431739, "label": "positive"}, "relevance": 0.523724}, {"text": "biotechnology company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486029}, {"text": "clinical development", "sentiment": {"score": -0.402514, "label": "negative"}, "relevance": 0.476482}, {"text": "higher earnings", "sentiment": {"score": 0.431739, "label": "positive"}, "relevance": 0.475877}, {"text": "lower revenue", "sentiment": {"score": -0.363995, "label": "negative"}, "relevance": 0.473851}, {"text": "preclinical pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471665}, {"text": "Arsanis analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47009}, {"text": "monoclonal antibody", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468661}, {"text": "Unum Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466278}, {"text": "ADC programs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464077}, {"text": "antibody-drug conjugate", "sentiment": {"score": -0.430104, "label": "negative"}, "relevance": 0.461748}, {"text": "ADC technology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.461488}, {"text": "clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460222}, {"text": "viral pathogens", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459278}, {"text": "infectious diseases", "sentiment": {"score": -0.641476, "label": "negative"}, "relevance": 0.45835}, {"text": "cancer worldwide", "sentiment": {"score": -0.338698, "label": "negative"}, "relevance": 0.45686}, {"text": "Genmab A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456736}, {"text": "cervical cancer", "sentiment": {"score": -0.613982, "label": "negative"}, "relevance": 0.454605}, {"text": "bladder cancer", "sentiment": {"score": -0.564155, "label": "negative"}, "relevance": 0.454008}, {"text": "enfortumab vedotin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453888}, {"text": "co-development agreement", "sentiment": {"score": 0.406588, "label": "positive"}, "relevance": 0.453142}, {"text": "tisotumab vedotin", "sentiment": {"score": -0.613982, "label": "negative"}, "relevance": 0.453047}, {"text": "Celldex Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452968}, {"text": "various biotechnology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450628}, {"text": "GlaxoSmithKline LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44812}, {"text": "ladiratuzumab vedotin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447702}, {"text": "CD30-expressing MTCL", "sentiment": {"score": -0.250457, "label": "negative"}, "relevance": 0.447275}, {"text": "denintuzumab mafodotin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444767}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444403}, {"text": "immuno-oncology agents", "sentiment": {"score": 0.32499, "label": "positive"}, "relevance": 0.444114}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441721}, {"text": "phase", "sentiment": {"score": -0.508248, "label": "negative"}, "relevance": 0.412691}, {"text": "patients", "sentiment": {"score": -0.414835, "label": "negative"}, "relevance": 0.400427}]}, "extracted_metadata": {"sha1": "b8beebd27dbb2e841765d726892e85edb7ab559f", "filename": "1542212356133.zip-450b4a9099feaad32eb0cffb3178beff.xml", "file_type": "json"}, "title": "Arsanis (ASNS) vs. Seattle Genetics (SGEN) Head to Head Survey", "forum_title": "The Lincolnian Online"}, {"id": "gD1cALUhRsi4viiRirN8_Sia2tkVjFYA2j3pZUXlH-Mm5BSn-VwKSfPzN-jdTfYS", "result_metadata": {"score": 32.871887}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.930119, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Major depressive disorder", "relevance": 0.949819, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.880267, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}], "categories": [{"score": 0.732333, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.726571, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.120916, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [], "keywords": [{"text": "Reflect Impressive Expansion", "sentiment": {"score": -0.733198, "label": "negative"}, "relevance": 0.960392}, {"text": "Major Depressive Disorder", "sentiment": {"score": -0.733198, "label": "negative"}, "relevance": 0.782396}]}, "crawl_date": "2018-11-15T08:44:00Z", "url": "https://www.findmarketresearch.org/2018/11/major-depressive-disorder-market-to-reflect-impressive-expansion-during-2015-2021-2/", "host": "findmarketresearch.org", "text": "Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T05:58:00+05:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": -0.719536, "label": "negative"}, "text": "depressive disorder", "relevance": 0.901724, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"count": 2, "sentiment": {"score": -0.568224, "label": "negative"}, "text": "North America", "relevance": 0.139002, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.38955, "label": "negative"}, "text": "depression", "relevance": 0.138438, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": -0.850614, "label": "negative"}, "text": "dysthymia", "relevance": 0.138296, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Asia", "relevance": 0.135774, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck A/S", "relevance": 0.122204, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.116137, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc", "relevance": 0.110445, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aripiprazole", "relevance": 0.108108, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "R&D", "relevance": 0.106861, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.105827, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.105449, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "India", "relevance": 0.105259, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": -0.317828, "label": "negative"}, "text": "Escitalopram", "relevance": 0.105064, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.503696, "label": "negative"}, "text": "U.S.", "relevance": 0.105028, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.104788, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quetiapine", "relevance": 0.103691, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.10112, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Duloxetine", "relevance": 0.0999762, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Venlafaxine", "relevance": 0.0988672, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.0985706, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vilazodone", "relevance": 0.0971837, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Milnacipran", "relevance": 0.096863, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.654068, "label": "negative"}, "text": "Spain", "relevance": 0.092003, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company", "relevance": 0.0884062, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.0871155, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.0869347, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Euthymics Bioscience, Inc.", "relevance": 0.0857164, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.0853587, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0.244607, "label": "positive"}, "text": "China", "relevance": 0.0847234, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes", "relevance": 0.0819765, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Japan", "relevance": 0.080546, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.077628, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "25%", "relevance": 0.077628, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "10%", "relevance": 0.077628, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.077628, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "44 years", "relevance": 0.077628, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12%", "relevance": 0.077628, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20%", "relevance": 0.077628, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5%", "relevance": 0.077628, "type": "Quantity"}], "sentiment": {"document": {"score": -0.830082, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "as major depression and clinical depression", "keywords": [{"text": "major depression"}, {"text": "clinical depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Major depressive disorder, also known as major depression and clinical depression,", "keywords": [{"text": "Major depressive disorder"}, {"text": "clinical depression"}, {"text": "major depression"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder characterized by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "mental disorder"}, {"text": "pleasure"}, {"text": "loss"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "pleasure"}, {"text": "loss"}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder", "keywords": [{"text": "mental disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "by major depression", "keywords": [{"text": "major depression"}]}, "sentence": " People are affected in different ways by major depression.", "object": {"text": "People", "keywords": [{"text": "People"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "are affected", "normalized": "be affect"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "trouble sleeping", "keywords": [{"text": "trouble sleeping"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "sudden weight loss", "keywords": [{"text": "sudden weight loss"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "they"}, "sentence": " Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "object": {"text": "other mental and physical symptoms such as fatigue", "keywords": [{"text": "physical symptoms"}, {"text": "fatigue"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "can have", "normalized": "can have"}}, {"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " Major depressive disorder can affect people in any stage of life.", "object": {"text": "people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "can affect", "normalized": "can affect"}}, {"subject": {"text": "those"}, "sentence": " In adults, major depressive disorder is most common in those who are 25-44 years of age.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "major depression", "keywords": [{"text": "major depression"}]}, "sentence": " Within an entire lifetime, major depression affects 10% \u2013 25% of women and 5% \u2013 12% of men.", "object": {"text": "10% \u2013 25% of women and 5% \u2013 12% of men", "keywords": [{"text": "women"}, {"text": "men"}], "entities": [{"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "12"}, {"type": "Quantity", "text": "25"}, {"type": "Quantity", "text": "5"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "10% \u2013 25% of people who develop major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "people"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "25"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "previously diagnosed with dysthymia", "keywords": [{"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people may suffer from dysthymia and major depressive disorder at the same time.", "object": {"text": "from dysthymia and major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "suffer", "tense": "future"}, "text": "may suffer", "normalized": "may suffer"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "known as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is known", "normalized": "be know"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "related to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "relate", "tense": "future"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "cancer, diabetes", "keywords": [{"text": "diabetes"}, {"text": "cancer"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions", "keywords": [{"text": "myocardial infarctions"}, {"text": "diabetes"}, {"text": "stroke"}, {"text": "people"}], "entities": [{"type": "Quantity", "text": "20"}, {"type": "Quantity", "text": "25"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "market"}]}, "sentence": " The global major depressive disorder market is categorized based on various types of therapeutic drugs used to manage this medical condition.", "object": {"text": "on various types of therapeutic drugs used to manage this medical condition", "keywords": [{"text": "therapeutic drugs"}, {"text": "various types"}, {"text": "medical condition"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " Based on type of therapeutic drug, the report covers selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics.", "object": {"text": "selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "serotonin-norepinephrine reuptake inhibitors"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran)", "keywords": [{"text": "Cymbalta"}, {"text": "Savella"}], "entities": [{"type": "Drug", "text": "Escitalopram"}, {"type": "Drug", "text": "Vilazodone"}, {"type": "Drug", "text": "Venlafaxine"}, {"type": "Drug", "text": "Duloxetine"}, {"type": "Drug", "text": "Milnacipran"}]}, "sentence": " Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "object": {"text": "Major brands of selective serotonin-reuptake inhibitors", "keywords": [{"text": "selective serotonin-reuptake inhibitors"}, {"text": "Major brands"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "commonly used in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are commonly used", "normalized": "be commonly use"}}, {"subject": {"text": "Abilify"}, "sentence": " Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "object": {"text": "antipsychotics", "keywords": [{"text": "antipsychotics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "object": {"text": "the global major depressive disorder market due to increased awareness about various depression conditions in the region", "keywords": [{"text": "major depressive disorder"}, {"text": "various depression conditions"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for major depressive disorder in North America, followed by Canada.", "object": {"text": "the largest market for major depressive disorder in North America, followed by Canada", "keywords": [{"text": "major depressive disorder"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "This market in Asia", "keywords": [{"text": "market"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " This market in Asia is expected to expand at a significant rate over the next five years.", "action": {"verb": {"text": "expand", "tense": "future"}, "text": "is expected to expand", "normalized": "be expect to expand"}}, {"subject": {"text": "various companies", "keywords": [{"text": "various companies"}]}, "sentence": " This is due to various companies setting up manufacturing facilities in the region.", "object": {"text": "manufacturing facilities in the region", "keywords": [{"text": "facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "setting", "normalized": "set"}}, {"subject": {"text": "awareness", "keywords": [{"text": "awareness"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "increasing awareness about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "the growth of the market in the region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are also driving", "normalized": "be also drive"}}, {"subject": {"text": "India, China, and Japan", "keywords": [{"text": "India"}, {"text": "China"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.", "object": {"text": "the fastest growing major depressive disorder markets in Asia", "keywords": [{"text": "major depressive disorder"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "investments", "keywords": [{"text": "investments"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "action": {"verb": {"text": "Increased", "tense": "past"}, "text": "Increased", "normalized": "Increased"}}, {"subject": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "object": {"text": "Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs", "keywords": [{"text": "pharmaceutical sector"}, {"text": "innovative drugs"}, {"text": "investments"}, {"text": "R&D"}], "entities": [{"type": "Location", "text": "R&D", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "have also fueled", "normalized": "have also fuel"}}, {"subject": {"text": "The ongoing development of drugs with properties, such as improved safety and high patient compliance,", "keywords": [{"text": "high patient compliance"}, {"text": "ongoing development"}, {"text": "improved safety"}, {"text": "drugs"}]}, "sentence": " The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the global major depressive disorder market.", "object": {"text": "the growth of the global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "are also supporting", "normalized": "be also support"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "immense potential to spur the growth of this market", "keywords": [{"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "spur", "tense": "future"}, "text": "to spur", "normalized": "to spur"}}, {"subject": {"text": "by various governments", "keywords": [{"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "stringent regulations", "keywords": [{"text": "stringent regulations"}]}, "action": {"verb": {"text": "impose", "tense": "past"}, "text": "imposed", "normalized": "impose"}}, {"subject": {"text": "stringent regulations imposed by various governments", "keywords": [{"text": "stringent regulations"}, {"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "the growth of global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "drugs", "keywords": [{"text": "drugs"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "an annual sale of USD 1.0 million and above", "keywords": [{"text": "annual sale"}, {"text": "USD"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "side-effects", "keywords": [{"text": "side-effects"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "with antidepressants", "keywords": [{"text": "antidepressants"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "side-effects associated with antidepressants", "keywords": [{"text": "side-effects"}, {"text": "antidepressants"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hinder", "tense": "past"}, "text": "have hindered", "normalized": "have hinder"}}, {"subject": {"text": "The major companies", "keywords": [{"text": "major companies"}], "entities": [{"type": "Company", "text": "H. Lundbeck A/S", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "sentence": " The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.969929, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Sertraline", "relevance": 0.753187, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Major depressive disorder", "relevance": 0.699122, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.665893, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Venlafaxine", "relevance": 0.641718, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Bipolar disorder", "relevance": 0.59495, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Serotonin", "relevance": 0.581639, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Paroxetine", "relevance": 0.561417, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Citalopram", "relevance": 0.513033, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Mood disorder", "relevance": 0.511549, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Escitalopram", "relevance": 0.497973, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Tricyclic antidepressant", "relevance": 0.494798, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Fluoxetine", "relevance": 0.48235, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Antidepressant", "relevance": 0.429037, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Atypical depression", "relevance": 0.418165, "dbpedia_resource": "http://dbpedia.org/resource/Atypical_depression"}, {"text": "Suicide", "relevance": 0.398292, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.390351, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Bupropion", "relevance": 0.387748, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Imipramine", "relevance": 0.372183, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Schizophrenia", "relevance": 0.354147, "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.350782, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}], "categories": [{"score": 0.774162, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.396607, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.307392, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [{"type": "hasAttribute", "sentence": "People are affected in different ways by major depression.", "score": 0.895334, "arguments": [{"text": "People", "location": [177, 183], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depression", "location": [224, 234], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "Approximately 20% - 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "score": 0.813019, "arguments": [{"text": "who", "location": [1192, 1195], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [1201, 1207], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.672047, "arguments": [{"text": "inhibitors", "location": [1667, 1677], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.681218, "arguments": [{"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}, {"text": "Escitalopram", "location": [1695, 1707], "entities": [{"type": "GeopoliticalEntity", "text": "Escitalopram"}]}]}, {"type": "playsRoleOf", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.419738, "arguments": [{"text": "Milnacipran", "location": [1844, 1855], "entities": [{"type": "Person", "text": "Levomilnacipran"}]}, {"text": "Savella", "location": [1835, 1842], "entities": [{"type": "Person", "text": "Savella"}]}]}, {"type": "hasAttribute", "sentence": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "score": 0.490678, "arguments": [{"text": "Vortioxetine", "location": [2055, 2067], "entities": [{"type": "Person", "text": "Vortioxetine"}]}, {"text": "depressive disorder", "location": [2115, 2134], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "productOf", "sentence": "Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "score": 0.527122, "arguments": [{"text": "Seroquel XR", "location": [2202, 2213], "entities": [{"type": "Product", "text": "Seroquel XR"}]}, {"text": "Abilify", "location": [2175, 2182], "entities": [{"type": "Organization", "text": "Abilify", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "score": 0.469682, "arguments": [{"text": "depression", "location": [2360, 2370], "entities": [{"type": "HealthCondition", "text": "depression"}]}, {"text": "depressive disorder", "location": [2292, 2311], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.943846, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2515, 2522], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.568243, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "France", "location": [2524, 2530], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.773073, "arguments": [{"text": "U.K.", "location": [2536, 2540], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Italy", "location": [2542, 2547], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.791566, "arguments": [{"text": "they", "location": [339, 343], "entities": [{"type": "Person", "text": "People"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "ownerOf", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.230617, "arguments": [{"text": "companies", "location": [2739, 2748], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.897746, "arguments": [{"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2792, 2798], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "hasAttribute", "sentence": "In recent times, increased demand for therapeutic products for the treatment of this medical condition is a key driver for the global major depressive disorder market.", "score": 0.690833, "arguments": [{"text": "driver", "location": [3173, 3179], "entities": [{"type": "Person", "text": "driver"}]}, {"text": "depressive disorder", "location": [3201, 3220], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "score": 0.323359, "arguments": [{"text": "drugs", "location": [3852, 3857], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3840, 3851], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "agentOf", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request Sample Report@ https://www.persistencemarketresearch.com/samples/4190", "score": 0.988447, "arguments": [{"text": "Pfizer Inc.", "location": [4455, 4466], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [4467, 4474], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "hasAttribute", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request Sample Report@ https://www.persistencemarketresearch.com/samples/4190", "score": 0.397752, "arguments": [{"text": "Pfizer Inc.", "location": [4455, 4466], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.persistencemarketresearch.com/samples/", "location": [4490, 4540], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/samples/"}]}]}, {"type": "agentOf", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request Sample Report@ https://www.persistencemarketresearch.com/samples/4190", "score": 0.688517, "arguments": [{"text": "Sample Report@", "location": [4475, 4489], "entities": [{"type": "Person", "text": "Sample Report@"}]}, {"text": "Request", "location": [4467, 4474], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "partOfMany", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.428244, "arguments": [{"text": "fatigue", "location": [396, 403], "entities": [{"type": "HealthCondition", "text": "fatigue"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "hasAttribute", "sentence": "Major depressive disorder can affect people in any stage of life.", "score": 0.668099, "arguments": [{"text": "people", "location": [528, 534], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depressive disorder", "location": [497, 516], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "In adults, major depressive disorder is most common in those who are 25-44 years of age.", "score": 0.629755, "arguments": [{"text": "adults", "location": [560, 566], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "depressive disorder", "location": [574, 593], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Within an entire lifetime, major depression affects 10% - 25% of women and 5% - 12% of men.", "score": 0.490187, "arguments": [{"text": "women", "location": [711, 716], "entities": [{"type": "Person", "text": "women"}]}, {"text": "depression", "location": [679, 689], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "It is estimated that 10% - 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "score": 0.80017, "arguments": [{"text": "who", "location": [779, 782], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [797, 816], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.90085, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "dysthymia", "location": [929, 938], "entities": [{"type": "HealthCondition", "text": "dysthymic disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.769645, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [949, 968], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}], "keywords": [{"text": "major depressive disorder", "sentiment": {"score": -0.697479, "label": "negative"}, "relevance": 0.92375}, {"text": "depressive disorder market", "sentiment": {"score": -0.698439, "label": "negative"}, "relevance": 0.708763}, {"text": "depressive disorder markets", "sentiment": {"score": -0.542704, "label": "negative"}, "relevance": 0.505101}, {"text": "major depression", "sentiment": {"score": -0.546771, "label": "negative"}, "relevance": 0.47776}, {"text": "reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475146}, {"text": "serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459034}, {"text": "serotonin-norepinephrine reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458409}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457492}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45368}, {"text": "Specific Serotonergic Antidepressants", "sentiment": {"score": -0.353355, "label": "negative"}, "relevance": 0.452892}, {"text": "various depression conditions", "sentiment": {"score": -0.632753, "label": "negative"}, "relevance": 0.452713}, {"text": "Major brands", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452017}, {"text": "selective serotonin-reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451843}, {"text": "various depression episodes", "sentiment": {"score": -0.38955, "label": "negative"}, "relevance": 0.449607}, {"text": "sudden weight loss", "sentiment": {"score": -0.6976, "label": "negative"}, "relevance": 0.447873}, {"text": "North America", "sentiment": {"score": -0.568224, "label": "negative"}, "relevance": 0.443944}, {"text": "medical condition", "sentiment": {"score": -0.76802, "label": "negative"}, "relevance": 0.443251}, {"text": "certain medical conditions", "sentiment": {"score": -0.72957, "label": "negative"}, "relevance": 0.443105}, {"text": "Otsuka Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441217}, {"text": "H. Lundbeck A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440281}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440178}, {"text": "drug manufacturing companies", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.439823}, {"text": "mental disorder", "sentiment": {"score": -0.769998, "label": "negative"}, "relevance": 0.43957}, {"text": "Request Sample Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438728}, {"text": "high patient compliance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438632}, {"text": "rapid product launches", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.437736}, {"text": "clinical depression", "sentiment": {"score": -0.636587, "label": "negative"}, "relevance": 0.437326}, {"text": "major share", "sentiment": {"score": -0.654068, "label": "negative"}, "relevance": 0.43631}, {"text": "dysthymic disorder", "sentiment": {"score": -0.7953, "label": "negative"}, "relevance": 0.436045}, {"text": "major companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435611}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.332703, "label": "negative"}, "relevance": 0.435112}, {"text": "major trends", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.434163}, {"text": "double depression", "sentiment": {"score": -0.479211, "label": "negative"}, "relevance": 0.433544}, {"text": "largest market", "sentiment": {"score": -0.503696, "label": "negative"}, "relevance": 0.430494}, {"text": "body aches", "sentiment": {"score": -0.584501, "label": "negative"}, "relevance": 0.427424}, {"text": "therapeutic drugs", "sentiment": {"score": -0.824404, "label": "negative"}, "relevance": 0.426968}, {"text": "memory loss", "sentiment": {"score": -0.473238, "label": "negative"}, "relevance": 0.426332}, {"text": "different ways", "sentiment": {"score": -0.674716, "label": "negative"}, "relevance": 0.4261}, {"text": "enjoyable environment", "sentiment": {"score": -0.769998, "label": "negative"}, "relevance": 0.426099}, {"text": "physical symptoms", "sentiment": {"score": -0.625794, "label": "negative"}, "relevance": 0.425823}, {"text": "blockbuster drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425313}, {"text": "various types", "sentiment": {"score": -0.824404, "label": "negative"}, "relevance": 0.425136}, {"text": "people", "sentiment": {"score": -0.759444, "label": "negative"}, "relevance": 0.424877}, {"text": "Seroquel XR", "sentiment": {"score": -0.440344, "label": "negative"}, "relevance": 0.42444}, {"text": "innovative drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424401}, {"text": "various companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424297}, {"text": "myocardial infarctions", "sentiment": {"score": -0.713444, "label": "negative"}, "relevance": 0.424044}, {"text": "therapeutic drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423259}, {"text": "Spain account", "sentiment": {"score": -0.654068, "label": "negative"}, "relevance": 0.422027}, {"text": "entire lifetime", "sentiment": {"score": 0.499582, "label": "positive"}, "relevance": 0.42198}]}, "extracted_metadata": {"sha1": "0dcef41ea97cd04b3fd380345c78ce0bc19d8c75", "filename": "1542271440293.zip-44c7e324928390555b4f36adaad779db.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/major-depressive-disorder-market.asp", "https://www.persistencemarketresearch.com/samples/4190"], "title": "Major Depressive Disorder to Reflect Impressive Expansion During 2015-2021", "forum_title": "Research Insights \u2013 Page 21 \u2013 Find Market Research"}, {"id": "ZbOsLVNklaTDpkY0kCPd3IdSzF5EWUbQ8-AvhNr-Hbw4Kaf6hxYr9GGYYwG8fKkX", "result_metadata": {"score": 32.691753}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impact Takeda Pharmaceutical", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "News Coverage", "keywords": [{"text": "News Coverage"}]}, "sentence": "Neutral News Coverage Likely to Impact Takeda Pharmaceutical (TKPYY) Share Price", "object": {"text": "Takeda Pharmaceutical (TKPYY) Share Price", "keywords": [{"text": "Share Price"}]}, "action": {"verb": {"text": "Impact", "tense": "future"}, "text": "to Impact", "normalized": "to Impact"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.712163, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.406004, "label": "/finance/financial news"}, {"score": 0.37159, "label": "/business and industrial/business news"}], "relations": [], "keywords": [{"text": "Neutral News Coverage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.921289}, {"text": "Share Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500565}]}, "crawl_date": "2018-11-15T05:07:52Z", "url": "https://www.americanbankingnews.com/2018/11/14/neutral-news-coverage-likely-to-impact-takeda-pharmaceutical-tkpyy-share-price.html", "host": "americanbankingnews.com", "text": "About Takeda Pharmaceutical Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide.", "main_image_url": "https://www.marketbeat.com/logos/takeda-pharmaceutical-co-ltd-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T03:02:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.596264, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.902408, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Daily", "relevance": 0.320168, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "OTC", "relevance": 0.0788898, "type": "Company", "disambiguation": {"subtype": [], "name": "OTC Markets Group", "dbpedia_resource": "http://dbpedia.org/resource/OTC_Markets_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Consumer Healthcare", "relevance": 0.0740723, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketBeat.com", "relevance": 0.0635251, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "52-week", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30.93 billion", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.86 billion", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$18.93", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$19.53", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$31.29", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.35%", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.15", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.61", "relevance": 0.0635251, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.84%", "relevance": 0.0635251, "type": "Quantity"}], "sentiment": {"document": {"score": -0.286195, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited \u2014 Moody", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Moody"}, {"text": "Limited"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Takeda Pharmaceutical Company Limited \u2014 Moody\u2019s assigns A2 to Takeda\u2019s proposed notes; places rating under review for downgrade (finance.yahoo.com)", "object": {"text": "assigns A2 to Takeda\u2019s proposed notes", "keywords": [{"text": "Takeda"}, {"text": "assigns"}, {"text": "notes"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": "Takeda Pharmaceutical Company Limited \u2014 Moody\u2019s assigns A2 to Takeda\u2019s proposed notes; places rating under review for downgrade (finance.yahoo.com)", "object": {"text": "under review for downgrade (finance.yahoo.com)", "keywords": [{"text": "downgrade"}, {"text": "finance.yahoo.com"}, {"text": "review"}]}, "action": {"verb": {"text": "place", "tense": "present"}, "text": "places", "normalized": "place"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}]}, "sentence": " Separately, ValuEngine upgraded Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "object": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Separately, ValuEngine upgraded Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Takeda Pharmaceutical stock", "keywords": [{"text": "Takeda Pharmaceutical stock"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical stock traded down $0.15 during midday trading on Wednesday, reaching $19.53.", "action": {"verb": {"text": "trade", "tense": "past"}, "text": "traded", "normalized": "trade"}}, {"subject": {"text": "Takeda Pharmaceutical stock", "keywords": [{"text": "Takeda Pharmaceutical stock"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical stock traded down $0.15 during midday trading on Wednesday, reaching $19.53.", "object": {"text": "$19.53", "entities": [{"type": "Quantity", "text": "$19.53"}]}, "action": {"verb": {"text": "reach", "tense": "present"}, "text": "reaching", "normalized": "reach"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company\u2019s stock had a trading volume of 3,229,224 shares, compared to its average volume of 463,855.", "object": {"text": "stock had a trading volume of 3,229,224 shares", "keywords": [{"text": "trading volume"}, {"text": "stock"}, {"text": "shares"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}]}, "sentence": " The company\u2019s stock had a trading volume of 3,229,224 shares, compared to its average volume of 463,855.", "object": {"text": "a trading volume of 3,229,224 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "a trading volume of 3,229,224 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "sentence": " The company\u2019s stock had a trading volume of 3,229,224 shares, compared to its average volume of 463,855.", "object": {"text": "to its average volume of 463,855", "keywords": [{"text": "average volume"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.12 and a current ratio of 1.42.", "object": {"text": "a debt-to-equity ratio of 0.48", "keywords": [{"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical has a 52-week low of $18.93 and a 52-week high of $31.29.", "object": {"text": "a 52-week low of $18.93 and a 52-week high of $31.29", "keywords": [{"text": "52-week low"}, {"text": "52-week high"}], "entities": [{"type": "Quantity", "text": "52-week"}, {"type": "Quantity", "text": "$18.93"}, {"type": "Quantity", "text": "$31.29"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market cap of $30.93 billion, a PE ratio of 14.45 and a beta of 0.44.", "object": {"text": "a market cap of $30.93 billion, a PE ratio of 14.45 and a beta of 0.44", "keywords": [{"text": "PE ratio"}, {"text": "market cap"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$30.93 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical (OTCMKTS:TKPYY)", "keywords": [{"text": "(OTCMKTS:TKPYY)"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical (OTCMKTS:TKPYY) last released its quarterly earnings results on Wednesday, October 31st.", "object": {"text": "its quarterly earnings results", "keywords": [{"text": "quarterly earnings"}, {"text": "results"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "released", "normalized": "release"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported $0.61 EPS for the quarter.", "object": {"text": "$0.61 EPS for the quarter", "keywords": [{"text": "EPS"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$0.61"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical had a return on equity of 11.35% and a net margin of 7.84%.", "object": {"text": "a return on equity of 11.35% and a net margin of 7.84%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "11.35"}, {"type": "Quantity", "text": "7.84"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company had revenue of $3.86 billion during the quarter.", "object": {"text": "revenue of $3.86 billion", "keywords": [{"text": "revenue"}], "entities": [{"type": "Quantity", "text": "$3.86 billion"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "It"}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "prescription, OTC, and quasi-drugs", "keywords": [{"text": "OTC"}, {"text": "prescription"}, {"text": "quasi-drugs"}], "entities": [{"type": "Company", "text": "OTC", "disambiguation": {"subtype": [], "name": "OTC Markets Group", "dbpedia_resource": "http://dbpedia.org/resource/OTC_Markets_Group"}}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "oncology, gastroenterology, central nervous system (CNS), vaccines, and others", "keywords": [{"text": "gastroenterology"}, {"text": "vaccines"}], "entities": []}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "reagents in various therapeutic areas", "keywords": [{"text": "various therapeutic areas"}, {"text": "reagents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "News & Ratings for Takeda Pharmaceutical Daily", "keywords": [{"text": "Takeda Pharmaceutical Daily"}, {"text": "Ratings"}, {"text": "News"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Daily"}]}, "sentence": " Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter . \u00ab", "object": {"text": "your email address", "keywords": [{"text": "email address"}]}, "action": {"verb": {"text": "Enter", "tense": "present"}, "text": "Enter", "normalized": "Enter"}}], "concepts": [{"text": "Central nervous system", "relevance": 0.973629, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "Financial ratios", "relevance": 0.947516, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Nervous system", "relevance": 0.906127, "dbpedia_resource": "http://dbpedia.org/resource/Nervous_system"}, {"text": "Financial ratio", "relevance": 0.869373, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Pharmacology", "relevance": 0.812536, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Stock", "relevance": 0.710768, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.71022, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Over-the-counter drug", "relevance": 0.661294, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Stock market", "relevance": 0.60811, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Revenue", "relevance": 0.595164, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}], "categories": [{"score": 0.542668, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.487937, "label": "/finance/financial news"}, {"score": 0.469332, "label": "/finance/investing/day trading"}], "relations": [{"type": "agentOf", "sentence": "The company reported $0.61 EPS for the quarter.", "score": 0.869998, "arguments": [{"text": "company", "location": [874, 881], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "reported", "location": [882, 890], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The company reported $0.61 EPS for the quarter.", "score": 0.320558, "arguments": [{"text": "EPS", "location": [897, 900], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "$0.61", "location": [891, 896], "entities": [{"type": "Money", "text": "$0.61"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.596264, "label": "negative"}, "relevance": 0.902139}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.766426}, {"text": "Takeda Pharmaceutical stock", "sentiment": {"score": -0.474561, "label": "negative"}, "relevance": 0.653971}, {"text": "Takeda Pharmaceutical Daily", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613729}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583366}, {"text": "quarterly earnings results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452618}, {"text": "various therapeutic areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443714}, {"text": "concise daily summary", "sentiment": {"score": 0.377413, "label": "positive"}, "relevance": 0.439888}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408948}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408715}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408483}, {"text": "PE ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40831}, {"text": "Moody\u2019s assigns", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40205}, {"text": "midday trading", "sentiment": {"score": -0.474561, "label": "negative"}, "relevance": 0.392247}, {"text": "research note", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38885}, {"text": "pharmaceutical products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38526}, {"text": "average volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383873}, {"text": "market cap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383278}, {"text": "net margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38307}, {"text": "52-week low", "sentiment": {"score": -0.717967, "label": "negative"}, "relevance": 0.382032}, {"text": "trading volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381979}, {"text": "52-week high", "sentiment": {"score": -0.717967, "label": "negative"}, "relevance": 0.381826}, {"text": "Prescription Drug", "sentiment": {"score": -0.258, "label": "negative"}, "relevance": 0.380498}, {"text": "related companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377005}, {"text": "Consumer Healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.3762}, {"text": "email address", "sentiment": {"score": 0.377413, "label": "positive"}, "relevance": 0.375589}, {"text": "latest news", "sentiment": {"score": 0.377413, "label": "positive"}, "relevance": 0.37527}, {"text": "email newsletter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374777}, {"text": "rating", "sentiment": {"score": -0.423674, "label": "negative"}, "relevance": 0.345059}, {"text": "Wednesday", "sentiment": {"score": -0.474561, "label": "negative"}, "relevance": 0.332904}, {"text": "downgrade", "sentiment": {"score": -0.423674, "label": "negative"}, "relevance": 0.328058}, {"text": "finance.yahoo.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328039}, {"text": "ValuEngine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327825}, {"text": "ratings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323482}, {"text": "27th", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.319782}, {"text": "EPS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.31651}, {"text": "OTC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.316227}, {"text": "notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.316186}, {"text": "review", "sentiment": {"score": -0.423674, "label": "negative"}, "relevance": 0.316158}, {"text": "vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314892}, {"text": "gastroenterology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314788}, {"text": "shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314743}, {"text": "Thursday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.31465}, {"text": "analysts", "sentiment": {"score": 0.377413, "label": "positive"}, "relevance": 0.314254}, {"text": "beta", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314123}, {"text": "revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314088}, {"text": "OTCMKTS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313996}, {"text": "segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313991}, {"text": "TKPYY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313985}, {"text": "reagents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313903}]}, "extracted_metadata": {"sha1": "8fa1cfe0d153f39118b0647b04ecf795b1eb9f7e", "filename": "1542258472313.zip-fd4ed9c1053764bf55feffc15748f709.xml", "file_type": "json"}, "external_links": ["http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=TKPYY", "https://www.marketbeat.com/stocks/OTCMKTS/TKPYY/news/", "https://finance.yahoo.com/m/cdbb93e9-de66-3d99-8c59-b90e757c6813/takeda-pharmaceutical-company.html?.tsrc=rss"], "title": "Neutral News Coverage Likely to Impact Takeda Pharmaceutical (TKPYY) Share Price", "forum_title": "American Banking News"}, {"id": "dGK2D8KIhZUrNn4JIEQkCc9VTW15WtX1TqZHIbkDefTn9H7yBqSRcAjk2tn_ewhK", "result_metadata": {"score": 32.52086}, "author": "Renee Jackson", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.270618, "label": "negative"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Neutral Media Coverage", "keywords": [{"text": "Neutral Media Coverage"}], "entities": []}, "sentence": "Neutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price", "object": {"text": "Takeda Pharmaceutical (TKPYY) Stock Price", "keywords": [{"text": "Stock Price"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "Affect", "tense": "future"}, "text": "to Affect", "normalized": "to Affect"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Stock", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.82944, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.731898, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.402938, "label": "/finance/investing/options"}], "relations": [], "keywords": [{"text": "Neutral Media Coverage", "sentiment": {"score": -0.270618, "label": "negative"}, "relevance": 0.872646}, {"text": "Stock Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527318}]}, "crawl_date": "2018-11-15T04:49:52Z", "url": "https://theolympiareport.com/2018/11/14/neutral-media-coverage-likely-to-affect-takeda-pharmaceutical-tkpyy-stock-price.html", "host": "theolympiareport.com", "text": "About Takeda Pharmaceutical Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide.", "main_image_url": "https://www.marketbeat.com/logos/takeda-pharmaceutical-co-ltd-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T22:02:00-06:00", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": -0.533105, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.927974, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Hires Banks", "relevance": 0.186146, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Finance Shire Takeover", "relevance": 0.0721219, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Consumer Healthcare", "relevance": 0.0668929, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "OTC", "relevance": 0.0658898, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Endo International", "relevance": 0.0641815, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.505427, "label": "negative"}, "text": "US", "relevance": 0.0630922, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.249533, "label": "negative"}, "text": "DJIA", "relevance": 0.0612029, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.391918, "label": "positive"}, "text": "EU", "relevance": 0.0603349, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 year", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30.93 billion", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.86 billion", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$18.93", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$19.53", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$31.29", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.35%", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.15", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.61", "relevance": 0.0593288, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.84%", "relevance": 0.0593288, "type": "Quantity"}], "sentiment": {"document": {"score": -0.393428, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Media", "keywords": [{"text": "Media"}]}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended neutral on Wednesday, InfoTrie Sentiment reports.", "object": {"text": "about Takeda Pharmaceutical (OTCMKTS:TKPYY)", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "OTCMKTS"}, {"text": "TKPYY"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "headline", "tense": "present"}, "text": "headlines", "normalized": "headline"}}, {"subject": {"text": "trended neutral"}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended neutral on Wednesday, InfoTrie Sentiment reports.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "TKPYY)"}, "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended neutral on Wednesday, InfoTrie Sentiment reports.", "object": {"text": "neutral"}, "action": {"verb": {"text": "trend", "tense": "past"}, "text": "have trended", "normalized": "have trend"}}, {"subject": {"text": "The research group", "keywords": [{"text": "research group"}]}, "sentence": " The research group scores the sentiment of media coverage by reviewing more than 6,000 news and blog sources in real time.", "object": {"text": "the sentiment of media coverage", "keywords": [{"text": "sentiment"}, {"text": "media coverage"}], "entities": []}, "action": {"verb": {"text": "score", "tense": "present"}, "text": "scores", "normalized": "score"}}, {"subject": {"text": "The research group scores", "keywords": [{"text": "research group scores"}]}, "sentence": " The research group scores the sentiment of media coverage by reviewing more than 6,000 news and blog sources in real time.", "object": {"text": "more than 6,000 news and blog", "keywords": [{"text": "news"}, {"text": "blog"}]}, "action": {"verb": {"text": "review", "tense": "present"}, "text": "reviewing", "normalized": "review"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable.", "object": {"text": "coverage of public companies", "keywords": [{"text": "public companies"}, {"text": "coverage"}], "entities": []}, "action": {"verb": {"text": "rank", "tense": "present"}, "text": "ranks", "normalized": "rank"}}, {"subject": {"text": "scores", "keywords": [{"text": "scores"}]}, "sentence": " The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable.", "object": {"text": "the most favorable"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical earned a media sentiment score of 0.23 on their scale.", "object": {"text": "a media sentiment score of 0.23", "keywords": [{"text": "media sentiment score"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "InfoTrie", "keywords": [{"text": "InfoTrie"}]}, "sentence": " InfoTrie also assigned media coverage about the company an news buzz score of 7 out of 10, meaning that recent media coverage is likely to have an effect on the company\u2019s share price in the next several days.", "object": {"text": "media coverage", "keywords": [{"text": "media coverage"}], "entities": []}, "action": {"verb": {"text": "assign", "tense": "past"}, "text": "assigned", "normalized": "assign"}}, {"subject": {"text": "InfoTrie", "keywords": [{"text": "InfoTrie"}]}, "sentence": " InfoTrie also assigned media coverage about the company an news buzz score of 7 out of 10, meaning that recent media coverage is likely to have an effect on the company\u2019s share price in the next several days.", "object": {"text": "that recent media coverage is likely to have an effect on the company\u2019s share price in the next several days", "keywords": [{"text": "recent media coverage"}, {"text": "share price"}, {"text": "effect"}, {"text": "company"}], "entities": []}, "action": {"verb": {"text": "mean", "tense": "present"}, "text": "meaning", "normalized": "mean"}}, {"subject": {"text": "recent media coverage", "keywords": [{"text": "recent media coverage"}], "entities": []}, "sentence": " InfoTrie also assigned media coverage about the company an news buzz score of 7 out of 10, meaning that recent media coverage is likely to have an effect on the company\u2019s share price in the next several days.", "object": {"text": "an effect on the company\u2019s share price", "keywords": [{"text": "effect"}, {"text": "share price"}, {"text": "company"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "to have", "normalized": "to have"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " InfoTrie also assigned media coverage about the company an news buzz score of 7 out of 10, meaning that recent media coverage is likely to have an effect on the company\u2019s share price in the next several days.", "object": {"text": "share price", "keywords": [{"text": "share price"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "some of the media headlines", "keywords": [{"text": "media headlines"}]}, "sentence": " These are some of the media headlines that may have impacted Takeda Pharmaceutical\u2019s score:", "object": {"text": "impacted Takeda Pharmaceutical\u2019s score", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "score"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "some of the media headlines", "keywords": [{"text": "media headlines"}]}, "sentence": " These are some of the media headlines that may have impacted Takeda Pharmaceutical\u2019s score:", "object": {"text": "Takeda Pharmaceutical\u2019s score", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "score"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "may have impacted", "normalized": "may have impact"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.48.", "object": {"text": "a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.48", "keywords": [{"text": "current ratio"}, {"text": "quick ratio"}, {"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market cap of $30.93 billion, a P/E ratio of 14.45 and a beta of 0.44.", "object": {"text": "a market cap of $30.93 billion, a P/E ratio of 14.45 and a beta of 0.44", "keywords": [{"text": "market cap"}, {"text": "P/E ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$30.93 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical has a 1 year low of $18.93 and a 1 year high of $31.29.", "object": {"text": "a 1 year low of $18.93 and a 1 year high of $31.29", "entities": [{"type": "Quantity", "text": "1 year"}, {"type": "Quantity", "text": "$18.93"}, {"type": "Quantity", "text": "$31.29"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical (OTCMKTS:TKPYY)", "keywords": [{"text": "(OTCMKTS:TKPYY)"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical (OTCMKTS:TKPYY) last announced its quarterly earnings results on Wednesday, October 31st.", "object": {"text": "its quarterly earnings results", "keywords": [{"text": "quarterly earnings"}, {"text": "results"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported $0.61 earnings per share for the quarter.", "object": {"text": "$0.61 earnings per share", "keywords": [{"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$0.61"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company had revenue of $3.86 billion during the quarter.", "object": {"text": "revenue of $3.86 billion", "keywords": [{"text": "revenue"}], "entities": [{"type": "Quantity", "text": "$3.86 billion"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical had a return on equity of 11.35% and a net margin of 7.84%.", "object": {"text": "a return on equity of 11.35% and a net margin of 7.84%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "11.35"}, {"type": "Quantity", "text": "7.84"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}]}, "sentence": " Separately, ValuEngine upgraded Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "object": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Separately, ValuEngine upgraded Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Neutral Media Coverage", "keywords": [{"text": "Neutral Media Coverage"}], "entities": []}, "sentence": " TRADEMARK VIOLATION WARNING: \u201cNeutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price\u201d was first published the sole property of of viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law.", "object": {"text": "Takeda Pharmaceutical (TKPYY) Stock Price", "keywords": [{"text": "Stock Price"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "Affect", "tense": "future"}, "text": "to Affect", "normalized": "to Affect"}}, {"subject": {"text": "Neutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price\u201d", "keywords": [{"text": "Neutral Media Coverage"}, {"text": "Stock Price"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " TRADEMARK VIOLATION WARNING: \u201cNeutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price\u201d was first published the sole property of of viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "this article", "keywords": [{"text": "article"}]}, "sentence": " TRADEMARK VIOLATION WARNING: \u201cNeutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price\u201d was first published the sole property of of viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law.", "object": {"text": "on another website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "viewing", "normalized": "view"}}, {"subject": {"text": "it"}, "sentence": " TRADEMARK VIOLATION WARNING: \u201cNeutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price\u201d was first published the sole property of of viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law.", "action": {"verb": {"text": "reposted", "tense": "past"}, "text": "reposted", "normalized": "reposted"}}, {"subject": {"text": "It"}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "prescription, OTC, and quasi-drugs", "keywords": [{"text": "OTC"}, {"text": "prescription"}, {"text": "quasi-drugs"}], "entities": [{"type": "Company", "text": "OTC"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "oncology, gastroenterology, central nervous system (CNS), vaccines, and others", "keywords": [{"text": "gastroenterology"}, {"text": "vaccines"}], "entities": []}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "reagents in various therapeutic areas", "keywords": [{"text": "various therapeutic areas"}, {"text": "reagents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}], "concepts": [{"text": "Stock", "relevance": 0.948839, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Dow Jones Industrial Average", "relevance": 0.94661, "dbpedia_resource": "http://dbpedia.org/resource/Dow_Jones_Industrial_Average"}, {"text": "Financial ratio", "relevance": 0.79242, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Financial ratios", "relevance": 0.68889, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Stock market", "relevance": 0.668867, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Central nervous system", "relevance": 0.631984, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.6141, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmacology", "relevance": 0.606524, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Trademark", "relevance": 0.581727, "dbpedia_resource": "http://dbpedia.org/resource/Trademark"}, {"text": "Revenue", "relevance": 0.539014, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Dow Jones & Company", "relevance": 0.519302, "dbpedia_resource": "http://dbpedia.org/resource/Dow_Jones_&_Company"}], "categories": [{"score": 0.583503, "label": "/finance/financial news"}, {"score": 0.538986, "label": "/finance/investing/stocks"}, {"score": 0.379086, "label": "/finance/investing/day trading"}], "relations": [{"type": "partOf", "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended neutral on Wednesday, InfoTrie Sentiment reports.", "score": 0.303859, "arguments": [{"text": "Media", "location": [0, 5], "entities": [{"type": "Organization", "text": "Media Coverage Likely to Affect Takeda Pharmaceutical"}]}, {"text": "Takeda Pharmaceutical", "location": [22, 43], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Media headlines about Takeda Pharmaceutical (OTCMKTS:TKPYY) have trended neutral on Wednesday, InfoTrie Sentiment reports.", "score": 0.992826, "arguments": [{"text": "InfoTrie Sentiment", "location": [95, 113], "entities": [{"type": "Organization", "text": "InfoTrie Sentiment", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reports", "location": [114, 121], "entities": [{"type": "EventCommunication", "text": "reports"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical earned a media sentiment score of 0.23 on their scale.", "score": 0.766519, "arguments": [{"text": "Takeda Pharmaceutical", "location": [381, 402], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "earned", "location": [403, 409], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "partOf", "sentence": "InfoTrie also assigned media coverage about the company an news buzz score of 7 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the next several days.", "score": 0.61169, "arguments": [{"text": "media", "location": [481, 486], "entities": [{"type": "Organization", "text": "media-", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [506, 513], "entities": [{"type": "Organization", "text": "Endo International for"}]}]}, {"type": "hasAttribute", "sentence": "Takeda Pharmaceutical (OTCMKTS:TKPYY) last announced its quarterly earnings results on Wednesday, October 31st.", "score": 0.916727, "arguments": [{"text": "Takeda Pharmaceutical", "location": [1735, 1756], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TKPYY", "location": [1766, 1771], "entities": [{"type": "Ticker", "text": "TKPYY"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical (OTCMKTS:TKPYY) last announced its quarterly earnings results on Wednesday, October 31st.", "score": 0.643326, "arguments": [{"text": "Takeda Pharmaceutical", "location": [1735, 1756], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [1778, 1787], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The company reported $0.61 earnings per share for the quarter.", "score": 0.851261, "arguments": [{"text": "company", "location": [1851, 1858], "entities": [{"type": "Organization", "text": "Endo International for"}]}, {"text": "reported", "location": [1859, 1867], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "Recommended Story: What is the Dow Jones Industrial Average (DJIA)?", "score": 0.968383, "arguments": [{"text": "Dow Jones Industrial Average", "location": [3155, 3183], "entities": [{"type": "Organization", "text": "Dow Jones Industrial Average", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "DJIA", "location": [3185, 3189], "entities": [{"type": "Ticker", "text": "DJIA"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.533105, "label": "negative"}, "relevance": 0.987536}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.732352}, {"text": "Takeda Hires Banks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.654442}, {"text": "media coverage", "sentiment": {"score": -0.342647, "label": "negative"}, "relevance": 0.64321}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581343}, {"text": "InfoTrie Sentiment reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522147}, {"text": "media sentiment score", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521668}, {"text": "recent media coverage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512312}, {"text": "Coverage Extremely Likely", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507729}, {"text": "Media Coverage Likely", "sentiment": {"score": -0.342647, "label": "negative"}, "relevance": 0.504822}, {"text": "news buzz score", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499572}, {"text": "Finance Shire Takeover", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499285}, {"text": "quarterly earnings results", "sentiment": {"score": -0.324471, "label": "negative"}, "relevance": 0.496408}, {"text": "Stock Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.494817}, {"text": "Jones Industrial Average", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488177}, {"text": "various therapeutic areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487525}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462923}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462843}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462763}, {"text": "P/E ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462241}, {"text": "media headlines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460973}, {"text": "pharmaceutical products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460614}, {"text": "research group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459511}, {"text": "real time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45902}, {"text": "public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458655}, {"text": "blog sources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458416}, {"text": "Endo International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454315}, {"text": "Moody\u2019s assigns", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454201}, {"text": "share price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454118}, {"text": "Revenue Projections", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453826}, {"text": "average volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45243}, {"text": "TRADEMARK VIOLATION", "sentiment": {"score": -0.620049, "label": "negative"}, "relevance": 0.451681}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45152}, {"text": "EU approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451447}, {"text": "Euro Bonds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450603}, {"text": "market cap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450527}, {"text": "net margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450189}, {"text": "Prescription Drug", "sentiment": {"score": -0.258, "label": "negative"}, "relevance": 0.450123}, {"text": "original version", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449314}, {"text": "Consumer Healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44904}, {"text": "sole property", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447855}, {"text": "research note", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447078}, {"text": "trademark law", "sentiment": {"score": -0.505427, "label": "negative"}, "relevance": 0.446918}, {"text": "international copyright", "sentiment": {"score": -0.505427, "label": "negative"}, "relevance": 0.445707}, {"text": "Wednesday", "sentiment": {"score": -0.417351, "label": "negative"}, "relevance": 0.430897}, {"text": "rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423412}, {"text": "OTCMKTS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418456}]}, "extracted_metadata": {"sha1": "47552d4e96e2031029634d3f3fa0125fcecf01aa", "filename": "1542257392101.zip-39ff843f9b0e963244840aae8f6b9c27.xml", "file_type": "json"}, "external_links": ["https://finance.yahoo.com/news/takeda-hires-banks-euro-bonds-173612913.html?.tsrc=rss", "https://www.marketbeat.com/stocks/OTCMKTS/TKPYY/news/", "https://www.marketbeat.com/financial-terms/what-is-dow-jones-industrial-average/", "https://finance.yahoo.com/m/87a19495-f535-30c3-8dab-630c18b90e4d/revenue-projections-for-endo.html?.tsrc=rss", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&#038;Symbol=TKPYY", "https://www.americanbankingnews.com/?p=8568338", "https://finance.yahoo.com/news/exclusive-eu-regulators-clear-62-163313637.html?.tsrc=rss", "https://finance.yahoo.com/m/cdbb93e9-de66-3d99-8c59-b90e757c6813/takeda-pharmaceutical-company.html?.tsrc=rss", "https://www.marketbeat.com/newsletter/default.aspx"], "title": "Neutral Media Coverage Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price", "forum_title": "TheOlympiaReport"}, {"id": "dyM15l08QWpSv0dHtL3E0wl7GL7qMVH5OtvHTnngJiRS4XlEmmlg2mfyh0hwigia", "result_metadata": {"score": 32.02513}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.333048, "label": "negative"}, "text": "SRS Pharmaceuticals Pvt. ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.254318, "label": "positive"}, "text": "Healthy Life Pharma Private Limited", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.474035, "label": "negative"}, "text": "Troikaa Pharmaceuticals Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.333048, "label": "negative"}, "text": "Anal Fissure", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$ 2.6 Billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.882194, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "$ 2.6 Billion", "entities": [{"type": "Quantity", "text": "$ 2.6 Billion"}]}, "sentence": "Anal Fissure Treatment Market 2018 Expected To Reach $ 2.6 Billion By The End Of 2023 | Top Key Players SRS Pharmaceuticals Pvt. ltd., Healthy Life Pharma Private Limited, Takeda Pharmaceutical Company Limited, Troikaa Pharmaceuticals Ltd and others", "object": {"text": "By The End Of 2023 | Top Key Players SRS Pharmaceuticals Pvt. ltd., Healthy Life Pharma Private Limited, Takeda Pharmaceutical Company Limited, Troikaa Pharmaceuticals Ltd and others", "keywords": [{"text": "Players SRS Pharmaceuticals"}, {"text": "Healthy Life Pharma"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Troikaa Pharmaceuticals"}], "entities": [{"type": "Company", "text": "SRS Pharmaceuticals Pvt. ltd."}, {"type": "Company", "text": "Healthy Life Pharma Private Limited"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Troikaa Pharmaceuticals Ltd"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "To Reach", "normalized": "To Reach"}}], "concepts": [{"text": "Anal fissure", "relevance": 0.94732, "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}, {"text": "Medicine", "relevance": 0.680077, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.669766, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmacy", "relevance": 0.645326, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5874, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical drug", "relevance": 0.56296, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}], "categories": [{"score": 0.687476, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.481038, "label": "/health and fitness/drugs"}], "relations": [{"type": "partOf", "sentence": "Anal Fissure Treatment Market 2018 Expected To Reach $ 2.6 Billion By The End Of 2023 | Top Key Players SRS Pharmaceuticals Pvt. ltd., Healthy Life Pharma Private Limited, Takeda Pharmaceutical Company Limited, Troikaa Pharmaceuticals Ltd and others", "score": 0.530755, "arguments": [{"text": "Key Players SRS Pharmaceuticals Pvt. ltd.", "location": [92, 133], "entities": [{"type": "Organization", "text": "Key Players SRS Pharmaceuticals Pvt. ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Healthy Life Pharma Private Limited", "location": [135, 170], "entities": [{"type": "Organization", "text": "Healthy Life Pharma Private Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anal Fissure Treatment", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.938218}, {"text": "Players SRS Pharmaceuticals", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.925305}, {"text": "Healthy Life Pharma", "sentiment": {"score": 0.254318, "label": "positive"}, "relevance": 0.788573}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763145}, {"text": "Troikaa Pharmaceuticals", "sentiment": {"score": -0.474035, "label": "negative"}, "relevance": 0.643898}, {"text": "Pvt. ltd.", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.495116}, {"text": "Private Limited", "sentiment": {"score": 0.254318, "label": "positive"}, "relevance": 0.489451}, {"text": "Expected", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.401731}, {"text": "Market", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.327154}, {"text": "End", "sentiment": {"score": -0.333048, "label": "negative"}, "relevance": 0.326433}]}, "crawl_date": "2018-11-14T15:29:28Z", "url": "https://www.openpr.com/news/1370749/Anal-Fissure-Treatment-Market-2018-Expected-To-Reach-2-6-Billion-By-The-End-Of-2023-Top-Key-Players-SRS-Pharmaceuticals-Pvt-ltd-Healthy-Life-Pharma-Private-Limited-Takeda-Pharmaceutical-Company-Limited-Troikaa-Pharmaceuticals-Ltd-and-others.html", "host": "openpr.com", "text": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T15:17:00Z", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": -0.627211, "label": "negative"}, "text": "anal fissure", "relevance": 0.9328, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"count": 1, "sentiment": {"score": -0.915672, "label": "negative"}, "text": "anal canal", "relevance": 0.216768, "type": "Anatomy"}, {"count": 5, "sentiment": {"score": 0.336637, "label": "positive"}, "text": "US", "relevance": 0.1649, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.148998, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 4, "sentiment": {"score": -0.718349, "label": "negative"}, "text": "Africa", "relevance": 0.127122, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Saudi Arabia", "relevance": 0.120766, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"count": 3, "sentiment": {"score": -0.534094, "label": "negative"}, "text": "Europe", "relevance": 0.108361, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.673336, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.107673, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "UAE", "relevance": 0.103912, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SRS Pharmaceuticals Pvt. ltd.", "relevance": 0.100554, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0972722, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.362612, "label": "negative"}, "text": "immunodeficiency", "relevance": 0.0920775, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.0895489, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.465854, "label": "negative"}, "text": "Geri-Care Pharmaceuticals", "relevance": 0.0889314, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.0888217, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0.254982, "label": "positive"}, "text": "Healthy Life Pharma Private Limited", "relevance": 0.0873052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Taj Pharmaceuticals Ltd.", "relevance": 0.0851329, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AIDS", "relevance": 0.0845523, "type": "HealthCondition", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}, {"count": 2, "sentiment": {"score": -0.284622, "label": "negative"}, "text": "North America", "relevance": 0.0845409, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.29412, "label": "negative"}, "text": "Troikaa Pharmaceuticals Ltd.", "relevance": 0.0840927, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.0778283, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.0741174, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0741174, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2023", "relevance": 0.0741174, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.2%", "relevance": 0.0741174, "type": "Quantity"}], "sentiment": {"document": {"score": -0.52416, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Market Research Future", "keywords": [{"text": "Market Research Future"}]}, "sentence": "Press release from: Market Research Future Anal fissure treatment Market An expert on premium research reports, Market Research Future has added a report titled \" Anal Fissure Treatment Market Research Report- Global Forecast till 2023\" to its offering.", "object": {"text": "added a report titled \" Anal Fissure Treatment Market Research Report- Global Forecast till 2023\" to its offering", "keywords": [{"text": "Anal Fissure Treatment"}, {"text": "Report- Global Forecast"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"type": "Quantity", "text": "2023\""}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top Market Players across the Globe.", "object": {"text": "an in-depth analysis of regional data and an accurate projection of the market size and share of the Top Market Players across the Globe", "keywords": [{"text": "accurate projection"}, {"text": "in-depth analysis"}, {"text": "regional data"}, {"text": "market size"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The global anal fissure treatment market", "keywords": [{"text": "global anal fissure"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " The global anal fissure treatment market is expected to attain USD 2.6 Bn and capture a CAGR of 5.2% over the forecast period of 2017-2023.", "object": {"text": "USD", "keywords": [{"text": "USD"}]}, "action": {"verb": {"text": "attain", "tense": "future"}, "text": "is expected to attain", "normalized": "be expect to attain"}}, {"subject": {"text": "An anal fissure", "keywords": [{"text": "anal fissure"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation", "keywords": [{"text": "painful medical condition"}, {"text": "anal canal"}, {"text": "defecation"}, {"text": "bleeding"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"type": "Anatomy", "text": "anal canal"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the anal canal", "keywords": [{"text": "anal canal"}], "entities": [{"type": "Anatomy", "text": "anal canal"}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "torn"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the anal canal", "keywords": [{"text": "anal canal"}], "entities": [{"type": "Anatomy", "text": "anal canal"}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "by pain and bleeding", "keywords": [{"text": "bleeding"}, {"text": "pain"}]}, "action": {"verb": {"text": "tear", "tense": "past"}, "text": "has been torn", "normalized": "have be tear"}}, {"subject": {"text": "There"}, "sentence": " There has been a steep rise in the incidence of anal fissures which is, in turn, propelling the market for anal fissure treatment.", "object": {"text": "been a steep rise", "keywords": [{"text": "steep rise"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The anal fissure market", "keywords": [{"text": "anal fissure market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " The anal fissure market is primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc.", "object": {"text": "primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "immunodeficiency syndrome"}, {"text": "constipation"}, {"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "immunodeficiency", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"type": "HealthCondition", "text": "AIDS", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "immunodeficiency syndrome"}, {"text": "constipation"}, {"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "immunodeficiency", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"type": "HealthCondition", "text": "AIDS", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}]}, "sentence": " The anal fissure market is primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc.", "object": {"text": "The anal fissure market", "keywords": [{"text": "anal fissure market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is primarily driven", "normalized": "be primarily drive"}}, {"subject": {"text": "The rise in the geriatric population", "keywords": [{"text": "geriatric population"}, {"text": "rise"}]}, "sentence": " The rise in the geriatric population who are at a higher risk of developing anal fissures owing to decreased blood flow to the anus is also a chief driver of the market.", "object": {"text": "at a higher risk of developing anal fissures owing to decreased blood flow to the anus is also a chief driver of the market", "keywords": [{"text": "anal fissures"}, {"text": "higher risk"}, {"text": "chief driver"}, {"text": "blood flow"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle", "keywords": [{"text": "Bad eating habits"}, {"text": "sedentary lifestyle"}, {"text": "hectic life"}]}, "sentence": " Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for anal fissure treatment.", "action": {"verb": {"text": "observe", "tense": "past"}, "text": "observed", "normalized": "observe"}}, {"subject": {"text": "all age groups", "keywords": [{"text": "age groups"}]}, "sentence": " Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for anal fissure treatment.", "object": {"text": "even driving the market for anal fissure treatment", "keywords": [{"text": "anal fissure treatment"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups", "keywords": [{"text": "Bad eating habits"}, {"text": "sedentary lifestyle"}, {"text": "hectic life"}, {"text": "age groups"}]}, "sentence": " Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for anal fissure treatment.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are even driving", "normalized": "be even drive"}}, {"subject": {"text": "Sample Copy", "keywords": [{"text": "Sample Copy"}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global anal fissure treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "@ www.marketresearchfuture.com/sample_request/3841 Segments: The global anal fissure treatment market", "keywords": [{"text": "global anal fissure"}, {"text": "Segments"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "Get", "tense": "present"}, "text": "Get", "normalized": "Get"}}, {"subject": {"text": "The global anal fissure treatment market", "keywords": [{"text": "global anal fissure"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global anal fissure treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "segmented on the basis of drugs and surgery", "keywords": [{"text": "drugs"}, {"text": "basis"}, {"text": "surgery"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global anal fissure treatment market", "keywords": [{"text": "global anal fissure"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global anal fissure treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "on the basis of drugs and surgery", "keywords": [{"text": "drugs"}, {"text": "basis"}, {"text": "surgery"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on drugs, the market has been segmented as topical nitroglycerin, calcium channel blockers, stool softeners, and others.", "object": {"text": "as topical nitroglycerin, calcium channel blockers, stool softeners, and others", "keywords": [{"text": "calcium channel blockers"}, {"text": "topical nitroglycerin"}, {"text": "stool softeners"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "object": {"text": "segmented as lateral internal sphincterotomy", "keywords": [{"text": "lateral internal sphincterotomy"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Regional analysis US", "keywords": [{"text": "Regional analysis"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Regional analysis US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare.", "object": {"text": "for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare", "keywords": [{"text": "favorable reimbursement scenario"}, {"text": "maximum market share"}, {"text": "greater expenditure"}, {"text": "healthcare"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe is the second largest market due to large disposable income and rising awareness.", "object": {"text": "the second largest market due to large disposable income and rising awareness", "keywords": [{"text": "large disposable income"}, {"text": "largest market"}, {"text": "awareness"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia Pacific region", "keywords": [{"text": "Asia Pacific region"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "the fastest growing region", "keywords": [{"text": "fastest growing region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "large unmet needs", "keywords": [{"text": "large unmet needs"}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "led by China and India", "keywords": [{"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by China and India", "keywords": [{"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "large unmet needs", "keywords": [{"text": "large unmet needs"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "is led", "normalized": "be lead"}}, {"subject": {"text": "The Middle East & Africa market", "keywords": [{"text": "Middle East"}, {"text": "Africa market"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "object": {"text": "led by the gulf nations particularly Saudi Arabia and UAE", "keywords": [{"text": "Saudi Arabia"}, {"text": "gulf nations"}, {"text": "UAE"}], "entities": [{"type": "Location", "text": "Saudi Arabia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"type": "Location", "text": "UAE", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the gulf nations particularly Saudi Arabia and UAE", "keywords": [{"text": "Saudi Arabia"}, {"text": "gulf nations"}, {"text": "UAE"}], "entities": [{"type": "Location", "text": "Saudi Arabia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"type": "Location", "text": "UAE", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}]}, "sentence": " The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "object": {"text": "The Middle East & Africa market", "keywords": [{"text": "Middle East"}, {"text": "Africa market"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "is led", "normalized": "be lead"}}, {"subject": {"text": "The poor regions of Africa", "keywords": [{"text": "poor regions"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.", "object": {"text": "a laggard due to poor economic and political conditions and poor healthcare penetration", "keywords": [{"text": "poor healthcare penetration"}, {"text": "political conditions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Regional Analysis The key markets of the global anal fissure treatment market", "keywords": [{"text": "global anal fissure"}, {"text": "Regional Analysis"}, {"text": "key markets"}, {"text": "treatment market"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " Regional Analysis The key markets of the global anal fissure treatment market are North America, Europe, Asia-Pacific, and the Middle East & Africa.", "object": {"text": "North America, Europe, Asia-Pacific, and the Middle East & Africa", "keywords": [{"text": "North America"}, {"text": "Asia-Pacific"}, {"text": "Middle East"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of anal fissure treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "estimated to lead the market owing to unmet medical needs of a large population pool", "keywords": [{"text": "large population pool"}, {"text": "medical needs"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of anal fissure treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "to lead the market owing to unmet medical needs of a large population pool and falling prices of anal fissure treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region", "keywords": [{"text": "anal fissure treatment"}, {"text": "large population pool"}, {"text": "increased expenditure"}, {"text": "disposable income"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of anal fissure treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "is estimated to lead", "normalized": "be estimate to lead"}}, {"subject": {"text": "healthcare", "keywords": [{"text": "healthcare"}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of anal fissure treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "in disposable income in the region", "keywords": [{"text": "disposable income"}, {"text": "region"}]}, "action": {"verb": {"text": "rise", "tense": "future"}, "text": "to rise", "normalized": "to rise"}}, {"subject": {"text": "the economically and socially backward regions of Africa", "keywords": [{"text": "socially backward regions"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "object": {"text": "staggered growth", "keywords": [{"text": "staggered growth"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "are expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "The key players", "keywords": [{"text": "key players"}]}, "sentence": " Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others", "keywords": [{"text": "SRS Pharmaceuticals Pvt."}, {"text": "Taj Pharmaceuticals Ltd."}, {"text": "Troikaa Pharmaceuticals Ltd."}, {"text": "Geri-Care Pharmaceuticals"}], "entities": [{"type": "Company", "text": "SRS Pharmaceuticals Pvt. ltd."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Healthy Life Pharma Private Limited"}, {"type": "Company", "text": "Troikaa Pharmaceuticals Ltd."}, {"type": "Company", "text": "Taj Pharmaceuticals Ltd."}, {"type": "Company", "text": "Geri-Care Pharmaceuticals"}]}, "sentence": " Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "object": {"text": "Competitive Landscape The key players operating in the market", "keywords": [{"text": "Competitive Landscape"}, {"text": "key players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Anal fissure", "relevance": 0.948317, "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}, {"text": "Middle East", "relevance": 0.603604, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "Saudi Arabia", "relevance": 0.529647, "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}, {"text": "United Arab Emirates", "relevance": 0.521628, "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}, {"text": "Arabian Peninsula", "relevance": 0.485827, "dbpedia_resource": "http://dbpedia.org/resource/Arabian_Peninsula"}, {"text": "AIDS", "relevance": 0.460548, "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}, {"text": "Lateral internal sphincterotomy", "relevance": 0.439539, "dbpedia_resource": "http://dbpedia.org/resource/Lateral_internal_sphincterotomy"}, {"text": "Fecal incontinence", "relevance": 0.427859, "dbpedia_resource": "http://dbpedia.org/resource/Fecal_incontinence"}, {"text": "Jordan", "relevance": 0.376879, "dbpedia_resource": "http://dbpedia.org/resource/Jordan"}, {"text": "Arabic language", "relevance": 0.361422, "dbpedia_resource": "http://dbpedia.org/resource/Arabic_language"}, {"text": "Dietary fiber", "relevance": 0.352431, "dbpedia_resource": "http://dbpedia.org/resource/Dietary_fiber"}, {"text": "Nifedipine", "relevance": 0.344895, "dbpedia_resource": "http://dbpedia.org/resource/Nifedipine"}, {"text": "Gulf War", "relevance": 0.34348, "dbpedia_resource": "http://dbpedia.org/resource/Gulf_War"}, {"text": "Hemorrhoid", "relevance": 0.338503, "dbpedia_resource": "http://dbpedia.org/resource/Hemorrhoid"}, {"text": "Economics", "relevance": 0.337088, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Qatar", "relevance": 0.33221, "dbpedia_resource": "http://dbpedia.org/resource/Qatar"}, {"text": "Medicine", "relevance": 0.32314, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Africa", "relevance": 0.319882, "dbpedia_resource": "http://dbpedia.org/resource/Africa"}, {"text": "North Africa", "relevance": 0.31788, "dbpedia_resource": "http://dbpedia.org/resource/North_Africa"}, {"text": "Glyceryl trinitrate", "relevance": 0.317476, "dbpedia_resource": "http://dbpedia.org/resource/Glyceryl_trinitrate_(pharmacology)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.316702, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Inflammatory bowel disease", "relevance": 0.305014, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Region", "relevance": 0.304767, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "Kuwait", "relevance": 0.302957, "dbpedia_resource": "http://dbpedia.org/resource/Kuwait"}, {"text": "Immunodeficiency", "relevance": 0.299039, "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}, {"text": "Asia", "relevance": 0.298659, "dbpedia_resource": "http://dbpedia.org/resource/Asia"}, {"text": "Botulinum toxin", "relevance": 0.297128, "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}, {"text": "Asia-Pacific", "relevance": 0.296804, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Riyadh", "relevance": 0.296131, "dbpedia_resource": "http://dbpedia.org/resource/Riyadh"}, {"text": "Calcium channel blocker", "relevance": 0.290699, "dbpedia_resource": "http://dbpedia.org/resource/Calcium_channel_blocker"}, {"text": "Egypt", "relevance": 0.289878, "dbpedia_resource": "http://dbpedia.org/resource/Egypt"}, {"text": "Pruritus ani", "relevance": 0.28944, "dbpedia_resource": "http://dbpedia.org/resource/Pruritus_ani"}, {"text": "Marketing", "relevance": 0.285676, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Iran", "relevance": 0.28218, "dbpedia_resource": "http://dbpedia.org/resource/Iran"}, {"text": "Western Asia", "relevance": 0.275206, "dbpedia_resource": "http://dbpedia.org/resource/Western_Asia"}, {"text": "Indian Ocean", "relevance": 0.258865, "dbpedia_resource": "http://dbpedia.org/resource/Indian_Ocean"}, {"text": "Rectum", "relevance": 0.25466, "dbpedia_resource": "http://dbpedia.org/resource/Rectum"}, {"text": "Proctology", "relevance": 0.249492, "dbpedia_resource": "http://dbpedia.org/resource/Proctology"}, {"text": "Ulcerative colitis", "relevance": 0.244973, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Immune system", "relevance": 0.2434, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Persian Gulf", "relevance": 0.242991, "dbpedia_resource": "http://dbpedia.org/resource/Persian_Gulf"}, {"text": "Defecation", "relevance": 0.238793, "dbpedia_resource": "http://dbpedia.org/resource/Defecation"}, {"text": "Fissure", "relevance": 0.236161, "dbpedia_resource": "http://dbpedia.org/resource/Fissure"}, {"text": "Islam", "relevance": 0.234724, "dbpedia_resource": "http://dbpedia.org/resource/Islam"}, {"text": "Pharmacology", "relevance": 0.227128, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Tuberculosis", "relevance": 0.220468, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Obesity", "relevance": 0.2136, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}], "categories": [{"score": 0.720581, "label": "/health and fitness/disease/incontinence"}, {"score": 0.393433, "label": "/health and fitness/therapy"}, {"score": 0.374153, "label": "/health and fitness/disorders"}], "relations": [{"type": "partOf", "sentence": "The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top Market Players across the Globe.", "score": 0.413768, "arguments": [{"text": "Market Players", "location": [379, 393], "entities": [{"type": "Organization", "text": "Market Players"}]}, {"text": "Globe", "location": [405, 410], "entities": [{"type": "Organization", "text": "Globe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.512321, "arguments": [{"text": "PurduePharma L.P.", "location": [3481, 3498], "entities": [{"type": "Person", "text": "PurduePharma L.P."}]}, {"text": "others", "location": [3624, 3630], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.969672, "arguments": [{"text": "Geri", "location": [3593, 3597], "entities": [{"type": "Person", "text": "Geri"}]}, {"text": "others", "location": [3624, 3630], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.681845, "arguments": [{"text": "Care Pharmaceuticals", "location": [3598, 3618], "entities": [{"type": "Person", "text": "Care Pharmaceuticals"}]}, {"text": "others", "location": [3624, 3630], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "educatedAt", "sentence": "Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/anal-fissure-treatme... Detailed Table of Contents:", "score": 0.242855, "arguments": [{"text": "Figures", "location": [3717, 3724], "entities": [{"type": "Person", "text": "Figures"}]}, {"text": "Browse Complete 110 Pages Premium Research Report Enabled", "location": [3632, 3689], "entities": [{"type": "Organization", "text": "Browse Complete 110 Pages Premium Research Report Enabled"}]}]}, {"type": "employedBy", "sentence": "Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global anal fissure treatment market is segmented on the basis of drugs and surgery.", "score": 0.474903, "arguments": [{"text": "Segments", "location": [1436, 1444], "entities": [{"type": "Person", "text": "Segments"}]}, {"text": "Copy @ www.marketresearchfuture.com/sample_request/", "location": [1380, 1431], "entities": [{"type": "Organization", "text": "Copy @ www.marketresearchfuture.com/sample_request/"}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "score": 0.274851, "arguments": [{"text": "Asia", "location": [2133, 2137], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2138, 2145], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "score": 0.585286, "arguments": [{"text": "region", "location": [2146, 2152], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "Pacific", "location": [2138, 2145], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "score": 0.281002, "arguments": [{"text": "nations", "location": [2296, 2303], "entities": [{"type": "GeopoliticalEntity", "text": "nations", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "gulf", "location": [2291, 2295], "entities": [{"type": "GeographicFeature", "text": "gulf"}]}]}, {"type": "locatedAt", "sentence": "The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.", "score": 0.903042, "arguments": [{"text": "regions", "location": [2348, 2355], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [2359, 2365], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "score": 0.909489, "arguments": [{"text": "regions", "location": [3208, 3215], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [3219, 3225], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "The Gulf nations mainly Saudi Arabia and UAE are the major contributors of the Middle East and Africa market.", "score": 0.558278, "arguments": [{"text": "nations", "location": [3059, 3066], "entities": [{"type": "GeopoliticalEntity", "text": "nations", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Gulf", "location": [3054, 3058], "entities": [{"type": "Organization", "text": "Gulf", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "locatedAt", "sentence": "The Gulf nations mainly Saudi Arabia and UAE are the major contributors of the Middle East and Africa market.", "score": 0.292315, "arguments": [{"text": "contributors", "location": [3109, 3121], "entities": [{"type": "Person", "text": "contributors"}]}, {"text": "Middle East", "location": [3129, 3140], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "score": 0.870845, "arguments": [{"text": "healthcare facilities", "location": [3295, 3316], "entities": [{"type": "Facility", "text": "healthcare facilities"}]}, {"text": "region", "location": [3324, 3330], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}], "keywords": [{"text": "anal fissure treatment", "sentiment": {"score": -0.544586, "label": "negative"}, "relevance": 0.955342}, {"text": "global anal fissure", "sentiment": {"score": -0.524151, "label": "negative"}, "relevance": 0.684511}, {"text": "fissure treatment market", "sentiment": {"score": -0.505333, "label": "negative"}, "relevance": 0.627906}, {"text": "anal fissure market", "sentiment": {"score": -0.622224, "label": "negative"}, "relevance": 0.499757}, {"text": "Future Anal fissure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499033}, {"text": "anal fissures", "sentiment": {"score": -0.630431, "label": "negative"}, "relevance": 0.39299}, {"text": "Market Research Future", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348202}, {"text": "anal canal", "sentiment": {"score": -0.915672, "label": "negative"}, "relevance": 0.347138}, {"text": "anal dilation", "sentiment": {"score": -0.553832, "label": "negative"}, "relevance": 0.341315}, {"text": "Treatment Market Research", "sentiment": {"score": -0.44888, "label": "negative"}, "relevance": 0.323656}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.300361}, {"text": "maximum market share", "sentiment": {"score": 0.483453, "label": "positive"}, "relevance": 0.292529}, {"text": "faster market uptake", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292449}, {"text": "Report- Global Forecast", "sentiment": {"score": -0.44888, "label": "negative"}, "relevance": 0.284629}, {"text": "Africa market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.282701}, {"text": "premium research reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279684}, {"text": "favorable reimbursement", "sentiment": {"score": 0.573858, "label": "positive"}, "relevance": 0.27248}, {"text": "Market An expert", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272328}, {"text": "Taj Pharmaceuticals Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27209}, {"text": "large unmet needs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27206}, {"text": "Market Players", "sentiment": {"score": 0.611915, "label": "positive"}, "relevance": 0.27185}, {"text": "Pharmaceuticals Pvt. ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271694}, {"text": "market size", "sentiment": {"score": 0.611915, "label": "positive"}, "relevance": 0.271479}, {"text": "Troikaa Pharmaceuticals Ltd.", "sentiment": {"score": -0.29412, "label": "negative"}, "relevance": 0.271432}, {"text": "painful medical condition", "sentiment": {"score": -0.915672, "label": "negative"}, "relevance": 0.270489}, {"text": "poor healthcare penetration", "sentiment": {"score": -0.959094, "label": "negative"}, "relevance": 0.270169}, {"text": "favorable reimbursement scenario", "sentiment": {"score": 0.483453, "label": "positive"}, "relevance": 0.270123}, {"text": "fastest growing region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.269443}, {"text": "Asia Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268149}, {"text": "Premium Research Report", "sentiment": {"score": 0.494719, "label": "positive"}, "relevance": 0.267879}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.493527, "label": "negative"}, "relevance": 0.267862}, {"text": "Saudi Arabia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267816}, {"text": "calcium channel blockers", "sentiment": {"score": -0.277987, "label": "negative"}, "relevance": 0.26698}, {"text": "regional analysis", "sentiment": {"score": 0.198831, "label": "positive"}, "relevance": 0.266777}, {"text": "favorable reimbursement landscape", "sentiment": {"score": 0.664263, "label": "positive"}, "relevance": 0.266581}, {"text": "disposable income", "sentiment": {"score": -0.586214, "label": "negative"}, "relevance": 0.265826}, {"text": "large disposable income", "sentiment": {"score": -0.534094, "label": "negative"}, "relevance": 0.26553}, {"text": "lateral internal sphincterotomy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265404}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263857}, {"text": "gulf nations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263848}, {"text": "Life Pharma Private", "sentiment": {"score": 0.254982, "label": "positive"}, "relevance": 0.262905}, {"text": "large population pool", "sentiment": {"score": -0.673336, "label": "negative"}, "relevance": 0.261662}, {"text": "Bad eating habits", "sentiment": {"score": -0.83296, "label": "negative"}, "relevance": 0.26159}, {"text": "largest market", "sentiment": {"score": -0.534094, "label": "negative"}, "relevance": 0.261381}, {"text": "socially backward regions", "sentiment": {"score": -0.477604, "label": "negative"}, "relevance": 0.258402}, {"text": "regional data", "sentiment": {"score": 0.611915, "label": "positive"}, "relevance": 0.242447}, {"text": "Geri-Care Pharmaceuticals", "sentiment": {"score": -0.465854, "label": "negative"}, "relevance": 0.241468}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241114}, {"text": "steep rise", "sentiment": {"score": -0.706251, "label": "negative"}, "relevance": 0.240918}, {"text": "forecast period", "sentiment": {"score": -0.716522, "label": "negative"}, "relevance": 0.240796}]}, "extracted_metadata": {"sha1": "43c3b97d7a4bd6552a49aa90e86dfd08be764c81", "filename": "1542209368538.zip-dbe3498706159f15d45608f2bcc1f6a2.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/reports/anal-fissure-treatment-market-3841", "https://www.marketresearchfuture.com/sample_request/3841"], "title": "Anal Fissure Treatment Market 2018 Expected To Reach $ 2.6 Billion By The End Of 2023 | Top Key Players SRS Pharmaceuticals Pvt. ltd., Healthy Life Pharma Private Limited, Takeda Pharmaceutical Company Limited, Troikaa Pharmaceuticals Ltd and others", "forum_title": "openPR.com - Newsfeed"}, {"id": "DJigxIoEJ4sGwUGF-8FGHQrdSnLiIDcv_qOzZJ3wadRQvQSvkYmEpRB8tMSCBq5a", "result_metadata": {"score": 31.39148}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.503812, "label": "negative"}, "text": "Therapeutics Review", "relevance": 0.33, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly & Company", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Becton", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Becton Dickinson", "dbpedia_resource": "http://dbpedia.org/resource/Becton_Dickinson"}}], "sentiment": {"document": {"score": -0.615681, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Bristol-Myers Squibb", "relevance": 0.96844, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.812964, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "New York City", "relevance": 0.797135, "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}], "categories": [{"score": 0.619435, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.440737, "label": "/business and industrial/company"}, {"score": 0.438074, "label": "/health and fitness/disease/cancer"}], "relations": [], "keywords": [{"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.986347}, {"text": "Key Competitors Upto", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.974454}, {"text": "Appendiceal Cancer Treatment", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.960146}, {"text": "F. Hoffman-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.844714}, {"text": "Eli Lilly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.755399}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.698183}, {"text": "Therapeutics Review", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.686542}, {"text": "Clinical Trials", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.614193}, {"text": "Becton", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552504}, {"text": "Market", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.428499}, {"text": "AbbVie", "sentiment": {"score": -0.503812, "label": "negative"}, "relevance": 0.427453}]}, "crawl_date": "2018-11-14T15:29:28Z", "url": "https://www.openpr.com/news/1370767/Appendiceal-Cancer-Treatment-Market-2018-Clinical-Trials-and-Therapeutics-Review-and-Key-Competitors-Upto-2023-AbbVie-Inc-Pfizer-Inc-Eli-Lilly-Company-Bristol-Myers-Squibb-Company-F-Hoffman-La-Roche-Ltd-Becton-and-others.html", "host": "openpr.com", "text": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T15:28:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.640142, "label": "negative"}, "text": "Appendiceal Cancer Treatment", "relevance": 0.878877, "type": "Facility"}, {"count": 5, "sentiment": {"score": -0.746099, "label": "negative"}, "text": "anal fissure", "relevance": 0.534081, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"count": 1, "sentiment": {"score": -0.605728, "label": "negative"}, "text": "Appendiceal Cancer Treatment", "relevance": 0.41834, "type": "Company"}, {"count": 5, "sentiment": {"score": 0.132353, "label": "positive"}, "text": "US", "relevance": 0.340228, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.292561, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.915672, "label": "negative"}, "text": "anal canal", "relevance": 0.275508, "type": "Anatomy"}, {"count": 4, "sentiment": {"score": -0.718349, "label": "negative"}, "text": "Africa", "relevance": 0.269654, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Saudi Arabia", "relevance": 0.231922, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"count": 3, "sentiment": {"score": -0.534094, "label": "negative"}, "text": "Europe", "relevance": 0.216743, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.770256, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.205622, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "UAE", "relevance": 0.199361, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SRS Pharmaceuticals Pvt. ltd.", "relevance": 0.184552, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.176959, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.362612, "label": "negative"}, "text": "immunodeficiency", "relevance": 0.165839, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"count": 1, "sentiment": {"score": -0.465854, "label": "negative"}, "text": "Geri-Care Pharmaceuticals", "relevance": 0.164439, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.357539, "label": "negative"}, "text": "North America", "relevance": 0.163549, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.162851, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.254982, "label": "positive"}, "text": "Healthy Life Pharma Private Limited", "relevance": 0.160148, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Taj Pharmaceuticals Ltd.", "relevance": 0.158724, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.29412, "label": "negative"}, "text": "Troikaa Pharmaceuticals Ltd.", "relevance": 0.156392, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.152582, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AIDS", "relevance": 0.152342, "type": "HealthCondition", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.140107, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.134128, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.134128, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.2%", "relevance": 0.134128, "type": "Quantity"}], "sentiment": {"document": {"score": -0.62863, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Market Research Future Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment market", "keywords": [{"text": "Appendiceal Cancer Treatment"}, {"text": "Research Future Appendiceal"}, {"text": "Global Appendiceal Cancer"}, {"text": "cancer treatment market"}]}, "sentence": "Press release from: Market Research Future Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment market is expected to attain USD 2.6 Bn and capture a CAGR of 5.2% over the forecast period of 2017-2023.", "object": {"text": "USD", "keywords": [{"text": "USD"}]}, "action": {"verb": {"text": "attain", "tense": "future"}, "text": "is expected to attain", "normalized": "be expect to attain"}}, {"subject": {"text": "An anal fissure", "keywords": [{"text": "anal fissure"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation", "keywords": [{"text": "painful medical condition"}, {"text": "anal canal"}, {"text": "defecation"}, {"text": "bleeding"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}, {"type": "Anatomy", "text": "anal canal"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the anal canal", "keywords": [{"text": "anal canal"}], "entities": [{"type": "Anatomy", "text": "anal canal"}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "torn"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the anal canal", "keywords": [{"text": "anal canal"}], "entities": [{"type": "Anatomy", "text": "anal canal"}]}, "sentence": " An anal fissure is a painful medical condition where the anal canal has been torn and is accompanied by pain and bleeding during and after defecation.", "object": {"text": "by pain and bleeding", "keywords": [{"text": "bleeding"}, {"text": "pain"}]}, "action": {"verb": {"text": "tear", "tense": "past"}, "text": "has been torn", "normalized": "have be tear"}}, {"subject": {"text": "There"}, "sentence": " There has been a steep rise in the incidence of anal fissures which is, in turn, propelling the market for Appendiceal Cancer Treatment.", "object": {"text": "been a steep rise", "keywords": [{"text": "steep rise"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " There has been a steep rise in the incidence of anal fissures which is, in turn, propelling the market for Appendiceal Cancer Treatment.", "object": {"text": "for Appendiceal Cancer Treatment", "keywords": [{"text": "Appendiceal Cancer Treatment"}], "entities": [{"type": "Facility", "text": "Appendiceal Cancer Treatment"}]}, "action": {"verb": {"text": "propel", "tense": "present"}, "text": "propelling", "normalized": "propel"}}, {"subject": {"text": "The anal fissure market", "keywords": [{"text": "anal fissure market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "sentence": " The anal fissure market is primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc.", "object": {"text": "primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "immunodeficiency syndrome"}, {"text": "constipation"}, {"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "immunodeficiency", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"type": "HealthCondition", "text": "AIDS", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "immunodeficiency syndrome"}, {"text": "constipation"}, {"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "immunodeficiency", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Symptom", "Disease"], "name": "Immunodeficiency", "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}}, {"type": "HealthCondition", "text": "AIDS", "disambiguation": {"subtype": ["Organization", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease", "OrganizationSector"], "name": "AIDS", "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}}]}, "sentence": " The anal fissure market is primarily driven by growing prevalence of constipation, diarrhea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease, etc.", "object": {"text": "The anal fissure market", "keywords": [{"text": "anal fissure market"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is primarily driven", "normalized": "be primarily drive"}}, {"subject": {"text": "The rise in the geriatric population", "keywords": [{"text": "geriatric population"}, {"text": "rise"}]}, "sentence": " The rise in the geriatric population who are at a higher risk of developing anal fissures owing to decreased blood flow to the anus is also a chief driver of the market.", "object": {"text": "at a higher risk of developing anal fissures owing to decreased blood flow to the anus is also a chief driver of the market", "keywords": [{"text": "anal fissures"}, {"text": "higher risk"}, {"text": "chief driver"}, {"text": "blood flow"}], "entities": [{"type": "HealthCondition", "text": "anal fissure", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Anal fissure", "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle", "keywords": [{"text": "Bad eating habits"}, {"text": "sedentary lifestyle"}, {"text": "hectic life"}]}, "sentence": " Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for Appendiceal Cancer Treatment.", "action": {"verb": {"text": "observe", "tense": "past"}, "text": "observed", "normalized": "observe"}}, {"subject": {"text": "Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups", "keywords": [{"text": "Bad eating habits"}, {"text": "sedentary lifestyle"}, {"text": "hectic life"}, {"text": "age groups"}]}, "sentence": " Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for Appendiceal Cancer Treatment.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are even driving", "normalized": "be even drive"}}, {"subject": {"text": "Sample Copy", "keywords": [{"text": "Sample Copy"}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global Appendiceal Cancer Treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "@ www.marketresearchfuture.com/sample_request/3841 Segments", "keywords": [{"text": "Segments"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "Get", "tense": "present"}, "text": "Get", "normalized": "Get"}}, {"subject": {"text": "The global Appendiceal Cancer Treatment market", "keywords": [{"text": "global Appendiceal Cancer"}], "entities": [{"type": "Company", "text": "Appendiceal Cancer Treatment"}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global Appendiceal Cancer Treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "segmented on the basis of drugs and surgery", "keywords": [{"text": "drugs"}, {"text": "basis"}, {"text": "surgery"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global Appendiceal Cancer Treatment market", "keywords": [{"text": "global Appendiceal Cancer"}], "entities": [{"type": "Company", "text": "Appendiceal Cancer Treatment"}]}, "sentence": " Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global Appendiceal Cancer Treatment market is segmented on the basis of drugs and surgery.", "object": {"text": "on the basis of drugs and surgery", "keywords": [{"text": "drugs"}, {"text": "basis"}, {"text": "surgery"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on drugs, the market has been segmented as topical nitroglycerin, calcium channel blockers, stool softeners, and others.", "object": {"text": "as topical nitroglycerin, calcium channel blockers, stool softeners, and others", "keywords": [{"text": "calcium channel blockers"}, {"text": "topical nitroglycerin"}, {"text": "stool softeners"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on the surgery, the market has been segmented as lateral internal sphincterotomy, anal dilation and others.", "object": {"text": "segmented as lateral internal sphincterotomy", "keywords": [{"text": "lateral internal sphincterotomy"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Regional analysis US", "keywords": [{"text": "Regional analysis"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Regional analysis US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare.", "object": {"text": "for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare", "keywords": [{"text": "favorable reimbursement scenario"}, {"text": "maximum market share"}, {"text": "greater expenditure"}, {"text": "healthcare"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe is the second largest market due to large disposable income and rising awareness.", "object": {"text": "the second largest market due to large disposable income and rising awareness", "keywords": [{"text": "large disposable income"}, {"text": "largest market"}, {"text": "awareness"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia Pacific region", "keywords": [{"text": "Asia Pacific region"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "the fastest growing region", "keywords": [{"text": "fastest growing region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "large unmet needs", "keywords": [{"text": "large unmet needs"}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "led by China and India", "keywords": [{"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by China and India", "keywords": [{"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "object": {"text": "large unmet needs", "keywords": [{"text": "large unmet needs"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "is led", "normalized": "be lead"}}, {"subject": {"text": "The Middle East & Africa market", "keywords": [{"text": "Middle East"}, {"text": "Africa market"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "object": {"text": "led by the gulf nations particularly Saudi Arabia and UAE", "keywords": [{"text": "Saudi Arabia"}, {"text": "gulf nations"}, {"text": "UAE"}], "entities": [{"type": "Location", "text": "Saudi Arabia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"type": "Location", "text": "UAE", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the gulf nations particularly Saudi Arabia and UAE", "keywords": [{"text": "Saudi Arabia"}, {"text": "gulf nations"}, {"text": "UAE"}], "entities": [{"type": "Location", "text": "Saudi Arabia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"type": "Location", "text": "UAE", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}]}, "sentence": " The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "object": {"text": "The Middle East & Africa market", "keywords": [{"text": "Middle East"}, {"text": "Africa market"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "is led", "normalized": "be lead"}}, {"subject": {"text": "The poor regions of Africa", "keywords": [{"text": "poor regions"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.", "object": {"text": "a laggard due to poor economic and political conditions and poor healthcare penetration", "keywords": [{"text": "poor healthcare penetration"}, {"text": "political conditions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Regional Analysis The key markets of the global Appendiceal Cancer Treatment market", "keywords": [{"text": "global Appendiceal Cancer"}, {"text": "Regional Analysis"}, {"text": "key markets"}, {"text": "Treatment market"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Facility", "text": "Appendiceal Cancer Treatment"}]}, "sentence": " Regional Analysis The key markets of the global Appendiceal Cancer Treatment market are North America, Europe, Asia-Pacific, and the Middle East & Africa.", "object": {"text": "North America, Europe, Asia-Pacific, and the Middle East & Africa", "keywords": [{"text": "North America"}, {"text": "Asia-Pacific"}, {"text": "Middle East"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of Appendiceal Cancer Treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "estimated to lead the market owing to unmet medical needs of a large population pool", "keywords": [{"text": "large population pool"}, {"text": "medical needs"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of Appendiceal Cancer Treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "to lead the market owing to unmet medical needs of a large population pool and falling prices of Appendiceal Cancer Treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region", "keywords": [{"text": "Appendiceal Cancer Treatment"}, {"text": "large population pool"}, {"text": "increased expenditure"}, {"text": "disposable income"}], "entities": [{"type": "Company", "text": "Appendiceal Cancer Treatment"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of Appendiceal Cancer Treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "is estimated to lead", "normalized": "be estimate to lead"}}, {"subject": {"text": "healthcare", "keywords": [{"text": "healthcare"}]}, "sentence": " Asia-Pacific is estimated to lead the market owing to unmet medical needs of a large population pool and falling prices of Appendiceal Cancer Treatment, growing number of hospitals and increased expenditure on healthcare due to rise in disposable income in the region.", "object": {"text": "in disposable income in the region", "keywords": [{"text": "disposable income"}, {"text": "region"}]}, "action": {"verb": {"text": "rise", "tense": "future"}, "text": "to rise", "normalized": "to rise"}}, {"subject": {"text": "the economically and socially backward regions of Africa", "keywords": [{"text": "socially backward regions"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "object": {"text": "staggered growth", "keywords": [{"text": "staggered growth"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "are expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "The key players", "keywords": [{"text": "key players"}]}, "sentence": " Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others", "keywords": [{"text": "SRS Pharmaceuticals Pvt."}, {"text": "Taj Pharmaceuticals Ltd."}, {"text": "Troikaa Pharmaceuticals Ltd."}, {"text": "Geri-Care Pharmaceuticals"}], "entities": [{"type": "Company", "text": "SRS Pharmaceuticals Pvt. ltd."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Healthy Life Pharma Private Limited"}, {"type": "Company", "text": "Troikaa Pharmaceuticals Ltd."}, {"type": "Company", "text": "Taj Pharmaceuticals Ltd."}, {"type": "Company", "text": "Geri-Care Pharmaceuticals"}]}, "sentence": " Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "object": {"text": "Competitive Landscape The key players operating in the market", "keywords": [{"text": "Competitive Landscape"}, {"text": "key players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Anal fissure", "relevance": 0.943109, "dbpedia_resource": "http://dbpedia.org/resource/Anal_fissure"}, {"text": "Middle East", "relevance": 0.825989, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "United Arab Emirates", "relevance": 0.741298, "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}, {"text": "AIDS", "relevance": 0.739483, "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}, {"text": "Saudi Arabia", "relevance": 0.73432, "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}, {"text": "Arabian Peninsula", "relevance": 0.689239, "dbpedia_resource": "http://dbpedia.org/resource/Arabian_Peninsula"}, {"text": "Lateral internal sphincterotomy", "relevance": 0.57425, "dbpedia_resource": "http://dbpedia.org/resource/Lateral_internal_sphincterotomy"}, {"text": "Fecal incontinence", "relevance": 0.558472, "dbpedia_resource": "http://dbpedia.org/resource/Fecal_incontinence"}, {"text": "Jordan", "relevance": 0.531851, "dbpedia_resource": "http://dbpedia.org/resource/Jordan"}, {"text": "Gulf War", "relevance": 0.499725, "dbpedia_resource": "http://dbpedia.org/resource/Gulf_War"}, {"text": "Arabic language", "relevance": 0.491933, "dbpedia_resource": "http://dbpedia.org/resource/Arabic_language"}, {"text": "Qatar", "relevance": 0.483734, "dbpedia_resource": "http://dbpedia.org/resource/Qatar"}, {"text": "Dietary fiber", "relevance": 0.466499, "dbpedia_resource": "http://dbpedia.org/resource/Dietary_fiber"}, {"text": "North Africa", "relevance": 0.465099, "dbpedia_resource": "http://dbpedia.org/resource/North_Africa"}, {"text": "Medicine", "relevance": 0.462062, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Asia", "relevance": 0.456741, "dbpedia_resource": "http://dbpedia.org/resource/Asia"}, {"text": "Nifedipine", "relevance": 0.455699, "dbpedia_resource": "http://dbpedia.org/resource/Nifedipine"}, {"text": "Immune system", "relevance": 0.450073, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Hemorrhoid", "relevance": 0.441588, "dbpedia_resource": "http://dbpedia.org/resource/Hemorrhoid"}, {"text": "Kuwait", "relevance": 0.441404, "dbpedia_resource": "http://dbpedia.org/resource/Kuwait"}, {"text": "Africa", "relevance": 0.428928, "dbpedia_resource": "http://dbpedia.org/resource/Africa"}, {"text": "Riyadh", "relevance": 0.427295, "dbpedia_resource": "http://dbpedia.org/resource/Riyadh"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.423111, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Egypt", "relevance": 0.422745, "dbpedia_resource": "http://dbpedia.org/resource/Egypt"}, {"text": "Glyceryl trinitrate", "relevance": 0.415851, "dbpedia_resource": "http://dbpedia.org/resource/Glyceryl_trinitrate_(pharmacology)"}, {"text": "Iran", "relevance": 0.412018, "dbpedia_resource": "http://dbpedia.org/resource/Iran"}, {"text": "Inflammatory bowel disease", "relevance": 0.406927, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Obesity", "relevance": 0.406807, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Calcium channel blocker", "relevance": 0.403865, "dbpedia_resource": "http://dbpedia.org/resource/Calcium_channel_blocker"}, {"text": "Western Asia", "relevance": 0.400693, "dbpedia_resource": "http://dbpedia.org/resource/Western_Asia"}, {"text": "Immunodeficiency", "relevance": 0.40056, "dbpedia_resource": "http://dbpedia.org/resource/Immunodeficiency"}, {"text": "Asia-Pacific", "relevance": 0.39667, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Botulinum toxin", "relevance": 0.385373, "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}, {"text": "Indian Ocean", "relevance": 0.378662, "dbpedia_resource": "http://dbpedia.org/resource/Indian_Ocean"}, {"text": "Cancer", "relevance": 0.378607, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Pruritus ani", "relevance": 0.375402, "dbpedia_resource": "http://dbpedia.org/resource/Pruritus_ani"}, {"text": "Marketing", "relevance": 0.370519, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Region", "relevance": 0.366895, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "Persian Gulf", "relevance": 0.354363, "dbpedia_resource": "http://dbpedia.org/resource/Persian_Gulf"}, {"text": "Defecation", "relevance": 0.345289, "dbpedia_resource": "http://dbpedia.org/resource/Defecation"}, {"text": "Islam", "relevance": 0.343076, "dbpedia_resource": "http://dbpedia.org/resource/Islam"}, {"text": "Rectum", "relevance": 0.341049, "dbpedia_resource": "http://dbpedia.org/resource/Rectum"}, {"text": "Ulcerative colitis", "relevance": 0.338867, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Proctology", "relevance": 0.326546, "dbpedia_resource": "http://dbpedia.org/resource/Proctology"}, {"text": "United States", "relevance": 0.325012, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Tuberculosis", "relevance": 0.319816, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Overweight", "relevance": 0.319713, "dbpedia_resource": "http://dbpedia.org/resource/Overweight"}, {"text": "Disease", "relevance": 0.316528, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Pharmacology", "relevance": 0.313934, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Biopsy", "relevance": 0.30954, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}], "categories": [{"score": 0.743975, "label": "/health and fitness/disease/incontinence"}, {"score": 0.386624, "label": "/health and fitness/disease/heart disease"}, {"score": 0.353153, "label": "/health and fitness/disorders"}], "relations": [{"type": "hasAttribute", "sentence": "Press release from: Market Research Future Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment market is expected to attain USD 2.6 Bn and capture a CAGR of 5.2% over the forecast period of 2017-2023.", "score": 0.746317, "arguments": [{"text": "Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment", "location": [43, 118], "entities": [{"type": "Organization", "text": "Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment"}]}, {"text": "2.6 Bn", "location": [152, 158], "entities": [{"type": "Money", "text": "2.6 Bn", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "The Gulf nations mainly Saudi Arabia and UAE are the major contributors of the Middle East and Africa market.", "score": 0.292315, "arguments": [{"text": "contributors", "location": [2818, 2830], "entities": [{"type": "Person", "text": "contributors"}]}, {"text": "Middle East", "location": [2838, 2849], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "score": 0.870845, "arguments": [{"text": "healthcare facilities", "location": [3004, 3025], "entities": [{"type": "Facility", "text": "healthcare facilities"}]}, {"text": "region", "location": [3033, 3039], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.512321, "arguments": [{"text": "PurduePharma L.P.", "location": [3190, 3207], "entities": [{"type": "Person", "text": "PurduePharma L.P."}]}, {"text": "others", "location": [3333, 3339], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.969672, "arguments": [{"text": "Geri", "location": [3302, 3306], "entities": [{"type": "Person", "text": "Geri"}]}, {"text": "others", "location": [3333, 3339], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Competitive Landscape The key players operating in the market include SRS Pharmaceuticals Pvt. ltd., Takeda Pharmaceutical Company Limited, Novasep, PurduePharma L.P., Healthy Life Pharma Private Limited, Troikaa Pharmaceuticals Ltd., Taj Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, and others.", "score": 0.681845, "arguments": [{"text": "Care Pharmaceuticals", "location": [3307, 3327], "entities": [{"type": "Person", "text": "Care Pharmaceuticals"}]}, {"text": "others", "location": [3333, 3339], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "educatedAt", "sentence": "Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/anal-fissure-treatme... Detailed Table of Contents:", "score": 0.242855, "arguments": [{"text": "Figures", "location": [3426, 3433], "entities": [{"type": "Person", "text": "Figures"}]}, {"text": "Browse Complete 110 Pages Premium Research Report Enabled", "location": [3341, 3398], "entities": [{"type": "Organization", "text": "Browse Complete 110 Pages Premium Research Report Enabled"}]}]}, {"type": "partOf", "sentence": "Bad eating habits, leading to stressful and hectic life, and sedentary lifestyle observed among all age groups are even driving the market for Appendiceal Cancer Treatment.", "score": 0.596049, "arguments": [{"text": "age groups", "location": [981, 991], "entities": [{"type": "Organization", "text": "age groups"}]}, {"text": "Appendiceal Cancer Treatment", "location": [1024, 1052], "entities": [{"type": "Organization", "text": "Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment"}]}]}, {"type": "employedBy", "sentence": "Get Sample Copy @ www.marketresearchfuture.com/sample_request/3841 Segments: The global Appendiceal Cancer Treatment market is segmented on the basis of drugs and surgery.", "score": 0.456253, "arguments": [{"text": "Segments", "location": [1121, 1129], "entities": [{"type": "Person", "text": "Segments"}]}, {"text": "Copy @ www.marketresearchfuture.com/sample_request/", "location": [1065, 1116], "entities": [{"type": "Organization", "text": "Copy @ www.marketresearchfuture.com/sample_request/"}]}]}, {"type": "employedBy", "sentence": "The faster market uptake of new technology in the US is also an important driver of the market for global Appendiceal Cancer Treatment.", "score": 0.418421, "arguments": [{"text": "driver", "location": [1679, 1685], "entities": [{"type": "Person", "text": "chief driver"}]}, {"text": "Appendiceal Cancer Treatment", "location": [1711, 1739], "entities": [{"type": "Organization", "text": "Appendiceal Cancer Treatment Market The Global Appendiceal Cancer Treatment"}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "score": 0.274851, "arguments": [{"text": "Asia", "location": [1830, 1834], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [1835, 1842], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India.", "score": 0.585286, "arguments": [{"text": "region", "location": [1843, 1849], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "Pacific", "location": [1835, 1842], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE.", "score": 0.281002, "arguments": [{"text": "nations", "location": [1993, 2000], "entities": [{"type": "GeopoliticalEntity", "text": "nations", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "gulf", "location": [1988, 1992], "entities": [{"type": "GeographicFeature", "text": "gulf"}]}]}, {"type": "locatedAt", "sentence": "The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.", "score": 0.903042, "arguments": [{"text": "regions", "location": [2045, 2052], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [2056, 2062], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "However, the economically and socially backward regions of Africa are expected to exhibit staggered growth owing to low penetration of healthcare facilities in the region.", "score": 0.909489, "arguments": [{"text": "regions", "location": [2917, 2924], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [2928, 2934], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "The Gulf nations mainly Saudi Arabia and UAE are the major contributors of the Middle East and Africa market.", "score": 0.558278, "arguments": [{"text": "nations", "location": [2768, 2775], "entities": [{"type": "GeopoliticalEntity", "text": "nations", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Gulf", "location": [2763, 2767], "entities": [{"type": "Organization", "text": "Gulf", "disambiguation": {"subtype": ["Multigov"]}}]}]}], "keywords": [{"text": "Appendiceal Cancer Treatment", "sentiment": {"score": -0.632271, "label": "negative"}, "relevance": 0.919893}, {"text": "global appendiceal cancer", "sentiment": {"score": -0.550249, "label": "negative"}, "relevance": 0.665536}, {"text": "cancer treatment market", "sentiment": {"score": -0.55375, "label": "negative"}, "relevance": 0.560914}, {"text": "Future Appendiceal Cancer", "sentiment": {"score": -0.625867, "label": "negative"}, "relevance": 0.474117}, {"text": "anal fissure market", "sentiment": {"score": -0.622224, "label": "negative"}, "relevance": 0.447699}, {"text": "anal fissures", "sentiment": {"score": -0.638464, "label": "negative"}, "relevance": 0.42728}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405338}, {"text": "faster market uptake", "sentiment": {"score": -0.611863, "label": "negative"}, "relevance": 0.394588}, {"text": "maximum market share", "sentiment": {"score": 0.483453, "label": "positive"}, "relevance": 0.393195}, {"text": "Africa market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383804}, {"text": "anal canal", "sentiment": {"score": -0.915672, "label": "negative"}, "relevance": 0.381246}, {"text": "painful medical condition", "sentiment": {"score": -0.915672, "label": "negative"}, "relevance": 0.379434}, {"text": "favorable reimbursement", "sentiment": {"score": 0.573858, "label": "positive"}, "relevance": 0.377467}, {"text": "Taj Pharmaceuticals Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377163}, {"text": "large unmet needs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377162}, {"text": "Pharmaceuticals Pvt. ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376574}, {"text": "Troikaa Pharmaceuticals Ltd.", "sentiment": {"score": -0.29412, "label": "negative"}, "relevance": 0.376265}, {"text": "favorable reimbursement scenario", "sentiment": {"score": 0.483453, "label": "positive"}, "relevance": 0.375612}, {"text": "anal dilation", "sentiment": {"score": -0.553832, "label": "negative"}, "relevance": 0.375584}, {"text": "poor healthcare penetration", "sentiment": {"score": -0.959094, "label": "negative"}, "relevance": 0.375421}, {"text": "Market The Global", "sentiment": {"score": -0.625867, "label": "negative"}, "relevance": 0.375306}, {"text": "fastest growing region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373933}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.493527, "label": "negative"}, "relevance": 0.372611}, {"text": "Asia Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372294}, {"text": "Saudi Arabia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372211}, {"text": "regional analysis", "sentiment": {"score": 0.125914, "label": "positive"}, "relevance": 0.371681}, {"text": "calcium channel blockers", "sentiment": {"score": -0.277987, "label": "negative"}, "relevance": 0.371524}, {"text": "favorable reimbursement landscape", "sentiment": {"score": 0.664263, "label": "positive"}, "relevance": 0.371257}, {"text": "large disposable income", "sentiment": {"score": -0.534094, "label": "negative"}, "relevance": 0.370273}, {"text": "lateral internal sphincterotomy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369556}, {"text": "gulf nations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367421}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367371}, {"text": "Life Pharma Private", "sentiment": {"score": 0.254982, "label": "positive"}, "relevance": 0.366347}, {"text": "Bad eating habits", "sentiment": {"score": -0.838369, "label": "negative"}, "relevance": 0.365739}, {"text": "large population pool", "sentiment": {"score": -0.770256, "label": "negative"}, "relevance": 0.365449}, {"text": "Research Report Enabled", "sentiment": {"score": 0.494719, "label": "positive"}, "relevance": 0.364087}, {"text": "socially backward regions", "sentiment": {"score": -0.477604, "label": "negative"}, "relevance": 0.362067}, {"text": "largest market", "sentiment": {"score": -0.534094, "label": "negative"}, "relevance": 0.361231}, {"text": "steep rise", "sentiment": {"score": -0.722318, "label": "negative"}, "relevance": 0.34695}, {"text": "Geri-Care Pharmaceuticals", "sentiment": {"score": -0.465854, "label": "negative"}, "relevance": 0.344665}, {"text": "greater expenditure", "sentiment": {"score": 0.483453, "label": "positive"}, "relevance": 0.343425}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343116}, {"text": "hectic life", "sentiment": {"score": -0.791225, "label": "negative"}, "relevance": 0.34183}, {"text": "forecast period", "sentiment": {"score": -0.625867, "label": "negative"}, "relevance": 0.341698}, {"text": "immunodeficiency syndrome", "sentiment": {"score": -0.362612, "label": "negative"}, "relevance": 0.34129}, {"text": "stool softeners", "sentiment": {"score": -0.366811, "label": "negative"}, "relevance": 0.340886}, {"text": "topical nitroglycerin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34057}, {"text": "increased expenditure", "sentiment": {"score": -0.662564, "label": "negative"}, "relevance": 0.339816}, {"text": "healthcare technology", "sentiment": {"score": 0.664263, "label": "positive"}, "relevance": 0.339758}, {"text": "blood flow", "sentiment": {"score": -0.55461, "label": "negative"}, "relevance": 0.339201}]}, "extracted_metadata": {"sha1": "970a8e61edd347011a5262096322fd11a37f932d", "filename": "1542209368538.zip-d9b7694949facdfc33d6f017bb15afaa.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/reports/anal-fissure-treatment-market-3841", "https://www.marketresearchfuture.com/sample_request/3841"], "title": "Appendiceal Cancer Treatment Market 2018 Clinical Trials and Therapeutics Review and Key Competitors Upto 2023| AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton and others", "forum_title": "openPR.com - Newsfeed"}, {"id": "009vgdzx2oSyjkQQrJ-KljRWtKfmMfcMwrQLofVkH6-w69G8edVUDB81y6VZug0s", "result_metadata": {"score": 31.31805}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.451284, "label": "negative"}, "text": "Novartis AG", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Company Limited", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acetelion Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.451284, "label": "negative"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astra Zeneca", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ranbaxy Laboratories Limited, Inc.", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Global Peptic Ulcer Drugs Market", "keywords": [{"text": "Peptic Ulcer Drugs"}]}, "sentence": "Global Peptic Ulcer Drugs Market Is Expected To Reach USD 36.27 Billion By 2022 with Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc. and others", "object": {"text": "USD 36.27 Billion", "keywords": [{"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "Is Expected To Reach", "normalized": "Is Expected To Reach"}}], "concepts": [{"text": "Ranbaxy Laboratories", "relevance": 0.986385, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}, {"text": "Daiichi Sankyo", "relevance": 0.967985, "dbpedia_resource": "http://dbpedia.org/resource/Daiichi_Sankyo"}, {"text": "Pharmaceutical industry", "relevance": 0.953049, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Multinational companies", "relevance": 0.759633, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "AstraZeneca", "relevance": 0.6141, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Peptic ulcer", "relevance": 0.59202, "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}, {"text": "Boehringer Ingelheim", "relevance": 0.58466, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Ranbaxy", "relevance": 0.565945, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy"}, {"text": "Malvinder Mohan Singh", "relevance": 0.558585, "dbpedia_resource": "http://dbpedia.org/resource/Malvinder_Mohan_Singh"}], "categories": [{"score": 0.640756, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.437455, "label": "/health and fitness/drugs"}], "relations": [{"type": "hasAttribute", "sentence": "Global Peptic Ulcer Drugs Market Is Expected To Reach USD 36.27 Billion By 2022 with Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc. and others", "score": 0.622885, "arguments": [{"text": "Global Peptic Ulcer Drugs Market", "location": [0, 32], "entities": [{"type": "Organization", "text": "Global Peptic Ulcer Drugs Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "36.27 Billion", "location": [58, 71], "entities": [{"type": "Money", "text": "36.27 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Global Peptic Ulcer Drugs Market Is Expected To Reach USD 36.27 Billion By 2022 with Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc. and others", "score": 0.492194, "arguments": [{"text": "Novartis AG", "location": [85, 96], "entities": [{"type": "Organization", "text": "Global Peptic Ulcer Drugs Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "36.27 Billion", "location": [58, 71], "entities": [{"type": "Money", "text": "36.27 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Peptic Ulcer Drugs", "sentiment": {"score": -0.451284, "label": "negative"}, "relevance": 0.96698}, {"text": "Daiichi Sankyo Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.956717}, {"text": "Astra Zeneca plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.920356}, {"text": "Boehringer Ingelheim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.76589}, {"text": "Ranbaxy Laboratories Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.69713}, {"text": "Novartis AG", "sentiment": {"score": -0.451284, "label": "negative"}, "relevance": 0.642994}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620114}, {"text": "USD", "sentiment": {"score": -0.451284, "label": "negative"}, "relevance": 0.422551}, {"text": "Billion", "sentiment": {"score": -0.451284, "label": "negative"}, "relevance": 0.402944}, {"text": "Market", "sentiment": {"score": -0.451284, "label": "negative"}, "relevance": 0.328832}, {"text": "Acetelion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327293}]}, "crawl_date": "2018-11-14T15:59:47Z", "url": "https://www.openpr.com/news/1370793/Global-Peptic-Ulcer-Drugs-Market-Is-Expected-To-Reach-USD-36-27-Billion-By-2022-with-Novartis-AG-Daiichi-Sankyo-Company-Limited-Acetelion-Ltd-Boehringer-Ingelheim-Sanofi-S-A-Astra-Zeneca-plc-Ranbaxy-Laboratories-Limited-Inc-and-others.html", "host": "openpr.com", "text": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T15:46:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.515655, "label": "negative"}, "text": "gastric ulcers", "relevance": 0.948526, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}, {"count": 4, "sentiment": {"score": -0.315726, "label": "negative"}, "text": "America", "relevance": 0.558793, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.522338, "label": "negative"}, "text": "Eumedica Pharmaceuticals", "relevance": 0.503735, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Company Limited", "relevance": 0.492728, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.356341, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.490669, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astra Zeneca", "relevance": 0.489704, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim", "relevance": 0.488059, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.479195, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.478045, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ranbaxy Laboratories Limited", "relevance": 0.462354, "type": "Company", "disambiguation": {"subtype": [], "name": "Ranbaxy Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.426838, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acetelion Ltd", "relevance": 0.353127, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.317704, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.317704, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$36.27 billion", "relevance": 0.317704, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$29 billion", "relevance": 0.317704, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.8 %", "relevance": 0.317704, "type": "Quantity"}], "sentiment": {"document": {"score": -0.369859, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Peptic ulcer drugs", "keywords": [{"text": "Peptic ulcer drugs"}]}, "sentence": "Press release from: Market Research Future Peptic Ulcer Drugs Market Synopsis of Global Peptic Ulcer Drugs Market Market Scenario Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors.", "object": {"text": "to treat erosion of the gastrointestinal lining due to a variety of factors", "keywords": [{"text": "gastrointestinal lining"}, {"text": "erosion"}, {"text": "factors"}, {"text": "variety"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "Peptic ulcer", "keywords": [{"text": "Peptic ulcer"}]}, "sentence": " Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach.", "object": {"text": "the result of an imbalance between aggressive and defensive fluids", "keywords": [{"text": "defensive fluids"}, {"text": "imbalance"}, {"text": "result"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "gastric, esophageal and duodenal ulcer", "keywords": [{"text": "duodenal ulcer"}], "entities": [{"type": "HealthCondition", "text": "gastric ulcers", "disambiguation": {"subtype": ["Disease"], "name": "Peptic ulcer", "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}}]}, "sentence": " Peptic ulcer includes gastric, esophageal and duodenal ulcer.", "object": {"text": "Peptic ulcer", "keywords": [{"text": "Peptic ulcer"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "The global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022.", "object": {"text": "valued at approximately $29 billion in 2015", "entities": [{"type": "Quantity", "text": "$29 billion"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022.", "object": {"text": "at approximately $29 billion in 2015", "entities": [{"type": "Quantity", "text": "$29 billion"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "was valued", "normalized": "be value"}}, {"subject": {"text": "The global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022.", "object": {"text": "$36.27 billion by 2022", "entities": [{"type": "Quantity", "text": "$36.27 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022.", "object": {"text": "an average growth", "keywords": [{"text": "average growth"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "is expected to show", "normalized": "be expect to show"}}, {"subject": {"text": "The major driving factors for petic ulcers drug market", "keywords": [{"text": "petic ulcers drug"}, {"text": "major driving factors"}]}, "sentence": " The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use.", "object": {"text": "stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use", "keywords": [{"text": "ulcers"}, {"text": "infection"}, {"text": "stress"}, {"text": "rate"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "rate of infection", "keywords": [{"text": "infection"}, {"text": "rate"}]}, "sentence": " The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use.", "object": {"text": "by H.Pyrroli", "keywords": [{"text": "H.Pyrroli"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food", "keywords": [{"text": "ulcers"}, {"text": "infection"}, {"text": "rate"}, {"text": "drug"}]}, "sentence": " The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use.", "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "Constraining factors of this market", "keywords": [{"text": "factors"}, {"text": "market"}]}, "sentence": " Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics.", "object": {"text": "patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics", "keywords": [{"text": "proton pump inhibitors"}, {"text": "extreme market fragmentation"}, {"text": "comparatively good treatment"}, {"text": "patent expiry"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Daiichi", "keywords": [{"text": "Daiichi"}], "entities": [{"type": "Company", "text": "Daiichi Sankyo Company Limited"}]}, "sentence": " Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc.", "object": {"text": "Company Limited, Acetelion Ltd, Boehringer Ingelheim", "keywords": [{"text": "Boehringer Ingelheim"}, {"text": "Company"}, {"text": "Acetelion"}], "entities": [{"type": "Company", "text": "Acetelion Ltd"}, {"type": "Company", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}]}, "action": {"verb": {"text": "Sankyo", "tense": "present"}, "text": "Sankyo", "normalized": "Sankyo"}}, {"subject": {"text": "Global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "object": {"text": "segmented on the basis of pharmacological class (proton pump inhibitors (PPIs", "keywords": [{"text": "proton pump inhibitors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Global peptic ulcer drugs market", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "object": {"text": "on the basis of pharmacological class (proton pump inhibitors (PPIs", "keywords": [{"text": "proton pump inhibitors"}, {"text": "basis"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Globally North America", "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Regional Analysis of Global Peptic Ulcer Drugs Market: Globally North America is the largest market of global peptic ulcer drugs.", "object": {"text": "the largest market of global peptic ulcer drugs", "keywords": [{"text": "peptic ulcer drugs"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Europe is the second largest market for global peptic ulcer drugs.", "object": {"text": "the second largest market for global peptic ulcer drugs", "keywords": [{"text": "peptic ulcer drugs"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by developing regions particularly Asia Pacific which will be the fastest growing region", "keywords": [{"text": "fastest growing region"}, {"text": "Asia Pacific"}, {"text": "regions"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region.", "object": {"text": "the market of peptic ulcer drugs", "keywords": [{"text": "peptic ulcer drugs"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "will be dominated", "normalized": "will be dominate"}}, {"subject": {"text": "the market of peptic ulcer drugs", "keywords": [{"text": "peptic ulcer drugs"}]}, "sentence": " Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region.", "object": {"text": "regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "developing", "normalized": "develop"}}], "concepts": [{"text": "Peptic ulcer", "relevance": 0.976324, "dbpedia_resource": "http://dbpedia.org/resource/Peptic_ulcer"}, {"text": "Stomach", "relevance": 0.746686, "dbpedia_resource": "http://dbpedia.org/resource/Stomach"}, {"text": "Ranbaxy Laboratories", "relevance": 0.524494, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}, {"text": "Helicobacter pylori", "relevance": 0.508904, "dbpedia_resource": "http://dbpedia.org/resource/Helicobacter_pylori"}, {"text": "Daiichi Sankyo", "relevance": 0.503223, "dbpedia_resource": "http://dbpedia.org/resource/Daiichi_Sankyo"}, {"text": "Gastroenterology", "relevance": 0.41131, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "H2 antagonist", "relevance": 0.397641, "dbpedia_resource": "http://dbpedia.org/resource/H2_antagonist"}, {"text": "Antacid", "relevance": 0.396997, "dbpedia_resource": "http://dbpedia.org/resource/Antacid"}, {"text": "Pharmacology", "relevance": 0.393885, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "AstraZeneca", "relevance": 0.342187, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Boehringer Ingelheim", "relevance": 0.333647, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}], "categories": [{"score": 0.93896, "label": "/health and fitness/disease/gerd and acid reflux"}], "relations": [{"type": "partOf", "sentence": "Press release from: Market Research Future Peptic Ulcer Drugs Market Synopsis of Global Peptic Ulcer Drugs Market Market Scenario Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors.", "score": 0.756402, "arguments": [{"text": "Market Research Future Peptic Ulcer Drugs Market Synopsis", "location": [20, 77], "entities": [{"type": "Organization", "text": "Market Research Future Peptic Ulcer Drugs Market Synopsis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Global Peptic Ulcer Drugs Market Market Scenario Peptic", "location": [81, 136], "entities": [{"type": "Organization", "text": "Global Peptic Ulcer Drugs Market Market Scenario Peptic", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region.", "score": 0.712428, "arguments": [{"text": "Pacific", "location": [1980, 1987], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [1975, 1979], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use.", "score": 0.709429, "arguments": [{"text": "H.Pyrroli", "location": [741, 750], "entities": [{"type": "Person", "text": "H.Pyrroli"}]}, {"text": "infection", "location": [728, 737], "entities": [{"type": "HealthCondition", "text": "infection"}]}]}, {"type": "basedIn", "sentence": "Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics.", "score": 0.559561, "arguments": [{"text": "companies", "location": [993, 1002], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "H.Pyrolli", "location": [943, 952], "entities": [{"type": "GeopoliticalEntity", "text": "H.Pyrolli"}]}]}, {"type": "partOf", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.57579, "arguments": [{"text": "Key Players", "location": [1108, 1119], "entities": [{"type": "Organization", "text": "Key Players", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Copy @ www.marketresearchfuture.com/sample_request/", "location": [1052, 1103], "entities": [{"type": "Organization", "text": "Copy @ www.marketresearchfuture.com/sample_request/"}]}]}, {"type": "partOfMany", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.878288, "arguments": [{"text": "PPIs", "location": [1525, 1529], "entities": [{"type": "Person", "text": "PPIs"}]}, {"text": "inhibitors", "location": [1513, 1523], "entities": [{"type": "Person", "text": "inhibitors"}]}]}, {"type": "partOfMany", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.796287, "arguments": [{"text": "H2 antagonists", "location": [1549, 1563], "entities": [{"type": "Person", "text": "H2 antagonists"}]}, {"text": "inhibitors", "location": [1513, 1523], "entities": [{"type": "Person", "text": "inhibitors"}]}]}, {"type": "partOfMany", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.498214, "arguments": [{"text": "PPIs", "location": [1525, 1529], "entities": [{"type": "Person", "text": "PPIs"}]}, {"text": "others", "location": [1591, 1597], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOfMany", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.831432, "arguments": [{"text": "H2 antagonists", "location": [1549, 1563], "entities": [{"type": "Person", "text": "H2 antagonists"}]}, {"text": "others", "location": [1591, 1597], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "hasAttribute", "sentence": "Access Sample Copy @ www.marketresearchfuture.com/sample_request/2445 Key Players For Global Peptic Ulcer Drugs Market: Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals Segments: Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.", "score": 0.572491, "arguments": [{"text": "others", "location": [1591, 1597], "entities": [{"type": "Person", "text": "others"}]}, {"text": "ulcers", "location": [1633, 1639], "entities": [{"type": "HealthCondition", "text": "ulcers"}]}]}], "keywords": [{"text": "peptic ulcer drugs", "sentiment": {"score": -0.457505, "label": "negative"}, "relevance": 0.995986}, {"text": "global peptic ulcer", "sentiment": {"score": -0.392303, "label": "negative"}, "relevance": 0.807046}, {"text": "ulcer drugs market", "sentiment": {"score": -0.487644, "label": "negative"}, "relevance": 0.682359}, {"text": "Future Peptic Ulcer", "sentiment": {"score": -0.62051, "label": "negative"}, "relevance": 0.456951}, {"text": "Scenario Peptic ulcer", "sentiment": {"score": -0.62051, "label": "negative"}, "relevance": 0.455571}, {"text": "duodenal ulcer", "sentiment": {"score": -0.486427, "label": "negative"}, "relevance": 0.320296}, {"text": "esophageal ulcer", "sentiment": {"score": -0.305645, "label": "negative"}, "relevance": 0.264379}, {"text": "Drugs Market Synopsis", "sentiment": {"score": -0.62051, "label": "negative"}, "relevance": 0.24714}, {"text": "proton pump inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241558}]}, "extracted_metadata": {"sha1": "08705a063d5088b5e288494dc6ecdbf3eb20f18e", "filename": "1542211187281.zip-19aa0359c1b7f429f9063626acfdd19c.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/2445", "https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445"], "title": "Global Peptic Ulcer Drugs Market Is Expected To Reach USD 36.27 Billion By 2022 with Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc. and others", "forum_title": "openPR.com - Newsfeed"}, {"id": "ZrgSgUrMhA-yVgIJXksFLbepN8zUzueW-EJxZuW4Sd2QdrMvufuWlgILiYs-3-q_", "result_metadata": {"score": 29.40937}, "author": "Hussain Shah", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Worldwide Industry Analysis", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.681366, "label": "/business and industrial/paper industry"}, {"score": 0.636088, "label": "/business and industrial/war industry"}], "relations": [], "keywords": [{"text": "Mild Laxatives Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.90527}, {"text": "Worldwide Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581328}]}, "crawl_date": "2018-11-15T09:01:36Z", "url": "https://www.findmarketresearch.org/2018/11/mild-laxatives-market-growth-with-worldwide-industry-analysis-to-2028/", "host": "findmarketresearch.org", "text": "KG, Sebela Pharmaceuticals, Inc., Purdue Pharma L.P., Takeda Pharmaceutical Company Ltd among others.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T11:55:00+05:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": -0.764252, "label": "negative"}, "text": "Constipation", "relevance": 0.906876, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}, {"count": 3, "sentiment": {"score": -0.482597, "label": "negative"}, "text": "stimulant", "relevance": 0.285849, "type": "Drug"}, {"count": 2, "sentiment": {"score": -0.518004, "label": "negative"}, "text": "United States", "relevance": 0.249198, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": -0.214275, "label": "negative"}, "text": "Japan", "relevance": 0.245961, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": -0.553251, "label": "negative"}, "text": "diarrhea", "relevance": 0.24206, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Diarrhea", "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}}, {"count": 2, "sentiment": {"score": -0.499596, "label": "negative"}, "text": "Obesity", "relevance": 0.232845, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": -0.873883, "label": "negative"}, "text": "bowel syndrome", "relevance": 0.229467, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": -0.746492, "label": "negative"}, "text": "Europe", "relevance": 0.229366, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "C. H. Boehringer Sohn AG", "relevance": 0.210421, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.414217, "label": "negative"}, "text": "Bayer AG", "relevance": 0.207093, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.190264, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.189265, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.449793, "label": "negative"}, "text": "Sebela Pharmaceuticals, Inc.", "relevance": 0.188044, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.341431, "label": "negative"}, "text": "North America", "relevance": 0.187585, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.772221, "label": "negative"}, "text": "North America", "relevance": 0.186644, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.181528, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Co", "relevance": 0.181107, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Purdue Pharma", "relevance": 0.17957, "type": "Company", "disambiguation": {"subtype": [], "name": "Purdue Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Purdue_Pharma"}}, {"count": 1, "sentiment": {"score": 0.277832, "label": "positive"}, "text": "Procter & Gamble Company", "relevance": 0.179173, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Procter & Gamble", "dbpedia_resource": "http://dbpedia.org/resource/Procter_&_Gamble"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.178043, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.173074, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pacific", "relevance": 0.172825, "type": "Vehicle", "disambiguation": {"subtype": ["Automobile"]}}, {"count": 1, "sentiment": {"score": -0.214275, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.156705, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc.", "relevance": 0.153547, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.143291, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "27.2%", "relevance": 0.143291, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "27%", "relevance": 0.143291, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "85%", "relevance": 0.143291, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2%", "relevance": 0.143291, "type": "Quantity"}], "sentiment": {"document": {"score": -0.562724, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Bulk-forming laxatives", "keywords": [{"text": "Bulk-forming laxatives"}]}, "sentence": " Bulk-forming laxatives helps in absorbing liquid in intestines, resulting in softer and easier passage of stools, which in turn positively impacts the growth of mild laxatives market.", "object": {"text": "liquid", "keywords": [{"text": "liquid"}]}, "action": {"verb": {"text": "absorb", "tense": "present"}, "text": "absorbing", "normalized": "absorb"}}, {"subject": {"text": "Demand for bulk-forming laxatives", "keywords": [{"text": "Demand"}, {"text": "bulk-forming laxatives"}]}, "sentence": " Demand for bulk-forming laxatives is anticipated to make impressive growth in mild laxatives market owing to its less risk chances of explosive or cramping diarrhea, which is otherwise likely to take place with stimulant laxatives.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Demand for bulk-forming laxatives", "keywords": [{"text": "Demand"}, {"text": "bulk-forming laxatives"}]}, "sentence": " Demand for bulk-forming laxatives is anticipated to make impressive growth in mild laxatives market owing to its less risk chances of explosive or cramping diarrhea, which is otherwise likely to take place with stimulant laxatives.", "object": {"text": "impressive growth", "keywords": [{"text": "impressive growth"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "is anticipated to make", "normalized": "be anticipate to make"}}, {"subject": {"text": "cramping diarrhea", "keywords": [{"text": "diarrhea"}], "entities": [{"type": "HealthCondition", "text": "diarrhea", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Diarrhea", "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}}]}, "sentence": " Demand for bulk-forming laxatives is anticipated to make impressive growth in mild laxatives market owing to its less risk chances of explosive or cramping diarrhea, which is otherwise likely to take place with stimulant laxatives.", "object": {"text": "otherwise likely to take place with stimulant laxatives", "keywords": [{"text": "stimulant laxatives"}, {"text": "place"}], "entities": [{"type": "Drug", "text": "stimulant"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "bulk-forming laxatives in mild laxatives category", "keywords": [{"text": "mild laxatives category"}, {"text": "bulk-forming laxatives"}]}, "sentence": " Furthermore, bulk-forming laxatives in mild laxatives category helps in improving medical conditions worsened by straining.", "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "Increasing number of patients with irritable bowel syndrome", "keywords": [{"text": "irritable bowel syndrome"}, {"text": "number"}, {"text": "patients"}], "entities": [{"type": "HealthCondition", "text": "bowel syndrome"}]}, "sentence": " Increasing number of patients with irritable bowel syndrome will further stimulate the demand and supply of mild laxatives.", "object": {"text": "the demand and supply of mild laxatives", "keywords": [{"text": "mild laxatives"}, {"text": "demand"}, {"text": "supply"}]}, "action": {"verb": {"text": "stimulate", "tense": "future"}, "text": "will further stimulate", "normalized": "will far stimulate"}}, {"subject": {"text": "Bulk-forming laxatives of mild laxatives product type", "keywords": [{"text": "mild laxatives product"}, {"text": "Bulk-forming laxatives"}, {"text": "type"}]}, "sentence": " Bulk-forming laxatives of mild laxatives product type have been mainly preferred and regarded safe for the healthy people.", "object": {"text": "mainly preferred and regarded safe for the healthy people", "keywords": [{"text": "healthy people"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Psyllium, type of bulk-forming laxatives", "keywords": [{"text": "Psyllium"}, {"text": "bulk-forming laxatives"}, {"text": "type"}]}, "sentence": " Psyllium, type of bulk-forming laxatives is additionally utilized in proper diets for treating high cholesterol, thereby driving the demand and supply of mild laxatives.", "object": {"text": "additionally utilized in proper diets for treating high cholesterol", "keywords": [{"text": "proper diets"}, {"text": "high cholesterol"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "type of bulk-forming laxatives", "keywords": [{"text": "bulk-forming laxatives"}, {"text": "type"}]}, "sentence": " Psyllium, type of bulk-forming laxatives is additionally utilized in proper diets for treating high cholesterol, thereby driving the demand and supply of mild laxatives.", "object": {"text": "in proper diets for treating high cholesterol", "keywords": [{"text": "proper diets"}, {"text": "high cholesterol"}]}, "action": {"verb": {"text": "utilize", "tense": "past"}, "text": "is additionally utilized", "normalized": "be additionally utilize"}}, {"subject": {"text": "Psyllium, type of bulk-forming laxatives is additionally utilized in proper diets for treating high cholesterol,", "keywords": [{"text": "proper diets"}, {"text": "high cholesterol"}, {"text": "bulk-forming laxatives"}, {"text": "Psyllium"}]}, "sentence": " Psyllium, type of bulk-forming laxatives is additionally utilized in proper diets for treating high cholesterol, thereby driving the demand and supply of mild laxatives.", "object": {"text": "the demand and supply of mild laxatives", "keywords": [{"text": "mild laxatives"}, {"text": "demand"}, {"text": "supply"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "thereby driving", "normalized": "thereby drive"}}, {"subject": {"text": "constipation", "keywords": [{"text": "constipation"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "sentence": " Treatment of constipation, which occurs following hospitalization or prolonged bed rest mainly drives the mild laxatives market on a larger basis.", "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "hospitalization or prolonged bed rest", "keywords": [{"text": "bed rest"}, {"text": "hospitalization"}]}, "sentence": " Treatment of constipation, which occurs following hospitalization or prolonged bed rest mainly drives the mild laxatives market on a larger basis.", "object": {"text": "the mild laxatives market", "keywords": [{"text": "mild laxatives market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drives", "normalized": "drive"}}, {"subject": {"text": "side-effects such as difficulty in breathing and swallowing, skin rash,", "keywords": [{"text": "skin rash"}, {"text": "side-effects"}, {"text": "swallowing"}, {"text": "breathing"}]}, "sentence": " However, side-effects such as difficulty in breathing and swallowing, skin rash, itching and intestinal blockage are likely to occur with bulk-forming laxatives, which in turn restraints the growth of mild laxatives market.", "object": {"text": "intestinal blockage", "keywords": [{"text": "intestinal blockage"}]}, "action": {"verb": {"text": "itch", "tense": "present"}, "text": "itching", "normalized": "itch"}}, {"subject": {"text": "bulk-forming laxatives", "keywords": [{"text": "bulk-forming laxatives"}]}, "sentence": " However, side-effects such as difficulty in breathing and swallowing, skin rash, itching and intestinal blockage are likely to occur with bulk-forming laxatives, which in turn restraints the growth of mild laxatives market.", "object": {"text": "the growth of mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "growth"}]}, "action": {"verb": {"text": "restraints", "tense": "present"}, "text": "restraints", "normalized": "restraints"}}, {"subject": {"text": "Constipation", "keywords": [{"text": "Constipation"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "sentence": " Constipation is a commonly occurring digestive disorder and its prevalence is anticipated to only increase over time due to lifestyle changes.", "object": {"text": "a commonly occurring digestive disorder", "keywords": [{"text": "digestive disorder"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "digestive disorder and its prevalence", "keywords": [{"text": "digestive disorder"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Constipation is a commonly occurring digestive disorder and its prevalence is anticipated to only increase over time due to lifestyle changes.", "object": {"text": "anticipated to only increase"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Approximately 2% to 27% people worldwide", "keywords": [{"text": "people"}], "entities": [{"type": "Quantity", "text": "27"}, {"type": "Quantity", "text": "2"}]}, "sentence": " Approximately 2% to 27% people worldwide are affected by constipation and self-reported constipation rate stands at 27.2%.", "object": {"text": "affected by constipation", "keywords": [{"text": "constipation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by constipation and self-reported constipation rate stands", "keywords": [{"text": "self-reported constipation rate"}]}, "sentence": " Approximately 2% to 27% people worldwide are affected by constipation and self-reported constipation rate stands at 27.2%.", "object": {"text": "Approximately 2% to 27% people worldwide", "keywords": [{"text": "people"}], "entities": [{"type": "Quantity", "text": "27"}, {"type": "Quantity", "text": "2"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "are affected", "normalized": "be affect"}}, {"subject": {"text": "constipation and self-reported constipation rate", "keywords": [{"text": "self-reported constipation rate"}]}, "sentence": " Approximately 2% to 27% people worldwide are affected by constipation and self-reported constipation rate stands at 27.2%.", "object": {"text": "at 27.2%", "entities": [{"type": "Quantity", "text": "27.2"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "Approximately 85% of the doctors", "keywords": [{"text": "doctors"}], "entities": [{"type": "Quantity", "text": "85"}]}, "sentence": " Approximately 85% of the doctors prescribe mild laxatives for constipation.", "object": {"text": "mild laxatives", "keywords": [{"text": "mild laxatives"}]}, "action": {"verb": {"text": "prescribe", "tense": "present"}, "text": "prescribe", "normalized": "prescribe"}}, {"subject": {"text": "The high prescription rate of mild laxatives", "keywords": [{"text": "high prescription rate"}, {"text": "mild laxatives"}]}, "sentence": " The high prescription rate of mild laxatives will create huge opportunities for growth of the mild laxatives market during the forecast period.", "object": {"text": "huge opportunities for growth of the mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "huge opportunities"}, {"text": "growth"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will create", "normalized": "will create"}}, {"subject": {"text": "Mild laxatives", "keywords": [{"text": "Mild laxatives"}]}, "sentence": " Mild laxatives are medicines used to relieve a person of constipation.", "object": {"text": "medicines", "keywords": [{"text": "medicines"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Mild laxatives are medicines", "keywords": [{"text": "Mild laxatives"}, {"text": "medicines"}]}, "sentence": " Mild laxatives are medicines used to relieve a person of constipation.", "object": {"text": "a person of constipation", "keywords": [{"text": "constipation"}, {"text": "person"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "action": {"verb": {"text": "relieve", "tense": "future"}, "text": "to relieve", "normalized": "to relieve"}}, {"subject": {"text": "provide sustained relief from constipation symptoms", "keywords": [{"text": "constipation symptoms"}, {"text": "relief"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "sentence": " Mild laxatives always provide sustained relief from constipation symptoms.", "action": {"verb": {"text": "laxatives", "tense": "present"}, "text": "laxatives", "normalized": "laxatives"}}, {"subject": {"text": "Mild laxatives", "keywords": [{"text": "Mild laxatives"}]}, "sentence": " Mild laxatives always provide sustained relief from constipation symptoms.", "object": {"text": "sustained relief", "keywords": [{"text": "relief"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "2 to 3 million patients", "keywords": [{"text": "patients"}]}, "sentence": " Every year, 2 to 3 million patients are prescribed laxatives by healthcare practitioners in the United States.", "object": {"text": "prescribed laxatives", "keywords": [{"text": "laxatives"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by healthcare practitioners in the United States", "keywords": [{"text": "healthcare practitioners"}, {"text": "United States"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Every year, 2 to 3 million patients are prescribed laxatives by healthcare practitioners in the United States.", "object": {"text": "laxatives", "keywords": [{"text": "laxatives"}]}, "action": {"verb": {"text": "prescribe", "tense": "past"}, "text": "are prescribed", "normalized": "be prescribe"}}, {"subject": {"text": "Mild laxatives", "keywords": [{"text": "Mild laxatives"}]}, "sentence": " Mild laxatives are available over the counter.", "object": {"text": "available over the counter", "keywords": [{"text": "counter"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The main mild laxatives used for constipation", "keywords": [{"text": "main mild laxatives"}, {"text": "constipation"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "sentence": " The main mild laxatives used for constipation are bulk-forming laxatives, osmotic laxatives, stimulant laxatives and stimulant laxatives.", "object": {"text": "bulk-forming laxatives", "keywords": [{"text": "bulk-forming laxatives"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "laxatives", "keywords": [{"text": "laxatives"}]}, "sentence": " The main mild laxatives used for constipation are bulk-forming laxatives, osmotic laxatives, stimulant laxatives and stimulant laxatives.", "object": {"text": "The main mild laxatives used for constipation", "keywords": [{"text": "main mild laxatives"}, {"text": "constipation"}], "entities": [{"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "action": {"verb": {"text": "bulk-forming", "tense": "present"}, "text": "are bulk-forming", "normalized": "be bulk-forming"}}, {"subject": {"text": "Bulk-forming laxatives", "keywords": [{"text": "Bulk-forming laxatives"}]}, "sentence": " Bulk-forming laxatives are most common laxatives recommend to the patients to increase slow transit time.", "object": {"text": "most common laxatives recommend to the patients", "keywords": [{"text": "common laxatives"}, {"text": "patients"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The growing prevalence and recurrence of constipation", "keywords": [{"text": "recurrence"}, {"text": "constipation"}, {"text": "prevalence"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "HealthCondition", "text": "Constipation", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Constipation", "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}}]}, "sentence": " The growing prevalence and recurrence of constipation is expected to be the major factor driving the growth of the mild laxatives market over the forecast period.", "object": {"text": "the major factor driving the growth of the mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "major factor"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "the major factor", "keywords": [{"text": "major factor"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " The growing prevalence and recurrence of constipation is expected to be the major factor driving the growth of the mild laxatives market over the forecast period.", "object": {"text": "the growth of the mild laxatives market over the forecast period", "keywords": [{"text": "mild laxatives market"}, {"text": "forecast period"}, {"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "lack of exercise and fewer sleep hours", "keywords": [{"text": "fewer sleep"}, {"text": "lack"}, {"text": "exercise"}]}, "sentence": " Inactive lifestyle and unhealthy eating habits, irregular eating timings, lack of exercise and fewer sleep hours can be held responsible for the growing prevalence of constipation.", "object": {"text": "held responsible"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "timings, lack of exercise and fewer sleep hours", "keywords": [{"text": "fewer sleep"}, {"text": "timings"}, {"text": "lack"}, {"text": "exercise"}]}, "sentence": " Inactive lifestyle and unhealthy eating habits, irregular eating timings, lack of exercise and fewer sleep hours can be held responsible for the growing prevalence of constipation.", "object": {"text": "responsible"}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "can be held", "normalized": "can be hold"}}, {"subject": {"text": "Rising obesity cases", "keywords": [{"text": "obesity cases"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Rising obesity cases make another reason for the growth of the mild laxative market.", "object": {"text": "another reason for the growth of the mild laxative market", "keywords": [{"text": "mild laxative market"}, {"text": "reason"}, {"text": "growth"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "make", "normalized": "make"}}, {"subject": {"text": "Mild laxatives", "keywords": [{"text": "Mild laxatives"}]}, "sentence": " Mild laxatives are safe to use for pregnant women and kids, which will create more growth opportunities for the players in the mild laxatives market.", "object": {"text": "safe"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Mild laxatives", "keywords": [{"text": "Mild laxatives"}]}, "sentence": " Mild laxatives are safe to use for pregnant women and kids, which will create more growth opportunities for the players in the mild laxatives market.", "object": {"text": "for pregnant women", "keywords": [{"text": "pregnant women"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "to use", "normalized": "to use"}}, {"subject": {"text": "women and kids", "keywords": [{"text": "women"}, {"text": "kids"}]}, "sentence": " Mild laxatives are safe to use for pregnant women and kids, which will create more growth opportunities for the players in the mild laxatives market.", "object": {"text": "more growth opportunities for the players in the mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "growth opportunities"}, {"text": "players"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will create", "normalized": "will create"}}, {"subject": {"text": "the counter product availability in the market", "keywords": [{"text": "counter product availability"}, {"text": "market"}]}, "sentence": " Over the counter product availability in the market will be a major factor expected to drive the mild laxatives market.", "object": {"text": "a major factor expected to drive the mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "major factor"}], "entities": [{"type": "HealthCondition", "text": "Obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "The high prescription rate of mild laxatives for primary constipation treatment", "keywords": [{"text": "high prescription rate"}, {"text": "primary constipation"}, {"text": "mild laxatives"}, {"text": "treatment"}]}, "sentence": " The high prescription rate of mild laxatives for primary constipation treatment is expected to boost the growth of the mild laxatives market.", "object": {"text": "the growth of the mild laxatives market", "keywords": [{"text": "mild laxatives market"}, {"text": "growth"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "is expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "Side effects", "keywords": [{"text": "effects"}]}, "sentence": " Side effects associated with some mild laxatives are some of the factors expected to restrain mild laxatives market.", "object": {"text": "with some mild laxatives", "keywords": [{"text": "mild laxatives"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "Side effects associated with some mild laxatives", "keywords": [{"text": "mild laxatives"}, {"text": "effects"}]}, "sentence": " Side effects associated with some mild laxatives are some of the factors expected to restrain mild laxatives market.", "object": {"text": "some of the factors expected", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the factors", "keywords": [{"text": "factors"}]}, "sentence": " Side effects associated with some mild laxatives are some of the factors expected to restrain mild laxatives market.", "object": {"text": "mild laxatives market", "keywords": [{"text": "mild laxatives market"}]}, "action": {"verb": {"text": "restrain", "tense": "future"}, "text": "expected to restrain", "normalized": "expect to restrain"}}, {"subject": {"text": "The global market for mild laxatives", "keywords": [{"text": "mild laxatives"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for mild laxatives is expected to witness moderate growth over the forecast period.", "object": {"text": "moderate growth", "keywords": [{"text": "moderate growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "the laxatives", "keywords": [{"text": "laxatives"}]}, "sentence": " Majority of the laxatives are introduced in the generic market and thus, there exists high competition among local and regional players.", "action": {"verb": {"text": "introduce", "tense": "past"}, "text": "are introduced", "normalized": "be introduce"}}, {"subject": {"text": "high competition", "keywords": [{"text": "high competition"}]}, "sentence": " Majority of the laxatives are introduced in the generic market and thus, there exists high competition among local and regional players.", "action": {"verb": {"text": "exist", "tense": "present"}, "text": "exists", "normalized": "exist"}}, {"subject": {"text": "the bulk-forming laxatives", "keywords": [{"text": "bulk-forming laxatives"}]}, "sentence": " Among the product types, the bulk-forming laxatives are expected to lead in the global mild laxatives market over the forecast period.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "are expected to lead", "normalized": "be expect to lead"}}, {"subject": {"text": "The Retail pharmacy distribution channel", "keywords": [{"text": "Retail pharmacy distribution"}]}, "sentence": " The Retail pharmacy distribution channel is expected to contribute high share in the global mild laxatives market as it is the most accessible channel and the majority of patients are recommended for outpatient treatment.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to contribute", "normalized": "be expect to contribute"}}, {"subject": {"text": "The Retail pharmacy distribution channel", "keywords": [{"text": "Retail pharmacy distribution"}]}, "sentence": " The Retail pharmacy distribution channel is expected to contribute high share in the global mild laxatives market as it is the most accessible channel and the majority of patients are recommended for outpatient treatment.", "object": {"text": "high share", "keywords": [{"text": "high share"}]}, "action": {"verb": {"text": "contribute", "tense": "future"}, "text": "is expected to contribute", "normalized": "be expect to contribute"}}], "concepts": [{"text": "Constipation", "relevance": 0.95796, "dbpedia_resource": "http://dbpedia.org/resource/Constipation"}, {"text": "Laxative", "relevance": 0.877069, "dbpedia_resource": "http://dbpedia.org/resource/Laxative"}, {"text": "Irritable bowel syndrome", "relevance": 0.757731, "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}, {"text": "Supply and demand", "relevance": 0.525295, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}, {"text": "Dietary fiber", "relevance": 0.460757, "dbpedia_resource": "http://dbpedia.org/resource/Dietary_fiber"}, {"text": "Qualitative research", "relevance": 0.444928, "dbpedia_resource": "http://dbpedia.org/resource/Qualitative_research"}, {"text": "Marketing", "relevance": 0.439928, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Gastroenterology", "relevance": 0.391929, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Polyethylene glycol", "relevance": 0.390905, "dbpedia_resource": "http://dbpedia.org/resource/Polyethylene_glycol"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.386946, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "United States", "relevance": 0.34774, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Bowel obstruction", "relevance": 0.345891, "dbpedia_resource": "http://dbpedia.org/resource/Bowel_obstruction"}, {"text": "Intestine", "relevance": 0.344666, "dbpedia_resource": "http://dbpedia.org/resource/Intestine"}], "categories": [{"score": 0.703003, "label": "/health and fitness"}, {"score": 0.47988, "label": "/health and fitness/disease/ibs and crohn's disease"}, {"score": 0.314079, "label": "/health and fitness/disorders"}], "relations": [{"type": "hasAttribute", "sentence": "Approximately 2% to 27% people worldwide are affected by constipation and self-reported constipation rate stands at 27.2%.", "score": 0.55973, "arguments": [{"text": "people", "location": [1585, 1591], "entities": [{"type": "Person", "text": "people"}]}, {"text": "constipation", "location": [1618, 1630], "entities": [{"type": "HealthCondition", "text": "constipation"}]}]}, {"type": "hasAttribute", "sentence": "Mild laxatives are medicines used to relieve a person of constipation.", "score": 0.76745, "arguments": [{"text": "person", "location": [1951, 1957], "entities": [{"type": "Person", "text": "person"}]}, {"text": "constipation", "location": [1961, 1973], "entities": [{"type": "HealthCondition", "text": "constipation"}]}]}, {"type": "locatedAt", "sentence": "Every year, 2 to 3 million patients are prescribed laxatives by healthcare practitioners in the United States.", "score": 0.714471, "arguments": [{"text": "patients", "location": [2077, 2085], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "United States", "location": [2146, 2159], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "The Retail pharmacy distribution channel is expected to contribute high share in the global mild laxatives market as it is the most accessible channel and the majority of patients are recommended for outpatient treatment.", "score": 0.715461, "arguments": [{"text": "majority", "location": [4024, 4032], "entities": [{"type": "Person", "text": "majority"}]}, {"text": "patients", "location": [4036, 4044], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "residesIn", "sentence": "Geographically, the global mild laxatives market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA).", "score": 0.38703, "arguments": [{"text": "Asia-Pacific", "location": [4192, 4204], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "Japan", "location": [4215, 4220], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The mild laxatives market in the Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the expansion of the product offerings by the key players.", "score": 0.79784, "arguments": [{"text": "Asia", "location": [4517, 4521], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [4522, 4529], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The mild laxatives market in the Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the expansion of the product offerings by the key players.", "score": 0.661345, "arguments": [{"text": "Pacific", "location": [4522, 4529], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Japan", "location": [4540, 4545], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the key players operating in the global mild laxatives market are Bayer AG, GlaxoSmithKline Plc., Procter & Gamble Company, Abbott Laboratories, C. H. Boehringer Sohn AG & Co. KG, Sebela Pharmaceuticals, Inc., Purdue Pharma L.P., Takeda Pharmaceutical Company Ltd among others.", "score": 0.767599, "arguments": [{"text": "Some", "location": [4833, 4837], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [4849, 4856], "entities": [{"type": "Person", "text": "players"}]}]}], "keywords": [{"text": "mild laxatives market", "sentiment": {"score": 0.039702, "label": "positive"}, "relevance": 0.993166}, {"text": "global mild laxatives", "sentiment": {"score": 0.111879, "label": "positive"}, "relevance": 0.616597}, {"text": "bulk-forming laxatives", "sentiment": {"score": -0.0852586, "label": "negative"}, "relevance": 0.517959}, {"text": "mild laxatives category", "sentiment": {"score": -0.67984, "label": "negative"}, "relevance": 0.501736}, {"text": "mild laxatives product", "sentiment": {"score": 0.539994, "label": "positive"}, "relevance": 0.492969}, {"text": "main mild laxatives", "sentiment": {"score": -0.644391, "label": "negative"}, "relevance": 0.480897}, {"text": "mild laxative market", "sentiment": {"score": -0.435543, "label": "negative"}, "relevance": 0.468446}, {"text": "forecast period", "sentiment": {"score": -0.717735, "label": "negative"}, "relevance": 0.448522}, {"text": "constipation", "sentiment": {"score": -0.747664, "label": "negative"}, "relevance": 0.434033}, {"text": "laxatives product type", "sentiment": {"score": 0.539994, "label": "positive"}, "relevance": 0.427112}, {"text": "Bulk-Forming Laxatives Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395364}, {"text": "high prescription rate", "sentiment": {"score": -0.778441, "label": "negative"}, "relevance": 0.395099}, {"text": "self-reported constipation rate", "sentiment": {"score": -0.756731, "label": "negative"}, "relevance": 0.394465}, {"text": "stimulant laxatives", "sentiment": {"score": -0.482597, "label": "negative"}, "relevance": 0.391769}, {"text": "primary constipation treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38866}, {"text": "major factor", "sentiment": {"score": -0.703179, "label": "negative"}, "relevance": 0.382512}, {"text": "constipation symptoms", "sentiment": {"score": -0.72201, "label": "negative"}, "relevance": 0.370083}, {"text": "constipation problems", "sentiment": {"score": -0.563649, "label": "negative"}, "relevance": 0.36749}, {"text": "various market factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360911}, {"text": "parent market trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359992}, {"text": "irritable bowel syndrome", "sentiment": {"score": -0.873883, "label": "negative"}, "relevance": 0.355937}, {"text": "osmotic laxatives", "sentiment": {"score": -0.559171, "label": "negative"}, "relevance": 0.354465}, {"text": "Gain Significant Traction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354049}, {"text": "common laxatives", "sentiment": {"score": -0.624209, "label": "negative"}, "relevance": 0.353031}, {"text": "United States", "sentiment": {"score": -0.518004, "label": "negative"}, "relevance": 0.352761}, {"text": "growth", "sentiment": {"score": -0.625885, "label": "negative"}, "relevance": 0.351313}, {"text": "North America", "sentiment": {"score": -0.556826, "label": "negative"}, "relevance": 0.349839}, {"text": "key players", "sentiment": {"score": -0.414217, "label": "negative"}, "relevance": 0.348508}, {"text": "slow transit time", "sentiment": {"score": -0.624209, "label": "negative"}, "relevance": 0.347898}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347883}, {"text": "unhealthy eating habits", "sentiment": {"score": -0.719606, "label": "negative"}, "relevance": 0.347725}, {"text": "counter product availability", "sentiment": {"score": -0.67564, "label": "negative"}, "relevance": 0.34756}, {"text": "irregular eating timings", "sentiment": {"score": -0.788665, "label": "negative"}, "relevance": 0.347477}, {"text": "H. Boehringer Sohn", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346973}, {"text": "Purdue Pharma L.P.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346653}, {"text": "common digestive complication", "sentiment": {"score": -0.759406, "label": "negative"}, "relevance": 0.346161}, {"text": "Retail pharmacy distribution", "sentiment": {"score": 0.707061, "label": "positive"}, "relevance": 0.346079}, {"text": "global market", "sentiment": {"score": -0.491941, "label": "negative"}, "relevance": 0.344816}, {"text": "market attractiveness", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341498}, {"text": "generic market", "sentiment": {"score": -0.375119, "label": "negative"}, "relevance": 0.340726}, {"text": "dominant market", "sentiment": {"score": -0.772221, "label": "negative"}, "relevance": 0.340484}, {"text": "market segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340356}, {"text": "impressive growth", "sentiment": {"score": -0.553251, "label": "negative"}, "relevance": 0.335823}, {"text": "high prevalence", "sentiment": {"score": -0.772221, "label": "negative"}, "relevance": 0.33157}, {"text": "medical conditions", "sentiment": {"score": -0.67984, "label": "negative"}, "relevance": 0.330956}, {"text": "high cholesterol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330885}, {"text": "growth opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330869}, {"text": "risk chances", "sentiment": {"score": -0.553251, "label": "negative"}, "relevance": 0.330862}, {"text": "moderate growth", "sentiment": {"score": -0.491941, "label": "negative"}, "relevance": 0.33014}, {"text": "intestinal blockage", "sentiment": {"score": -0.56741, "label": "negative"}, "relevance": 0.329433}]}, "extracted_metadata": {"sha1": "168adbcfd757c0873fece00e24d27941ffa0d0a4", "filename": "1542272496374.zip-f9573ed152ae9360a898d220ca34857e.xml", "file_type": "json"}, "external_links": ["https://www.factmr.com/connectus/sample?flag=S&rep_id=964", "https://www.factmr.com/report/964/mild-laxatives-market"], "title": "Mild Laxatives Growth with Worldwide Industry Analysis to", "forum_title": "Research Insights \u2013 Page 34 \u2013 Find Market Research"}, {"id": "ASrpvajpawP9klIKBSozsCc2xjmo9eJlDyXrPsvN_DCaa--mneAz2vVI_Wrfb1NO", "result_metadata": {"score": 29.183815}, "author": "PRNewswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Myovant Sciences", "keywords": [{"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences", "action": {"verb": {"text": "Participate", "tense": "future"}, "text": "to Participate", "normalized": "to Participate"}}], "concepts": [], "categories": [{"score": 0.627609, "label": "/finance/investing"}, {"score": 0.627609, "label": "/finance/investing/beginning investing"}, {"score": 0.260389, "label": "/finance/investing/funds"}], "relations": [], "keywords": [{"text": "Upcoming Investor Conferences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.954867}, {"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.671792}]}, "crawl_date": "2018-11-15T13:42:53Z", "url": "https://www.centralcharts.com/en/16572-myovant-sciences/news/1807305-myovant-sciences-to-participate-in-two-upcoming-investor-conferences", "host": "centralcharts.com", "text": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "main_image_url": "https://www.centralcharts.com/medias/images/social/og-image-default_EN.png", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T20:59:00+01:00", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences", "relevance": 0.875716, "type": "Company"}, {"count": 7, "sentiment": {"score": -0.0481589, "label": "negative"}, "text": "Myovant", "relevance": 0.682241, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.389588, "label": "negative"}, "text": "endocrine diseases", "relevance": 0.535838, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "BASEL", "relevance": 0.409257, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Basel", "dbpedia_resource": "http://dbpedia.org/resource/Basel"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.371696, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0.622117, "label": "positive"}, "text": "Evercore", "relevance": 0.335104, "type": "Company", "disambiguation": {"subtype": [], "name": "Evercore Partners", "dbpedia_resource": "http://dbpedia.org/resource/Evercore_Partners"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.329373, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.622117, "label": "positive"}, "text": "Myovant", "relevance": 0.329193, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International AG", "relevance": 0.289686, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Citi", "relevance": 0.28351, "type": "Company", "disambiguation": {"subtype": [], "name": "Citigroup", "dbpedia_resource": "http://dbpedia.org/resource/Citigroup"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Financial Officer", "relevance": 0.282841, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lynn Seely", "relevance": 0.276624, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISI", "relevance": 0.273057, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "female infertility", "relevance": 0.259617, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Female infertility", "dbpedia_resource": "http://dbpedia.org/resource/Female_infertility"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston", "relevance": 0.258245, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Boston", "dbpedia_resource": "http://dbpedia.org/resource/Boston"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.253501, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.25054, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0.655655, "label": "positive"}, "text": "Frank Karbe", "relevance": 0.245587, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Julie Normart", "relevance": 0.24438, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.241701, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.232968, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.229501, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "investors@myovant.com", "relevance": 0.229501, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "jnormart@w2ogroup.com", "relevance": 0.229501, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15 minutes", "relevance": 0.229501, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30 days", "relevance": 0.229501, "type": "Quantity"}], "sentiment": {"document": {"score": 0.550891, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Myovant Sciences", "keywords": [{"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire", "action": {"verb": {"text": "Participate", "tense": "future"}, "text": "to Participate", "normalized": "to Participate"}}, {"subject": {"text": "Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "Myovant Sciences"}, {"text": "NYSE"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}, {"type": "Company", "text": "NYSE"}]}, "sentence": " BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences:", "object": {"text": "its participation", "keywords": [{"text": "participation"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "President and Chief Executive Officer, Lynn Seely , M.D.,", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Lynn Seely"}, {"text": "President"}, {"text": "M.D"}], "entities": [{"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Person", "text": "Lynn Seely"}]}, "sentence": " President and Chief Executive Officer, Lynn Seely , M.D., will participate in a fireside chat on Tuesday, November 27, 2018 , at 9:30 a.m.", "object": {"text": "in a fireside chat", "keywords": [{"text": "fireside chat"}]}, "action": {"verb": {"text": "participate", "tense": "future"}, "text": "will participate", "normalized": "will participate"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}]}, "sentence": " Citi's 2018 Global Healthcare Conference in New York , NY. Myovant will host meetings with investors on Wednesday, December 5 and Thursday, December 6, 2018 .", "object": {"text": "meetings with investors", "keywords": [{"text": "investors"}, {"text": "meetings"}]}, "action": {"verb": {"text": "host", "tense": "future"}, "text": "will host", "normalized": "will host"}}, {"subject": {"text": "A live webcast of the Evercore presentation", "keywords": [{"text": "Evercore presentation"}, {"text": "live webcast"}], "entities": [{"type": "Company", "text": "Evercore", "disambiguation": {"subtype": ["Company"], "name": "Evercore Partners", "dbpedia_resource": "http://dbpedia.org/resource/Evercore_Partners"}}]}, "sentence": " A live webcast of the Evercore presentation will be accessible on the Events page under the Investors and Media section of the Myovant website at www.myovant.com .", "object": {"text": "accessible on the Events page", "keywords": [{"text": "Events"}, {"text": "page"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "to the company", "keywords": [{"text": "company"}]}, "sentence": " Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast.", "action": {"verb": {"text": "connect", "tense": "present"}, "text": "connect", "normalized": "connect"}}, {"subject": {"text": "any software", "keywords": [{"text": "software"}]}, "sentence": " Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast.", "object": {"text": "to the webcast", "keywords": [{"text": "webcast"}]}, "action": {"verb": {"text": "listen", "tense": "future"}, "text": "may be required to listen", "normalized": "may be require to listen"}}, {"subject": {"text": "A replay of the webcast", "keywords": [{"text": "replay"}, {"text": "webcast"}]}, "sentence": " A replay of the webcast will be available for 30 days following the conference.", "object": {"text": "available"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "A replay of the webcast", "keywords": [{"text": "replay"}, {"text": "webcast"}]}, "sentence": " A replay of the webcast will be available for 30 days following the conference.", "object": {"text": "the conference", "keywords": [{"text": "conference"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "Myovant Sciences", "keywords": [{"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}]}, "sentence": " Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.", "object": {"text": "a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases", "keywords": [{"text": "clinical-stage biopharmaceutical company"}, {"text": "endocrine diseases"}, {"text": "innovative therapies"}, {"text": "treatment"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}, {"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Myovant's lead product candidate", "keywords": [{"text": "lead product candidate"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "object": {"text": "relugolix", "keywords": [{"text": "relugolix"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an oral, once-daily small molecule", "keywords": [{"text": "once-daily small molecule"}]}, "sentence": " Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "object": {"text": "as a GnRH receptor antagonist", "keywords": [{"text": "GnRH receptor antagonist"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acts", "normalized": "act"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "object": {"text": "initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials", "keywords": [{"text": "international Phase"}, {"text": "clinical programs"}, {"text": "clinical trials"}, {"text": "relugolix"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "object": {"text": "three clinical programs", "keywords": [{"text": "clinical programs"}]}, "action": {"verb": {"text": "initiate", "tense": "past"}, "text": "has initiated", "normalized": "have initiate"}}, {"subject": {"text": "bleeding", "keywords": [{"text": "bleeding"}]}, "sentence": " Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "object": {"text": "with uterine fibroids", "keywords": [{"text": "uterine fibroids"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction.", "object": {"text": "MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction", "keywords": [{"text": "kisspeptin-1 receptor agonist"}, {"text": "female infertility"}, {"text": "Phase"}, {"text": "reproduction"}], "entities": [{"type": "HealthCondition", "text": "female infertility", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Female infertility", "dbpedia_resource": "http://dbpedia.org/resource/Female_infertility"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is also developing", "normalized": "be also develop"}}, {"subject": {"text": "an oligopeptide kisspeptin-1 receptor agonist", "keywords": [{"text": "kisspeptin-1 receptor agonist"}]}, "sentence": " Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction.", "object": {"text": "in Phase 2a development for the treatment of female infertility", "keywords": [{"text": "female infertility"}, {"text": "Phase"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "female infertility", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Female infertility", "dbpedia_resource": "http://dbpedia.org/resource/Female_infertility"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceuticals International AG", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "International AG"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG"}]}, "sentence": " Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "object": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Company", "text": "Myovant"}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "Takeda Pharmaceuticals International AG", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "International AG"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals International AG"}]}, "sentence": " Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "object": {"text": "relugolix", "keywords": [{"text": "relugolix"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop and commercialize", "normalized": "to develop and commercialize"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Company", "text": "Myovant"}]}, "sentence": " Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "object": {"text": "relugolix", "keywords": [{"text": "relugolix"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "to develop and commercialize", "normalized": "to develop and commercialize"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "object": {"text": "exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide", "keywords": [{"text": "exclusive rights"}, {"text": "exclusive license"}, {"text": "countries"}]}, "action": {"verb": {"text": "retain", "tense": "present"}, "text": "retains", "normalized": "retain"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "object": {"text": "MVT-602", "keywords": [{"text": "MVT-602"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "to develop and commercialize", "normalized": "to develop and commercialize"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "object": {"text": "to expand its development pipeline to include other potential treatments for women's health and endocrine diseases", "keywords": [{"text": "development pipeline"}, {"text": "endocrine diseases"}, {"text": "potential treatments"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "intend", "tense": "present"}, "text": "intends", "normalized": "intend"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "object": {"text": "its development pipeline", "keywords": [{"text": "development pipeline"}]}, "action": {"verb": {"text": "expand", "tense": "future"}, "text": "intends to expand", "normalized": "intend to expand"}}], "concepts": [{"text": "Receptor antagonist", "relevance": 0.956528, "dbpedia_resource": "http://dbpedia.org/resource/Receptor_antagonist"}, {"text": "Inverse agonist", "relevance": 0.875151, "dbpedia_resource": "http://dbpedia.org/resource/Inverse_agonist"}, {"text": "Agonist", "relevance": 0.818065, "dbpedia_resource": "http://dbpedia.org/resource/Agonist"}, {"text": "Buprenorphine", "relevance": 0.665569, "dbpedia_resource": "http://dbpedia.org/resource/Buprenorphine"}, {"text": "Pharmacology", "relevance": 0.641802, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Clinical trial", "relevance": 0.63352, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Chief executive officer", "relevance": 0.631008, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Executive officer", "relevance": 0.562018, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Receptor", "relevance": 0.561531, "dbpedia_resource": "http://dbpedia.org/resource/Receptor_(biochemistry)"}, {"text": "Receptor theory", "relevance": 0.551683, "dbpedia_resource": "http://dbpedia.org/resource/Receptor_theory"}], "categories": [{"score": 0.780396, "label": "/health and fitness/disease/infertility"}, {"score": 0.441474, "label": "/health and fitness/women's health"}], "relations": [{"type": "locatedAt", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.586096, "arguments": [{"text": "Investor Conferences PR Newswire\nBASEL", "location": [48, 86], "entities": [{"type": "Organization", "text": "Investor Conferences PR Newswire\nBASEL"}]}, {"text": "Switzerland", "location": [88, 99], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Citi's 2018 Global Healthcare Conference in New York , NY.", "score": 0.984644, "arguments": [{"text": "New York", "location": [619, 627], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}, {"text": "NY", "location": [630, 632], "entities": [{"type": "GeopoliticalEntity", "text": "NY"}]}]}, {"type": "participantIn", "sentence": "Myovant will host meetings with investors on Wednesday, December 5 and Thursday, December 6, 2018 .", "score": 0.955249, "arguments": [{"text": "investors", "location": [666, 675], "entities": [{"type": "Person", "text": "Investors"}]}, {"text": "meetings", "location": [652, 660], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "timeOf", "sentence": "Myovant will host meetings with investors on Wednesday, December 5 and Thursday, December 6, 2018 .", "score": 0.931836, "arguments": [{"text": "Wednesday", "location": [679, 688], "entities": [{"type": "Date", "text": "December 5"}]}, {"text": "meetings", "location": [652, 660], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "hasAttribute", "sentence": "A live webcast of the Evercore presentation will be accessible on the Events page under the Investors and Media section of the Myovant website at www.myovant.com .", "score": 0.558439, "arguments": [{"text": "website", "location": [869, 876], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "www.myovant.com", "location": [880, 895], "entities": [{"type": "Web", "text": "www.myovant.com"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit Myovant's website at www.myovant.com .", "score": 0.693945, "arguments": [{"text": "website", "location": [2514, 2521], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "www.myovant.com", "location": [2525, 2540], "entities": [{"type": "Web", "text": "www.myovant.com"}]}]}, {"type": "timeOf", "sentence": "A replay of the webcast will be available for 30 days following the conference.", "score": 0.690056, "arguments": [{"text": "30 days", "location": [1127, 1134], "entities": [{"type": "Duration", "text": "30 days"}]}, {"text": "conference", "location": [1149, 1159], "entities": [{"type": "EventMeeting", "text": "conference"}]}]}, {"type": "hasAttribute", "sentence": "About Myovant Sciences Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.", "score": 0.748964, "arguments": [{"text": "women", "location": [1331, 1336], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [1360, 1368], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "score": 0.317786, "arguments": [{"text": "candidate", "location": [1393, 1402], "entities": [{"type": "Person", "text": "candidate"}]}, {"text": "Myovant", "location": [1370, 1377], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.926071, "arguments": [{"text": "men", "location": [1788, 1791], "entities": [{"type": "Person", "text": "women"}]}, {"text": "prostate cancer", "location": [1806, 1821], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.833615, "arguments": [{"text": "HERO", "location": [1823, 1827], "entities": [{"type": "Person", "text": "HERO"}]}, {"text": "prostate cancer", "location": [1806, 1821], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.905444, "arguments": [{"text": "Takeda Pharmaceuticals International AG", "location": [2019, 2058], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals International AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "granted", "location": [2059, 2066], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "locatedAt", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.717629, "arguments": [{"text": "BASEL", "location": [115, 120], "entities": [{"type": "GeopoliticalEntity", "text": "BASEL"}]}, {"text": "Switzerland", "location": [122, 133], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.521072, "arguments": [{"text": "Myovant", "location": [2067, 2074], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "granted", "location": [2059, 2066], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.574594, "arguments": [{"text": "countries", "location": [2187, 2196], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Asian", "location": [2181, 2186], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "residesIn", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.241344, "arguments": [{"text": "Takeda", "location": [2203, 2209], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "where", "location": [2197, 2202], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "employedBy", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.307066, "arguments": [{"text": "women", "location": [2430, 2435], "entities": [{"type": "Person", "text": "women"}]}, {"text": "its", "location": [2363, 2366], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.66745, "arguments": [{"text": "women", "location": [2430, 2435], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [2459, 2467], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Investor Contact: Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact: Julie Normart W2O pure jnormart@w2ogroup.com 559.974.3245 View original content to download multimedia: http://www.prnewswire.com/news-releases/myovant-sciences-to-participate-in-two-upcoming-investor-conferences-300751000.html SOURCE Myovant Sciences, Ltd.", "score": 0.53927, "arguments": [{"text": "Julie Normart\nW2O", "location": [2657, 2674], "entities": [{"type": "Person", "text": "Julie Normart\nW2O"}]}, {"text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact", "location": [2597, 2655], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.566024, "arguments": [{"text": "Myovant Sciences", "location": [166, 182], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "MYOV", "location": [190, 194], "entities": [{"type": "Ticker", "text": "MYOV"}]}]}, {"type": "hasAttribute", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.845307, "arguments": [{"text": "women", "location": [259, 264], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [288, 296], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "timeOf", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.945218, "arguments": [{"text": "today", "location": [298, 303], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [304, 313], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.365198, "arguments": [{"text": "investor conferences", "location": [358, 378], "entities": [{"type": "Organization", "text": "Investor Conferences PR Newswire\nBASEL"}]}, {"text": "Evercore ISI HealthConX Conference", "location": [380, 414], "entities": [{"type": "Organization", "text": "Evercore ISI HealthConX Conference", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.800317, "arguments": [{"text": "Evercore ISI HealthConX Conference", "location": [380, 414], "entities": [{"type": "Organization", "text": "Evercore ISI HealthConX Conference", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Boston", "location": [418, 424], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "locatedAt", "sentence": "Myovant Sciences to Participate in Two Upcoming Investor Conferences PR Newswire BASEL, Switzerland, Nov. 15, 2018 BASEL, Switzerland , Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences: Evercore ISI HealthConX Conference in Boston , MA.", "score": 0.986381, "arguments": [{"text": "Boston", "location": [418, 424], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}, {"text": "MA", "location": [427, 429], "entities": [{"type": "GeopoliticalEntity", "text": "MA"}]}]}, {"type": "locatedAt", "sentence": "Citi's 2018 Global Healthcare Conference in New York , NY.", "score": 0.538461, "arguments": [{"text": "Global Healthcare Conference", "location": [587, 615], "entities": [{"type": "Organization", "text": "Global Healthcare Conference"}]}, {"text": "New York", "location": [619, 627], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}], "keywords": [{"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.980831}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": -0.238859, "label": "negative"}, "relevance": 0.836595}, {"text": "upcoming investor conferences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74729}, {"text": "endocrine diseases", "sentiment": {"score": -0.389588, "label": "negative"}, "relevance": 0.679195}, {"text": "Evercore ISI HealthConX", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543804}, {"text": "Investor Conferences PR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520646}, {"text": "following upcoming investor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515351}, {"text": "GnRH receptor antagonist", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515171}, {"text": "kisspeptin-1 receptor agonist", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497723}, {"text": "Global Healthcare Conference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.489127}, {"text": "Takeda Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485662}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483244}, {"text": "once-daily small molecule", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472802}, {"text": "heavy menstrual bleeding", "sentiment": {"score": -0.528794, "label": "negative"}, "relevance": 0.47249}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469278}, {"text": "advanced prostate cancer", "sentiment": {"score": -0.27174, "label": "negative"}, "relevance": 0.463686}, {"text": "View original content", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454553}, {"text": "Chief Financial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452492}, {"text": "Myovant website", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.411145}, {"text": "NY. Myovant", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410561}, {"text": "Evercore presentation", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.398932}, {"text": "live webcast", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.383577}, {"text": "visit Myovant", "sentiment": {"score": 0.443999, "label": "positive"}, "relevance": 0.381467}, {"text": "Lynn Seely", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367469}, {"text": "fireside chat", "sentiment": {"score": 0.276945, "label": "positive"}, "relevance": 0.36374}, {"text": "adequate time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355264}, {"text": "New York", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355162}, {"text": "Events page", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.35332}, {"text": "Media section", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.352925}, {"text": "software download", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351282}, {"text": "Investor Contact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350639}, {"text": "uterine fibroids", "sentiment": {"score": -0.528794, "label": "negative"}, "relevance": 0.349658}, {"text": "exclusive rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347272}, {"text": "exclusive license", "sentiment": {"score": 0.356035, "label": "positive"}, "relevance": 0.346963}, {"text": "international Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346595}, {"text": "clinical programs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345716}, {"text": "clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345349}, {"text": "innovative therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343079}, {"text": "Frank Karbe", "sentiment": {"score": 0.655655, "label": "positive"}, "relevance": 0.341118}, {"text": "worldwide license", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341006}, {"text": "Asian countries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340688}, {"text": "potential treatments", "sentiment": {"score": -0.540317, "label": "negative"}, "relevance": 0.339077}, {"text": "Media Contact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338325}, {"text": "female infertility", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.337998}, {"text": "jnormart@w2ogroup.com", "sentiment": {"score": 0.450964, "label": "positive"}, "relevance": 0.336877}, {"text": "development pipeline", "sentiment": {"score": -0.540317, "label": "negative"}, "relevance": 0.335654}, {"text": "Julie Normart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334204}, {"text": "assisted reproduction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330301}, {"text": "women", "sentiment": {"score": -0.461323, "label": "negative"}, "relevance": 0.320548}, {"text": "investors", "sentiment": {"score": 0.622117, "label": "positive"}, "relevance": 0.270666}]}, "extracted_metadata": {"sha1": "6747ef63266f657d88c18e588bf9da37fb203910", "filename": "1542289373888.zip-fb9a2134189141e6285d841111871fcc.xml", "file_type": "json"}, "external_links": ["http://www.myovant.com/", "http://www.prnewswire.com/news-releases/myovant-sciences-to-participate-in-two-upcoming-investor-conferences-300751000.html"], "title": "Myovant Sciences to Participate in Two Upcoming Investor Conferences", "forum_title": "CentralCharts : The trading social network"}]}